[
  {
    "objectID": "index.html#biostatistics-epidemiology-solutions-for-clinical-research",
    "href": "index.html#biostatistics-epidemiology-solutions-for-clinical-research",
    "title": "Ousmane DIALLO, MPH, PhD",
    "section": "Biostatistics & Epidemiology Solutions for Clinical Research",
    "text": "Biostatistics & Epidemiology Solutions for Clinical Research\nI am a rigorous biostatistician and epidemiologist certified in SAS Base Programming and Clinical Trials Programming, transitioning from academia to the pharmaceutical industry. I specialize in CDISC standards (SDTM/ADaM) and real-world evidence (RWE) to support clinical research and regulatory submissions.\n\nView My Portfolio Let‚Äôs Connect"
  },
  {
    "objectID": "index.html#core-competencies",
    "href": "index.html#core-competencies",
    "title": "Ousmane Diallo, MPH-PhD",
    "section": "Core Competencies",
    "text": "Core Competencies\n\n\n\nüíª\n\n\nProgramming & Tools\n\nSAS (Certified Base & Clinical Trials)\nR Programming (tidyverse, survival, spatial)\nPython ‚Ä¢ Quarto ‚Ä¢ GitHub\nTableau & Power-BI\n\n\n\n\n\nüè•\n\n\nClinical & Regulatory Standards\n\nCDISC: SDTM, ADaM & define.xml\nClinical Trials Programming\nStatistical Analysis Plans (SAPs)\nGCP/ICH Compliance & Validation\n\n\n\n\n\nüìä\n\n\nStatistical & Analytical Methods\n\nAdvanced Statistical Modeling (GLM, Survival)\nReal-World Evidence (RWE)\nGeospatial Analysis & Visualization\nComplex Survey Data Analysis\n\n\n\n\n\nüåç\n\n\nProfessional & Collaborative Skills\n\nCross-Functional Team Collaboration\nInternational Project Management\nTraining & Mentorship Programs\nQuality Control & Data Validation"
  },
  {
    "objectID": "index.html#my-transition-to-pharmaindustry",
    "href": "index.html#my-transition-to-pharmaindustry",
    "title": "Ousmane Diallo ‚Äì Portfolio",
    "section": "My Transition to Pharma/Industry",
    "text": "My Transition to Pharma/Industry\n\nMy academic background in epidemiology and biostatistics, combined with hands-on SAS training and CDISC projects, has prepared me to contribute to clinical trials and RWE studies. Projects like my end-to-end CDISC workflow (SDTM/ADaM, TLF, define.xml) demonstrate my ability to deliver regulatory-compliant deliverables, while my R-based analyses showcase transferable skills for RWE and observational studies.\nAvailable for: Clinical Biostatistician ‚Ä¢ Statistical Programmer ‚Ä¢ Data Scientist roles"
  },
  {
    "objectID": "index.html#areas-of-expertise",
    "href": "index.html#areas-of-expertise",
    "title": "Ousmane DIALLO, MPH, PhD",
    "section": "Areas of Expertise",
    "text": "Areas of Expertise\n\n\nüìä Advanced Statistical Analysis\n\nLogistic & linear regression\nGEE, GAM, GLM, GLMM models\nSurvival analysis\nPredictive modeling\n\n\n\nüî¨ Clinical Research\n\nObservational studies\nEpidemiological surveillance\nReal-World Evidence (RWE)\nRegulatory submissions"
  },
  {
    "objectID": "portfolio/portfolio-1.html",
    "href": "portfolio/portfolio-1.html",
    "title": "Factors associated with the ownership and use of insecticide-treated nets in Guinea: an analysis of the 2018 Demographic and Health Survey",
    "section": "",
    "text": "This is an item in your portfolio. It can be have images or nice text. If you name the file .md, it will be parsed as markdown. If you name the file .html, it will be parsed as HTML."
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About Ousmane Diallo, MPH, PhD",
    "section": "",
    "text": "I am a rigorous biostatistician and epidemiologist with over 9 years of experience in health data analytics, statistical modeling, and large-scale data management. Certified in SAS Base Programming and Clinical Trials Programming, I am transitioning from academia to the pharmaceutical industry to apply my expertise in CDISC standards (SDTM/ADaM) and real-world evidence (RWE) to clinical research and regulatory submissions.\nWith a proven track record in international projects, I excel in collaborative environments, delivering submission-ready insights and supporting high-quality publications.\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician, Data Scientist & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "about.html#my-journey",
    "href": "about.html#my-journey",
    "title": "About Ousmane Diallo, MPH, PhD",
    "section": "",
    "text": "I am a rigorous biostatistician and epidemiologist with over 9 years of experience in health data analytics, statistical modeling, and large-scale data management. Certified in SAS Base Programming and Clinical Trials Programming, I am transitioning from academia to the pharmaceutical industry to apply my expertise in CDISC standards (SDTM/ADaM) and real-world evidence (RWE) to clinical research and regulatory submissions.\nWith a proven track record in international projects, I excel in collaborative environments, delivering submission-ready insights and supporting high-quality publications."
  },
  {
    "objectID": "about.html#education",
    "href": "about.html#education",
    "title": "About Ousmane Diallo, MPH, PhD",
    "section": "Education",
    "text": "Education\n\nMaster‚Äôs in Public Health - Aix Marseille University\nPHD in Infectious Disease - Aix Marseille University\nSAS Certifications - Base Programming and Clinical Trials Programming\nAdditional Training - Introduction to the Principles and Practice of Clinical Research\nAdditional Training - Infectious Disease Transmission Models for Decision-Makers & R Programming"
  },
  {
    "objectID": "about.html#professional-experience",
    "href": "about.html#professional-experience",
    "title": "About Ousmane Diallo, MPH, PhD",
    "section": "Professional Experience",
    "text": "Professional Experience\n\nAcademic Research\n\nLed multiple epidemiological studies involving complex survey data\nDeveloped statistical models for population health research\nPublished findings in peer-reviewed journals\n\n\n\nStatistical Consulting\n\nProvided biostatistical expertise to research teams\nDesigned and implemented analysis plans for clinical studies\nTrained researchers in statistical methods and software\n\n\n\nInternational Collaborations\n\nCollaborated with international research teams on health data projects\nExperience with multi-country surveillance systems\nCross-cultural project management and communication"
  },
  {
    "objectID": "about.html#technical-expertise",
    "href": "about.html#technical-expertise",
    "title": "About Ousmane Diallo, MPH, PhD",
    "section": "Technical Expertise",
    "text": "Technical Expertise\n\nProgramming Languages\n\nSAS: Advanced proficiency with macros, PROC SQL, ODS\nR: Extensive use of tidyverse, survival analysis, geospatial packages\nPython: Data manipulation and statistical analysis\n\n\n\nSpecialized Skills\n\nCDISC standards implementation (SDTM, ADaM, define.xml)\nRegulatory submission preparation\nReal-World Evidence (RWE) & Statistical Modeling\nHealth Economics & Outcomes Research (HEOR)\nGeospatial Analysis & Epidemiology\nMachine Learning & Predictive Analytics"
  },
  {
    "objectID": "about.html#publications-presentations",
    "href": "about.html#publications-presentations",
    "title": "About Ousmane Diallo, MPH, PhD",
    "section": "Publications & Presentations",
    "text": "Publications & Presentations\n[Add your publications, presentations, or notable projects here]"
  },
  {
    "objectID": "about.html#professional-development",
    "href": "about.html#professional-development",
    "title": "About Ousmane Diallo, MPH, PhD",
    "section": "Professional Development",
    "text": "Professional Development\n\nContinuous learning in pharmaceutical industry standards\nRegular attendance at biostatistics and epidemiology conferences\nActive member of relevant professional associations"
  },
  {
    "objectID": "about.html#what-drives-me",
    "href": "about.html#what-drives-me",
    "title": "About Ousmane Diallo, MPH, PhD",
    "section": "What Drives Me",
    "text": "What Drives Me\nI am passionate about transforming complex health data into actionable insights that can improve patient outcomes and support evidence-based decision making in healthcare and pharmaceutical development."
  },
  {
    "objectID": "projects/cdisc-sdtm.html",
    "href": "projects/cdisc-sdtm.html",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "Automation of SDTM-Demographics (DM) creation in SAS for CDISC-compliant clinical data using a metadata-driven approach.\nView Code on Github\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician, Data Scientist & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "projects/cdisc-sdtm.html#overview",
    "href": "projects/cdisc-sdtm.html#overview",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "Goal: Build SDTM DM (Demographics) and SUPPDM from raw/source data using a metadata-driven approach (empty shells ‚Üí mapping ‚Üí derivations ‚Üí sort/export).\nWhy: Ensure CDISC consistency (identifiers, timing in ISO 8601, roles/keys) and reproducibility in SAS OnDemand.\nOutputs: TARGET.DM (1 record per subject) and TARGET.SUPPDM (non-standard qualifiers).\n\n\n\n\n\n\nNote\n\n\n\nContext: Tools: SAS OnDemand 9.4, macros from study notes. Source folders: SOURCE (raw tables), LIB (formats), TARGET (SDTM outputs). Metadata: SDTM_METADATA1.csv."
  },
  {
    "objectID": "projects/cdisc-sdtm.html#inputs",
    "href": "projects/cdisc-sdtm.html#inputs",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "Metadata Specification:\n\nFile: SDTM_METADATA1.csv (variables, roles, lengths, types, sort keys).\n\nVariable definitions (names, types, lengths, labels)\nCDISC role classifications (Identifier, Timing, Qualifier)\nSort order specifications\n\n\nSource Data:\n\nSOURCE.DEMOGRAPHIC (1 row per subject, e.g., subject, dob, gender, trt, uniqueid)\nSOURCE.DOSING (e.g., subject, startdt, enddt)\n\nEnvironment Setup\n\nPlatform: SAS OnDemand 9.4\nLibraries: SOURCE (raw data), LIB (formats), TARGET (outputs)"
  },
  {
    "objectID": "projects/cdisc-sdtm.html#library-setup",
    "href": "projects/cdisc-sdtm.html#library-setup",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "/* Common paths & librefs */\n%include \"/home/u64197545/CDISC/appendix/common.sas\";\n/* expects:\n libname source \"/home/u64197545/CDISC/data\";\n libname lib \"/home/u64197545/CDISC/formats\";\n libname target \"/home/u64197545/CDISC/sdtm\";\n*/"
  },
  {
    "objectID": "projects/cdisc-sdtm.html#create-empty-dm-from-metadata",
    "href": "projects/cdisc-sdtm.html#create-empty-dm-from-metadata",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "Create an empty shell (EMPTY_DM) using the CSV metadata to ensure correct attributes (type, length, label, order).\n/* Create empty based on metadata CSV */\n%macro make_empty_dataset(metadatafile=, dataset=);\n/* Import csv file and rename it _temp */\n    proc import datafile=\"&metadatafile\" out=_temp dbms=csv replace;\n        guessingrows=max;\n        delimiter=\";\";\n        encoding='utf-8';\n    run;\n\n    /* Sort the dataset by expected specified variable order (varnum) */\n    proc sort data=_temp;\n        where domain=\"&dataset\";\n        by varnum;\n    run;\n\n    /* Create keepstring macro variable and load metadata information into macro variables */\n    %global &dataset.KEEPSTRING;\n\n    data _null_;\n        set _temp nobs=nobs end=eof;\n        if _n_=1 then\n            call symput(\"vars\", compress(put(nobs, 3.)));\n        call symputx('var'    || compress(put(_n_, 3.)), variable);\n        call symputx('label'  || compress(put(_n_, 3.)), label);\n        call symputx('length' || compress(put(_n_, 3.)), put(length, 3.));\n        /* Valid ODM types include TEXT, INTEGER, FLOAT, DATETIME, DATE, TIME and map to SAS numeric or character */\n        if upcase(type) in (\"INTEGER\", \"FLOAT\") then\n            call symputx('type' || compress(put(_n_, 3.)), \"\");\n        else if upcase(type) in (\"TEXT\", \"DATE\", \"DATETIME\", \"TIME\") then\n            call symputx('type' || compress(put(_n_, 3.)), \"$\");\n        else\n            put \"ERR\" \"OR: not using a valid ODM type.  \" type=;\n        /* Create KEEPSTRING macro variable */\n        length keepstring $ 32767;\n        retain keepstring;\n        keepstring=compress(keepstring) || \"|\" || left(variable);\n        if eof then\n            call symputx(upcase(compress(\"&dataset\" || 'KEEPSTRING')), \n                left(trim(translate(keepstring, \" \", \"|\"))));\n    run;\n\n    /* Create a 0-observation template data set used for assigning variable attributes */\n    data EMPTY_&dataset;\n        %do i=1 %to &vars;\n            attrib &&var&i label=\"&&label&i\" \n            %if \"&&length&i\" ne \"\" %then\n                length=&&type&i.&&length&i...;\n            ;\n            %if &&type&i=$ %then\n                retain &&var&i '';\n            %else\n                retain &&var&i .;\n            ;\n        %end;\n        if 0;\n    run;\n%mend make_empty_dataset;\n\n/* Result: WORK.EMPTY_DM with 0 obs, all expected variables/attributes */"
  },
  {
    "objectID": "projects/cdisc-sdtm.html#mapping-raw-data-to-sdtm-dm",
    "href": "projects/cdisc-sdtm.html#mapping-raw-data-to-sdtm-dm",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "Mapping raw data to SDTM DM variables using SDTMIG v3.4.\n\n\n\n\n\n\n\n\nClass\nVariables (examples)\nNotes\n\n\n\n\nIdentifier\nSTUDYID, DOMAIN, USUBJID, SUBJID\n1 record per subject\n\n\nTiming\nRFSTDTC, RFENDTC, RFXSTDTC, RFXENDTC, BRTHDTC\nISO 8601 dates\n\n\nQualifier\nSITEID, SEX, RACE, COUNTRY, AGE, AGEU\nCoded via formats where applicable\n\n\nArm\nARMCD, ARM, ACTARMCD, ACTARM\nFrom treatment assignments"
  },
  {
    "objectID": "projects/cdisc-sdtm.html#create-formats",
    "href": "projects/cdisc-sdtm.html#create-formats",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "/* Creating custom format for the variables sex, race, arm, and armcd */\nproc format;\n    value sex 1='M' 2='F' .='U';\n    value race 1='White' 2='Black or African American' 3='Asian';\n    value armcd 0='PLACEBO' 1='ALG123';\n    value arm 0='Placebo' 1='Analgezia HCL 30mg';\nrun;"
  },
  {
    "objectID": "projects/cdisc-sdtm.html#derive-logic-variables-dosing",
    "href": "projects/cdisc-sdtm.html#derive-logic-variables-dosing",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "/* First/last dose (for RFSTDTC/RFENDTC) */\nproc sort \n  data=source.dosing(keep=subject startdt enddt) \n  out=dosing;\n   by subject startdt;\nrun;\n\ndata dosing;\n  set dosing; \n    by subject;\n    retain firstdose lastdose;\n  if first.subject then \n    do; \n       firstdose=.; \n       lastdose=.; \n    end;\n  firstdose = min(firstdose, startdt, enddt);\n  lastdose  = max(lastdose , startdt, enddt);\n  if last.subject;\nrun;"
  },
  {
    "objectID": "projects/cdisc-sdtm.html#combine-all-data",
    "href": "projects/cdisc-sdtm.html#combine-all-data",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "/* Get demographics data */\nproc sort\n  data=source.demographic\n  out=demographic;\n    by subject;\nrun;\n\n/* Merge demographics and first dose date */\ndata demog_dose;\n  merge demographic\n        dosing;\n    by subject;\nrun;\n\n/* Derive the majority of SDTM DM variables */\noptions missing = ' ';\ndata dm;\n  set EMPTY_DM\n    demog_dose(rename=(race=_race));\n    studyid = 'XYZ123';\n    domain = 'DM';\n    usubjid = left(uniqueid);\n    subjid = put(subject,3.); \n    rfstdtc = put(firstdose,yymmdd10.);  \n    rfendtc = put(lastdose,yymmdd10.); \n    rfxstdtc = put(firstdose,yymmdd10.);  \n    rfxendtc = put(lastdose,yymmdd10.);\n    rficdtc = put(icdate,yymmdd10.);\n    rfpendtc = put(lastdoc,yymmdd10.);\n    dthfl = 'N';\n    siteid = substr(subjid,1,1) || \"00\";\n    brthdtc = put(dob,yymmdd10.);\n    age = floor ((intck('month',dob,firstdose) - \n          (day(firstdose) &lt; day(dob))) / 12);\n    if age ne . then\n      ageu = 'YEARS';\n    sex = put(gender,sex.);\n    race = put(_race,race.);\n    armcd = put(trt,armcd.);\n    arm = put(trt,arm.);\n    actarmcd = put(trt,armcd.);\n    actarm = put(trt,arm.);\n    country = \"USA\"; \nrun;"
  },
  {
    "objectID": "projects/cdisc-sdtm.html#order-keys-export",
    "href": "projects/cdisc-sdtm.html#order-keys-export",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "/* Create sort order */\n%macro make_sort_order(metadatafile=, dataset=);\n    proc import datafile=\"&metadatafile\" out=_temp dbms=csv replace;\n        guessingrows=max;\n        delimiter=\";\";\n        encoding='utf-8';\n    run;\n\n    proc sort data=_temp;\n        where keysequence ne . and domain=\"&dataset\";\n        by keysequence;\n    run;\n\n    %global &dataset.SORTSTRING;\n    data _null_;\n        set _temp end=eof;\n        length domainkeys $ 200;\n        retain domainkeys '';\n        domainkeys=trim(domainkeys) || ' ' || trim(put(variable, 8.));\n        if eof then\n            call symputx(compress(\"&dataset\" || \"SORTSTRING\"), domainkeys);\n    run;\n%mend make_sort_order;\n\n/* Sort DM according to metadata and save permanent dataset */\n%make_sort_order(metadatafile=/home/u64197545/CDISC/Chap2/SDTM_METADATA1.csv,dataset=DM);\nproc sort\n  data=dm(keep = &DMKEEPSTRING)\n  out=target.dm;\n    by &DMSORTSTRING;\nrun;"
  },
  {
    "objectID": "projects/cdisc-sdtm.html#qc-validation",
    "href": "projects/cdisc-sdtm.html#qc-validation",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "Structural checks: Variable names, type, length, labels match metadata.\nControlled terminology: Values mapped via formats/codelists.\nTiming: ISO 8601, completeness of RFSTDTC/RFXSTDTC.\nKeys: 1 record per subject; USUBJID uniqueness.\nCross-domain: Consistency with EX/AE/VS if applicable.\n\n/* 1 record per USUBJID? */\nproc sql;\n  select usubjid, count(*) as n\n  from target.dm\n  group by usubjid\n  having calculated n &gt; 1;\nquit;\n\n/* Required fields not missing? */\nproc freq data=target.dm;\n  tables studyid*usubjid*domain / missing list;\nrun;"
  },
  {
    "objectID": "projects/cdisc-sdtm.html#outputs",
    "href": "projects/cdisc-sdtm.html#outputs",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "SDTM-DM: Datasets DM.sas7bdat and SUPPDM.sas7bdat compliant with CDISC standards.\nSample DM Dataset:\n\n\n\nUSUBJID\nSTUDYID\nSEX\nAGE\nRACE\nARMCD\n\n\n\n\n001\nXYZ123\nM\n45\nWhite\nPLACEBO\n\n\n002\nXYZ123\nF\n32\nAsian\nALG123\n\n\n\nProc Contents: Structure and attributes of the final dataset.\n\n\n\n\n\n\nNote\n\n\n\nNote: The sample dataset above is an example. Actual data can be visualized or tabulated for further illustration."
  },
  {
    "objectID": "projects/cdisc-sdtm.html#contact",
    "href": "projects/cdisc-sdtm.html#contact",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "Contact",
    "text": "Contact\nInterested in this project or my expertise in biostatistics and CDISC standards?\nSend an Email | LinkedIn"
  },
  {
    "objectID": "contact.html",
    "href": "contact.html",
    "title": "Contact Me",
    "section": "",
    "text": "Let‚Äôs Connect\n      \n        I am available for collaboration or consultation in biostatistics, \n        epidemiology, SAS clinical programming (CDISC), \n        and real-world evidence (RWE). For roles, \n        project work, or research collaborations, reach out below.\n      \n\n      \n      \n        \n        \n          \n          GitHub\n        \n\n        \n        \n          \n          LinkedIn\n        \n\n        \n        \n          \n          Email\n        \n      \n\n      \n      \n        \n        \n        \n        \n        \n        \n          Don't fill this out if you're human:\n          \n        \n\n        \n          Full Name\n          \n        \n\n        \n          Email address\n          \n        \n\n        \n          Subject\n          \n        \n\n        \n          Organization\n          \n        \n\n        \n          Message\n          \n        \n\n        \n\n        Send Message\n\n        \n        \n          ‚úÖ Thank you! Your message has been sent. I‚Äôll reply shortly.\n        \n      \n\n      \n      \n\n      \n      \n        Based in Chicago, IL, USA ‚Ä¢ Typically replies within 2‚Äì3 business days\n      \n\n    \n  \n\n\n\n\n  \n\n\n\n\n\n\n\n\n\n\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research. Back to top"
  },
  {
    "objectID": "contact.html#lets-discuss-your-project",
    "href": "contact.html#lets-discuss-your-project",
    "title": "Contact Me",
    "section": "",
    "text": "I am available for collaborations and consulting opportunities in biostatistics, epidemiology, and clinical research. Whether you need support with data analysis, regulatory submissions, or training, I‚Äôm here to help deliver high-quality, evidence-based solutions."
  },
  {
    "objectID": "contact.html#services-offered",
    "href": "contact.html#services-offered",
    "title": "Contact Me",
    "section": "Services Offered",
    "text": "Services Offered\n\nStatistical Analysis & Consulting\n\nClinical trial design and analysis\nReal-world evidence studies\nObservational research\nSurvival analysis and time-to-event modeling\nComplex survey data analysis\n\n\n\nCDISC & Regulatory Support\n\nSDTM and ADaM implementation\nDefine.xml creation and validation\nRegulatory submission preparation\nQuality control and data validation\nFDA/EMA compliance consulting\n\n\n\nTraining & Mentorship\n\nSAS programming for clinical trials\nR programming for biostatistics\nCDISC standards training\nStatistical methods workshops\nReproducible research practices\n\n\n\nData Management & Visualization\n\nDatabase design and management\nInteractive dashboard creation\nGeospatial analysis and mapping\nAutomated reporting solutions"
  },
  {
    "objectID": "contact.html#contact-information",
    "href": "contact.html#contact-information",
    "title": "Contact Me",
    "section": "Contact Information",
    "text": "Contact Information\n\nProfessional Networks\n\nLinkedIn: linkedin.com/in/ousmane-rabi\nGitHub: github.com/ousmanerabi\n\n\n\nEmail\nPrimary: ousmanerabi12@gmail.com\n\n\nLocation\nBased in [Chicago, USA] - Available for remote collaborations worldwide"
  },
  {
    "objectID": "contact.html#project-inquiry",
    "href": "contact.html#project-inquiry",
    "title": "Contact Me",
    "section": "Project Inquiry",
    "text": "Project Inquiry\nWhen reaching out, please include:\n\nProject Overview: Brief description of your needs\nTimeline: Expected project duration and key milestones\nTechnical Requirements: Specific tools, standards, or methodologies needed\nCollaboration Preferences: Remote, on-site, or hybrid arrangements"
  },
  {
    "objectID": "contact.html#ready-to-accelerate-your-research",
    "href": "contact.html#ready-to-accelerate-your-research",
    "title": "Contact Me",
    "section": "Ready to Accelerate Your Research?",
    "text": "Ready to Accelerate Your Research?\nI bring over 9 years of experience in transforming complex health data into actionable insights. My expertise in both academic research and industry standards positions me to deliver solutions that meet the highest quality and regulatory requirements.\n\nWhat Sets Me Apart\n\nProven Track Record: Successfully delivered regulatory-compliant analyses\nInternational Experience: Worked with diverse teams across multiple continents\nContinuous Learning: Stay current with evolving industry standards and methodologies\nQuality Focus: Committed to reproducible, well-documented, and validated results\n\n\nLooking forward to discussing how we can work together to advance your research goals and deliver impactful results.\n\nResponse time: I typically respond to inquiries within 24-48 hours. For urgent matters, please mention ‚ÄúURGENT‚Äù in your subject line."
  },
  {
    "objectID": "projects/itn-ownership-use-guinea-dhs2018.html",
    "href": "projects/itn-ownership-use-guinea-dhs2018.html",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "Period: 2021‚Äì2022 ¬∑ Role: Lead Data Analyst ¬∑ Country: Guinea\n\n\n\nAnalysis of the 2018 Guinea Demographic and Health Survey (DHS) to identify determinants of ownership and use of insecticide-treated nets (ITNs) at both household and individual levels. Understanding the factors influencing household ITN ownership and usage among those with access will enable the Guinea National Malaria Control Programme to design targeted interventions aimed at increasing bed net coverage and utilization.\n\n\n\n\nMain variables: wealth quintiles, education level, urban/rural setting, Age of household head, Age of individual, Sex of household head, Sex of individual, Household size, Number of rooms, Marital status, Children under five, Pregnant status, Region.\nTwo main outcomes: ITN ownership and ITN use the previous night (among those with access).\nAccounted for complex survey design: weights, strata, and clusters.\n\n\n\n\nSurvey-weighted logistic regression models were implemented in R (survey, srvyr, dplyr, ggplot2, tmap) to estimate adjusted odds ratios and visualize disparities.\n\n\n\n\nTables and figures for manuscript and policy brief.\nFully reproducible R scripts (data cleaning, indicator generation, modeling).\n\n\n\n\n\nEvidence to better target priority groups in ITN distribution campaigns.\nRecommendations to tailor behavior change communication messages.\n\n\n\n\n![ITN Usage]({{ ‚Äú/assets/projects/itn/Fichier_8.png‚Äù | relative_url }}) Regional variation in Guinea of A household ITN ownership; B proportion of the population with access to an ITN; C ITN usage; and D ITN usage among those with access.\n![ITN Usage Map]({{ ‚Äú/assets/projects/itn/two_dimensionel.png‚Äù | relative_url }}) Two-dimensional histogram showing the number of people who could use nets owned by the household if all nets were in use, stratified by household size, in the 2018 Guinea DHS."
  },
  {
    "objectID": "projects/itn-ownership-use-guinea-dhs2018.html#overview",
    "href": "projects/itn-ownership-use-guinea-dhs2018.html#overview",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "Analysis of the 2018 Guinea Demographic and Health Survey (DHS) to identify determinants of ownership and use of insecticide-treated nets (ITNs) at both household and individual levels. Understanding the factors influencing household ITN ownership and usage among those with access will enable the Guinea National Malaria Control Programme to design targeted interventions aimed at increasing bed net coverage and utilization."
  },
  {
    "objectID": "projects/itn-ownership-use-guinea-dhs2018.html#key-highlights",
    "href": "projects/itn-ownership-use-guinea-dhs2018.html#key-highlights",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "Main variables: wealth quintiles, education level, urban/rural setting, Age of household head, Age of individual, Sex of household head, Sex of individual, Household size, Number of rooms, Marital status, Children under five, Pregnant status, Region.\nTwo main outcomes: ITN ownership and ITN use the previous night (among those with access).\nAccounted for complex survey design: weights, strata, and clusters."
  },
  {
    "objectID": "projects/itn-ownership-use-guinea-dhs2018.html#methods-tools",
    "href": "projects/itn-ownership-use-guinea-dhs2018.html#methods-tools",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "Survey-weighted logistic regression models were implemented in R (survey, srvyr, dplyr, ggplot2, tmap) to estimate adjusted odds ratios and visualize disparities."
  },
  {
    "objectID": "projects/itn-ownership-use-guinea-dhs2018.html#deliverables",
    "href": "projects/itn-ownership-use-guinea-dhs2018.html#deliverables",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "Tables and figures for manuscript and policy brief.\nFully reproducible R scripts (data cleaning, indicator generation, modeling)."
  },
  {
    "objectID": "projects/itn-ownership-use-guinea-dhs2018.html#impact",
    "href": "projects/itn-ownership-use-guinea-dhs2018.html#impact",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "Evidence to better target priority groups in ITN distribution campaigns.\nRecommendations to tailor behavior change communication messages."
  },
  {
    "objectID": "projects/itn-ownership-use-guinea-dhs2018.html#visual-highlights",
    "href": "projects/itn-ownership-use-guinea-dhs2018.html#visual-highlights",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "![ITN Usage]({{ ‚Äú/assets/projects/itn/Fichier_8.png‚Äù | relative_url }}) Regional variation in Guinea of A household ITN ownership; B proportion of the population with access to an ITN; C ITN usage; and D ITN usage among those with access.\n![ITN Usage Map]({{ ‚Äú/assets/projects/itn/two_dimensionel.png‚Äù | relative_url }}) Two-dimensional histogram showing the number of people who could use nets owned by the household if all nets were in use, stratified by household size, in the 2018 Guinea DHS."
  },
  {
    "objectID": "CONTRIBUTING.html",
    "href": "CONTRIBUTING.html",
    "title": "Ousmane Rabi",
    "section": "",
    "text": "Contributions are welcome! Please add issues and make pull requests. There are no stupid questions. All ideas are welcome. This is a volunteer project. Be excellent to each other.\nFork from master and go from there. This repository is intended to remain a generic, ready-to-fork template that demonstrates the features of academicpages.\nIf you make a pull request and change code, please make sure there is a closed issue tagged with ‚Äòcode change‚Äô that has some comment linking to either the single commit (if the change was just one commit) or a diff comparing before/after the change (see issue 21 for example). This is so that those who have forked this repo and modified it for their purposes can more easily patch bugs and new features."
  },
  {
    "objectID": "portfolio.html",
    "href": "portfolio.html",
    "title": "Portfolio",
    "section": "",
    "text": "A curated showcase of clinical research, real-world evidence (RWE), and health analytics projects developed using\nSAS, R, and Python ‚Äî bridging statistical rigor, reproducibility, and regulatory science.\n\n\n\n\nClinical Trials Programming (CDISC, SAS)\nHealth Economics & Outcomes Research (HEOR)\nReal-World Evidence (RWE) Analytics\nMachine Learning & Advanced Statistical Modeling\nGeospatial Epidemiology\n\nExplore each section for methodology, R/SAS code, and key results.\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician, Data Scientist & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "portfolio.html#thematic-areas",
    "href": "portfolio.html#thematic-areas",
    "title": "Key Projects (2020‚Äì2025)",
    "section": "",
    "text": "Modeling: Scenario modeling to guide policy.\n\nAnalytics: Statistical and geospatial analysis for decision-making.\n\nSNT Support: Data pipelines, stratification, and intervention targeting.\n\nTraining: Capacity building for graduate students."
  },
  {
    "objectID": "portfolio.html#r-epidemiology-projects",
    "href": "portfolio.html#r-epidemiology-projects",
    "title": "Key Projects",
    "section": "",
    "text": "Comprehensive analysis of insecticide-treated nets usage patterns\n\nMethods: Complex survey analysis, logistic regression, geospatial mapping\nTools: R (survey, dplyr, ggplot2, sf), DHS data\nImpact: Identified key barriers to ITN usage for policy interventions\nPeriod: 2021‚Äì2022\n\nTags: Survey Analysis ‚Ä¢ Malaria Prevention ‚Ä¢ Guinea ‚Ä¢ R Programming\n\n\n\nRetrospective analysis of malaria incidence trends using health facility data\n\nMethods: Time series analysis, seasonal decomposition, spatial clustering\nTools: R (surveillance, forecast, tmap), HMIS data\nImpact: Informed national malaria control strategy and resource allocation\nPeriod: 2023‚Äì2024\n\nTags: Time Series ‚Ä¢ HMIS Data ‚Ä¢ Burkina Faso ‚Ä¢ Trend Analysis\n\n\n\nData management and intervention targeting across three West African countries\n\nMethods: Risk stratification, intervention mapping, data pipeline development\nTools: R, Python, QGIS, multiple data sources integration\nImpact: Optimized malaria intervention targeting for SNT programs\nPeriod: 2023\n\nTags: Multi-Country ‚Ä¢ Data Pipelines ‚Ä¢ Stratification ‚Ä¢ Togo, Guinea, Burkina\n\n\n\nFine-scale risk mapping for urban malaria control in Guinea‚Äôs capital\n\nMethods: Spatial analysis, remote sensing integration, risk modeling\nTools: R (sf, raster, leaflet), satellite imagery, demographic data\nImpact: Enabled targeted urban malaria interventions at sub-district level\nPeriod: 2023‚Äì2024\n\nTags: Urban Health ‚Ä¢ Microstratification ‚Ä¢ Remote Sensing ‚Ä¢ Guinea\n\n\n\nComprehensive capacity building in biostatistics and epidemiology\n\nMethods: Curriculum development, hands-on training, research supervision\nTools: R, SAS, statistical software training, research methodology\nImpact: Trained 15+ graduate students across Benin and Guinea\nPeriod: 2020‚Äì2024\n\nTags: Capacity Building ‚Ä¢ Training ‚Ä¢ Mentorship ‚Ä¢ West Africa"
  },
  {
    "objectID": "portfolio.html#cdisc-sas-clinical-programming",
    "href": "portfolio.html#cdisc-sas-clinical-programming",
    "title": "Key Projects",
    "section": "",
    "text": "Automated regulatory metadata documentation for clinical trials\n\nMethods: CDISC standards implementation, automated validation, QC procedures\nTools: SAS, CDISC Pinnacle 21, define.xml specifications\nImpact: Streamlined regulatory submission preparation and compliance\nPeriod: 2025\n\nTags: Regulatory Compliance ‚Ä¢ define.xml ‚Ä¢ Validation ‚Ä¢ Clinical Trials\n\n\n\nComplete Study Data Tabulation Model mapping and programming\n\nMethods: SDTM domain mapping, data transformation, regulatory compliance\nTools: SAS programming, CDISC standards, clinical data management\nImpact: Delivered submission-ready datasets for regulatory agencies\nPeriod: 2025\n\nTags: SDTM ‚Ä¢ Clinical Data ‚Ä¢ Regulatory Submission ‚Ä¢ SAS Programming\n\n\n\nAdvanced statistical datasets for clinical trial analysis and reporting\n\nMethods: ADaM BDS programming, derived variables, statistical analysis datasets\nTools: SAS macros, ADaM specifications, clinical trial protocols\nImpact: Enabled efficient statistical analysis and TLF generation\nPeriod: 2025\n\nTags: ADaM BDS ‚Ä¢ Efficacy Analysis ‚Ä¢ Safety Analysis ‚Ä¢ Clinical Programming"
  },
  {
    "objectID": "projects/risk_factors.html",
    "href": "projects/risk_factors.html",
    "title": "Risk Factors of ITN Ownership and Use ‚Äì Guinea DHS 2018",
    "section": "",
    "text": "Project Role: Research Assistant Professor & Lead Author\nStatus: Published in malaria journal\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "index.html#core-expertise",
    "href": "index.html#core-expertise",
    "title": "Ousmane DIALLO, MPH, PhD",
    "section": "Core Expertise",
    "text": "Core Expertise\n\n\nüíª Programming & Analytics SAS, R, Python, Quarto CDISC, Statistical Modeling\n\n\nüè• Clinical Research Clinical Trials Programming Regulatory Submissions Quality Control & Validation\n\n\nüìä Data Science Geospatial Analysis Survival Analysis Real-World Evidence\n\n\nüåç Global Experience International Projects Cross-Functional Collaboration Training & Mentorship"
  },
  {
    "objectID": "index.html#ready-to-accelerate-your-research",
    "href": "index.html#ready-to-accelerate-your-research",
    "title": "Ousmane DIALLO, MPH, PhD",
    "section": "Ready to Accelerate Your Research?",
    "text": "Ready to Accelerate Your Research?\nMy academic background combined with hands-on industry training has prepared me to deliver regulatory-compliant solutions. From end-to-end CDISC workflows to advanced statistical modeling, I bring proven expertise to transform complex health data into actionable insights.\nExplore My Projects Get In Touch"
  },
  {
    "objectID": "index.html#biostatistician-epidemiologist",
    "href": "index.html#biostatistician-epidemiologist",
    "title": "Ousmane Diallo, MPH-PhD",
    "section": "Biostatistician & Epidemiologist",
    "text": "Biostatistician & Epidemiologist\n9+ Years Experience ‚Ä¢ SAS Certified ‚Ä¢ CDISC Expert ‚Ä¢ Ready to Contribute\nüíº Portfolio ‚Ä¢ üìß Contact ‚Ä¢ üìÑ LinkedIn ‚Ä¢ üíª GitHub"
  },
  {
    "objectID": "index.html#key-experience-projects",
    "href": "index.html#key-experience-projects",
    "title": "Ousmane Diallo, MPH-PhD",
    "section": "Key Experience & Projects",
    "text": "Key Experience & Projects\n\n\nAcademic Research (2020-2024) - Led epidemiological studies across Guinea, Burkina Faso, Togo - Advanced statistical modeling and geospatial analysis - International collaboration and data management\n\n\nCDISC Implementation (2025) - End-to-end SDTM/ADaM workflows - define.xml generation and validation - Regulatory-compliant deliverables\n\n\nTraining & Mentorship (2020-2024) - Graduate student supervision (Benin & Guinea) - Statistical methods workshops - Capacity building programs"
  },
  {
    "objectID": "index.html#why-hire-me",
    "href": "index.html#why-hire-me",
    "title": "Ousmane Diallo, MPH-PhD",
    "section": "Why Hire Me?",
    "text": "Why Hire Me?\n\n\nüéØ Industry-Ready Academic experience + industry training = immediate contribution to clinical teams\n\n\nüìã Regulatory Focus Proven ability to deliver submission-ready, compliant analyses and documentation\n\n\nü§ù Collaborative 9+ years of international teamwork, training, and cross-functional collaboration\n\n\nüìà Results-Driven Track record of transforming complex data into actionable insights for decision-making"
  },
  {
    "objectID": "index.html#ready-to-discuss-opportunities",
    "href": "index.html#ready-to-discuss-opportunities",
    "title": "Ousmane Diallo, MPH-PhD",
    "section": "Ready to Discuss Opportunities",
    "text": "Ready to Discuss Opportunities\nAvailable for: Clinical Biostatistician ‚Ä¢ Statistical Programmer ‚Ä¢ Data Scientist roles in pharmaceutical industry\nüìß Let‚Äôs Connect üìÅ View Portfolio"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Ousmane Diallo ‚Äì Portfolio",
    "section": "",
    "text": "I‚Äôm Ousmane Diallo. I develop statistical models, regulatory-compliant workflows, and data analytics solutions to accelerate discovery in pharmaceutical and clinical research. My work integrates biostatistics, epidemiology, and CDISC standards to deliver insights for clinical trials and regulatory submissions.\n\nüîç View Projects üì¨ Work With Me\n\nWith a background in epidemiology, biostatistics, and SAS clinical programming, I specialize in building CDISC-compliant solutions that accelerate pharmaceutical research. My work bridges statistical analysis, regulatory standards, and real-world evidence, supporting both academic research and industry applications.\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician, Data Scientist & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "index.html#about-ousmane-diallo",
    "href": "index.html#about-ousmane-diallo",
    "title": "Ousmane Diallo ‚Äì Portfolio",
    "section": "About Ousmane Diallo",
    "text": "About Ousmane Diallo\n\nOusmane Diallo is a rigorous biostatistician and epidemiologist specializing in health data analytics, statistical modeling, CDISC standards, and real-world evidence (RWE). With over 9 years of experience, he collaborates with academic researchers, pharmaceutical teams, and international health organizations to design regulatory-compliant analyses, reproducible workflows, and evidence-based solutions. His work connects biostatistics with clinical research and regulatory science, supporting discovery in both academia and industry."
  },
  {
    "objectID": "index.html#professional-credentials",
    "href": "index.html#professional-credentials",
    "title": "Ousmane Diallo ‚Äì Portfolio",
    "section": "Professional Credentials",
    "text": "Professional Credentials\n\nüéì PhD in Infectious disease, Aix Marseille University\n‚öôÔ∏è Research Assistant Professor in Health Data Analytics & Statistical Modeling, Northwestern University\nüß¨ Postdoctoral Researcher in  in Health Data Analytics & Statistical Modeling, Northwestern University"
  },
  {
    "objectID": "index.html#key-projects-achievements",
    "href": "index.html#key-projects-achievements",
    "title": "Ousmane Diallo ‚Äì Portfolio",
    "section": "Key Projects & Achievements",
    "text": "Key Projects & Achievements\n\nüîó Developed end-to-end CDISC workflows for regulatory submissions in pharmaceutical research\nüï∏ Led geospatial analysis projects for malaria surveillance and intervention targeting across West Africa\nü¶† Implemented statistical modeling pipelines for real-world evidence studies and observational research\nüìÇ Open-source workflows and reproducible analyses available on GitHub\n\nReady to accelerate your clinical research with regulatory-compliant insights?\nüëâ Contact Me to discuss collaborations or consulting opportunities."
  },
  {
    "objectID": "index.html#frequently-asked-questions",
    "href": "index.html#frequently-asked-questions",
    "title": "Ousmane Diallo ‚Äì Portfolio",
    "section": "Frequently Asked Questions",
    "text": "Frequently Asked Questions\n\n\n\nWhat types of projects do you specialize in?\n\n\nI specialize in clinical research projects, collaborating with pharmaceutical companies, academic institutions, and health organizations. My expertise includes CDISC implementation, statistical analysis for clinical trials, real-world evidence studies, and regulatory submission support across both industry and academic settings.\n\n\n\n\nWhat kind of data do you analyze?\n\n\nAs a biostatistician and epidemiologist, I work with clinical trial data, real-world evidence datasets, health surveillance data, and complex survey data requiring advanced statistical methods for analysis. I also develop CDISC-compliant datasets (SDTM/ADaM) and create regulatory submission packages. I work at all stages of the research process, from study design to final reporting.\n\n\n\n\nDo you offer training or consulting?\n\n\nYes! I provide mentorship and consulting in biostatistics, SAS programming, and CDISC standards for students and research teams. I also offer training in clinical trials programming, statistical analysis plans, and regulatory compliance workflows.\n\n\n\n\nWhere are you based and available for work?\n\n\nI am actively seeking Biostatistician, RWE Epidemiologist and Data Scientist positions in the pharmaceutical industry. I‚Äôm available for remote work and relocation opportunities worldwide, with experience in international collaborations."
  },
  {
    "objectID": "index.html#quick-facts",
    "href": "index.html#quick-facts",
    "title": "Ousmane Diallo ‚Äì Portfolio",
    "section": "Quick Facts",
    "text": "Quick Facts\n\n\n\n\nAttribute\nDetail\n\n\n\n\nName\nOusmane Diallo\n\n\nSpecialization\nBiostatistics, Epidemiology, HEOR, CDISC Standards\n\n\nExperience\n9+ years in health data analytics & statistical modeling\n\n\nCertifications\nSAS Base Programming & Clinical Trials Programming\n\n\nIndustry Focus\nPharmaceutical, Clinical Research, Regulatory Science\n\n\nSkills\nSAS, R, Python, CDISC (SDTM/ADaM), Statistical Modeling, RWE\n\n\nAvailability\nSeeking clinical biostatistician & statistical programmer roles\n\n\nPortfolio\nView Projects"
  },
  {
    "objectID": "index.html#core-competencies-1",
    "href": "index.html#core-competencies-1",
    "title": "Ousmane Diallo, MPH-PhD",
    "section": "Core Competencies",
    "text": "Core Competencies\n\n\nüíª Programming - SAS (Base & Clinical Trials Certified) - R (tidyverse, survival, spatial) - Python ‚Ä¢ Quarto ‚Ä¢ GitHub\n\n\nüè• Clinical Standards - CDISC (SDTM, ADaM, define.xml) - Clinical Trials Programming - Statistical Analysis Plans (SAPs) - GCP/ICH Compliance\n\n\nüìä Analytics - Statistical Modeling (GLM, Survival) - Real-World Evidence (RWE) - Geospatial Analysis - Complex Survey Data\n\n\nüåç Professional - International Projects - Cross-Functional Collaboration - Training & Mentorship - Quality Control & Validation"
  },
  {
    "objectID": "projects/microstratification-conakry.html",
    "href": "projects/microstratification-conakry.html",
    "title": "Microstratification in Conakry",
    "section": "",
    "text": "Period: 2023‚Äì2024\nRole: Lead Analyst\n\nContext & Objective\nDeveloped an urban micro-stratification framework to sharpen targeting in Conakry.\n\n\nMethods & Tools\n\nSpatial clustering\nUrban risk mapping\n\n\n\nKey Deliverables\n\nMicrostratification maps\nOperational guidance\n\n\n\nImpact\nEnhanced precision of urban malaria interventions.\n\nLinks:\n- Code: to be added\n- Report/Publication: to be added\n- Contact: Email"
  },
  {
    "objectID": "portfolio.html#core-expertise-areas",
    "href": "portfolio.html#core-expertise-areas",
    "title": "Key Projects",
    "section": "",
    "text": "üìä Statistical Modeling\nAdvanced analytics for policy guidance and decision-making\n\n\nüó∫Ô∏è Geospatial Analytics\nSpatial analysis and visualization for health surveillance\n\n\nüè• Clinical Programming\nCDISC-compliant workflows for regulatory submissions\n\n\nüë®‚Äçüè´ Capacity Building\nTraining and mentorship for graduate students and teams"
  },
  {
    "objectID": "portfolio.html#ready-to-collaborate",
    "href": "portfolio.html#ready-to-collaborate",
    "title": "Key Projects",
    "section": "",
    "text": "I bring proven expertise in both academic epidemiology and industry-standard clinical programming. My work spans from complex survey analysis in resource-limited settings to regulatory-compliant CDISC implementations for pharmaceutical submissions.\nLooking for: Clinical Biostatistician ‚Ä¢ Statistical Programmer ‚Ä¢ Senior Data Scientist roles\nüìß Let‚Äôs Connect"
  },
  {
    "objectID": "itn-ownership-use-guinea-dhs2018.html",
    "href": "itn-ownership-use-guinea-dhs2018.html",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "Period: 2021‚Äì2022 ¬∑ Role: Lead Data Analyst ¬∑ Country: Guinea\n\n\n\nAnalysis of the 2018 Guinea Demographic and Health Survey (DHS) to identify determinants of ownership and use of insecticide-treated nets (ITNs) at both household and individual levels. Understanding the factors influencing household ITN ownership and usage among those with access will enable the Guinea National Malaria Control Programme to design targeted interventions aimed at increasing bed net coverage and utilization.\n\n\n\n\nMain variables: wealth quintiles, education level, urban/rural setting, Age of household head, Age of individual, Sex of household head, Sex of individual, Household size, Number of rooms, Marital status, Children under five, Pregnant status, Region.\nTwo main outcomes: ITN ownership and ITN use the previous night (among those with access).\nAccounted for complex survey design: weights, strata, and clusters.\n\n\n\n\nSurvey-weighted logistic regression models were implemented in R (survey, srvyr, dplyr, ggplot2, tmap) to estimate adjusted odds ratios and visualize disparities.\n\n\n\n\nTables and figures for manuscript and policy brief.\nFully reproducible R scripts (data cleaning, indicator generation, modeling).\n\n\n\n\n\nEvidence to better target priority groups in ITN distribution campaigns.\nRecommendations to tailor behavior change communication messages.\n\n\n\n\n![ITN Usage]({{ ‚Äú/assets/projects/itn/Fichier_8.png‚Äù | relative_url }}) Regional variation in Guinea of A household ITN ownership; B proportion of the population with access to an ITN; C ITN usage; and D ITN usage among those with access.\n![ITN Usage Map]({{ ‚Äú/assets/projects/itn/two_dimensionel.png‚Äù | relative_url }}) Two-dimensional histogram showing the number of people who could use nets owned by the household if all nets were in use, stratified by household size, in the 2018 Guinea DHS."
  },
  {
    "objectID": "itn-ownership-use-guinea-dhs2018.html#overview",
    "href": "itn-ownership-use-guinea-dhs2018.html#overview",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "Analysis of the 2018 Guinea Demographic and Health Survey (DHS) to identify determinants of ownership and use of insecticide-treated nets (ITNs) at both household and individual levels. Understanding the factors influencing household ITN ownership and usage among those with access will enable the Guinea National Malaria Control Programme to design targeted interventions aimed at increasing bed net coverage and utilization."
  },
  {
    "objectID": "itn-ownership-use-guinea-dhs2018.html#key-highlights",
    "href": "itn-ownership-use-guinea-dhs2018.html#key-highlights",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "Main variables: wealth quintiles, education level, urban/rural setting, Age of household head, Age of individual, Sex of household head, Sex of individual, Household size, Number of rooms, Marital status, Children under five, Pregnant status, Region.\nTwo main outcomes: ITN ownership and ITN use the previous night (among those with access).\nAccounted for complex survey design: weights, strata, and clusters."
  },
  {
    "objectID": "itn-ownership-use-guinea-dhs2018.html#methods-tools",
    "href": "itn-ownership-use-guinea-dhs2018.html#methods-tools",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "Survey-weighted logistic regression models were implemented in R (survey, srvyr, dplyr, ggplot2, tmap) to estimate adjusted odds ratios and visualize disparities."
  },
  {
    "objectID": "itn-ownership-use-guinea-dhs2018.html#deliverables",
    "href": "itn-ownership-use-guinea-dhs2018.html#deliverables",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "Tables and figures for manuscript and policy brief.\nFully reproducible R scripts (data cleaning, indicator generation, modeling)."
  },
  {
    "objectID": "itn-ownership-use-guinea-dhs2018.html#impact",
    "href": "itn-ownership-use-guinea-dhs2018.html#impact",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "Evidence to better target priority groups in ITN distribution campaigns.\nRecommendations to tailor behavior change communication messages."
  },
  {
    "objectID": "itn-ownership-use-guinea-dhs2018.html#visual-highlights",
    "href": "itn-ownership-use-guinea-dhs2018.html#visual-highlights",
    "title": "Risk Factors ‚Äì ITN Guinea DHS 2018",
    "section": "",
    "text": "![ITN Usage]({{ ‚Äú/assets/projects/itn/Fichier_8.png‚Äù | relative_url }}) Regional variation in Guinea of A household ITN ownership; B proportion of the population with access to an ITN; C ITN usage; and D ITN usage among those with access.\n![ITN Usage Map]({{ ‚Äú/assets/projects/itn/two_dimensionel.png‚Äù | relative_url }}) Two-dimensional histogram showing the number of people who could use nets owned by the household if all nets were in use, stratified by household size, in the 2018 Guinea DHS."
  },
  {
    "objectID": "cdisc-sdtm-test.html",
    "href": "cdisc-sdtm-test.html",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "Automatisation de la cr√©ation de tables SDTM DM & SUPPDM (CDISC) via une approche pilot√©e par m√©tadonn√©es (SAS OnDemand).\n\n\n\n&lt;span class=\"badge\"&gt;SAS OnDemand 9.4&lt;/span&gt;\n&lt;span class=\"badge\"&gt;SDTM IG 3.4&lt;/span&gt;\n&lt;span class=\"badge\"&gt;DM + SUPPDM&lt;/span&gt;\n&lt;span class=\"badge\"&gt;Metadata-driven&lt;/span&gt;"
  },
  {
    "objectID": "cdisc-sdtm-test.html#overview",
    "href": "cdisc-sdtm-test.html#overview",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "Overview",
    "text": "Overview\nGoal ‚Äî Construire SDTM DM (1 enregistrement / sujet) et SUPPDM (qualificateurs non standards) depuis des tables sources, en : 1) cr√©ant des coquilles vides depuis un CSV de m√©tadonn√©es,\n2) mappant et d√©rivant les variables SDTM,\n3) appliquant formats / tri et export vers la lib TARGET.\nOutputs ‚Äî TARGET.DM et TARGET.SUPPDM conformes SDTM, valid√©s par PROC CONTENTS et contr√¥les structurels.\n\n\n\n\n\n\nNote\n\n\n\nId√©e-cl√© : metadata ‚Üí EMPTY_DM ‚Üí mapping/derivations ‚Üí sort/order ‚Üí TARGET."
  },
  {
    "objectID": "cdisc-sdtm-test.html#inputs",
    "href": "cdisc-sdtm-test.html#inputs",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "Inputs",
    "text": "Inputs\n\nMetadata CSV ‚Äî SDTM_METADATA1.csv (variables, types, longueurs, labels, r√¥les, cl√©s).\nDonn√©es sources (libref SOURCE)\n\nSOURCE.DEMOGRAPHIC (ex. subject, dob, gender, trt, uniqueid)\n\nSOURCE.DOSING (ex. subject, startdt, enddt)\n\nFormats (libref LIB)\n\nsex_demographic_gender., race_demographic_race., armcd_demographic_trt., $arm_demographic_trt.\n\nCible (libref TARGET) ‚Äî contiendra DM et SUPPDM\nMacros ‚Äî %make_empty_dataset et %make_sort_order (inclues via common.sas)\n\n\nSAS OnDemand : d√©finir libname source, libname lib, libname target dans appendix/common.sas.\nEx√©cuter %include en t√™te de job."
  },
  {
    "objectID": "cdisc-sdtm-test.html#library-setup",
    "href": "cdisc-sdtm-test.html#library-setup",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "1) Library Setup",
    "text": "1) Library Setup\n\n\nAfficher/Masquer le code\n\n```sas /* Common paths & librefs / %include ‚Äú/home/uXXXXXX/CDISC/appendix/common.sas‚Äù; / Attendu dans common.sas : libname source ‚Äú/home/uXXXXXX/CDISC/data‚Äù; libname lib ‚Äú/home/uXXXXXX/CDISC/formats‚Äù; libname target ‚Äú/home/uXXXXXX/CDISC/sdtm‚Äù; */ options fmtsearch=(lib work);"
  },
  {
    "objectID": "subnational-tailoring-guinea.html",
    "href": "subnational-tailoring-guinea.html",
    "title": "Predicting the Impact of Subnational Tailoring of Interventions in Guinea",
    "section": "",
    "text": "Period: 2020‚Äì2021\nRole: Lead Modeler & Data Analyst\n\nContext & Objective\nModeled malaria intervention scenarios to guide national planning and resource allocation in Guinea.\n\n\nMethods & Tools\n\nEMOD malaria model\nR (data wrangling, visualization)\nGIS risk mapping\n\n\n\nKey Deliverables\n\nScenario models and reports for NMCP\nMaps and decision briefs\n\n\n\nImpact\nSupported subnational targeting and resource allocation decisions.\n\nLinks:\n- Code: to be added\n- Report/Publication: to be added\n- Contact: Email"
  },
  {
    "objectID": "cdisc-sdtm-adam-tlf.html",
    "href": "cdisc-sdtm-adam-tlf.html",
    "title": "End-to-end CDISC Workflow (Mock Study)",
    "section": "",
    "text": "This portfolio project shows an end-to-end CDISC pipeline implemented in SAS OnDemand: curation of raw-like sources ‚Üí SDTM domains ‚Üí ADaM analysis datasets ‚Üí TLFs (tables/listings/figures).\nRepo: https://github.com/Ousmanerabi/clinical-trials-programming-portfolio\n\n\n\nObjective: produce regulatory-ready data flow (SDTM ‚Üí ADaM ‚Üí TLF) for a mock clinical study.\nStack: SAS (OnDemand), CDISC SDTM & ADaM principles.\nWhat you‚Äôll see here: a concise walkthrough, code excerpts, and links to the full programs and outputs.\n\n\n\n\n\n\n\nNote\n\n\n\nWhy a mock study?\nTo demonstrate real-world clinical programming skills without sharing proprietary datasets, while following CDISC conventions and good programming practices.\n\n\n\n\nInputs: synthetic/raw-like CSV/XLSX files and SAS datasets stored in the repo (for demonstration).\nStudy artifacts: trial design shells and example CRF mapping logic where needed.\nOutputs: SDTM domains (e.g., DM, AE, EX, VS), then ADaM datasets (e.g., ADSL, ADAE), and selected TLFs.\n\nRepository layout (key folders)\nclinical-trials-programming-portfolio/ 01_RAW/ # raw-like inputs (csv/xlsx/sas7bdat)\n02_SDTM/\nprograms/ # SAS programs (domain-specific)\nout/ # SDTM outputs (sas7bdat/preview png)\n03_ADaM/\nprograms/ # SAS programs (ADSL, ADAE, etc.)\nout/ # ADaM outputs\n04_TLF/\nprograms/ # TLF SAS code (tables, listings, figures)\nout/ # rendered artefacts (rtf/pdf/png)\ndocs/ # helper docs (specs, trial design)"
  },
  {
    "objectID": "cdisc-sdtm-adam-tlf.html#sdtm-study-data-tabulation-model",
    "href": "cdisc-sdtm-adam-tlf.html#sdtm-study-data-tabulation-model",
    "title": "End-to-end CDISC Workflow (Mock Study)",
    "section": "SDTM (Study Data Tabulation Model)",
    "text": "SDTM (Study Data Tabulation Model)\nGoal: create standardized, submission-ready domains that mirror CRF content and study design.\nHighlights - Patient key: USUBJID built from STUDYID + subject identifier.\n- Controlled terminology & value-level mapping (e.g., SEX, ARM, AESER).\n- Date handling (partial dates), label/length alignment.\nExample ‚Äî DM (Demography) derivation (excerpt)\n/* 02_SDTM/programs/sdtm_dm.sas */ \n\ndata sdtm.dm(label=\"Demographics\"); \n\nset raw.demography; \n\nlength STUDYID $12 USUBJID $40 DOMAIN $2 ARM $20 ARMCD $8 SEX $1 AGEU $5; \n\nDOMAIN = \"DM\"; \n\nUSUBJID = catx(\"-\", STUDYID, put(SUBJID, z4.)); \n\nAGEU = \"YEARS\"; \n\n/* ‚Ä¶ additional recodes / controlled terms ‚Ä¶ */\n\n keep STUDYID DOMAIN USUBJID SUBJID SEX AGE AGEU ARM ARMCD; run;\n\nproc sort data=sdtm.dm; by USUBJID; \n\nrun;\n\nFull program: https://github.com/Ousmanerabi/clinical-trials-programming-portfolio/tree/main/02_SDTM/programs\nSDTM outputs: https://github.com/Ousmanerabi/clinical-trials-programming-portfolio/tree/main/02_SDTM/out\n\n\nQuality gates (SDTM): uniqueness of USUBJID, required variables by domain, controlled codes, and basic cross-domain checks (e.g., DM vs AE subject coverage)."
  },
  {
    "objectID": "retrospective-trend-burkina.html",
    "href": "retrospective-trend-burkina.html",
    "title": "Retrospective Analysis of Malaria Trend in Burkina Faso",
    "section": "",
    "text": "Period: 2023‚Äì2024\nRole: Data Scientist\n\nContext & Objective\nTime-series analysis of malaria incidence from routine health information systems.\n\n\nMethods & Tools\n\nSeasonal decomposition\nChangepoint detection\nForecasting\n\n\n\nKey Deliverables\n\nTrend analysis report\nReproducible scripts\n\n\n\nImpact\nIdentified high-risk periods to support timely response.\n\nLinks:\n- Code: to be added\n- Report/Publication: to be added\n- Contact: Email"
  },
  {
    "objectID": "snt-stratification-targeting.html",
    "href": "snt-stratification-targeting.html",
    "title": "Data Management, Stratification & Intervention Targeting (Togo, Guinea, Burkina Faso)",
    "section": "",
    "text": "Period: 2023\nRole: Technical Lead ‚Äì Data Integration & Analytics\n\nContext & Objective\nBuilt stratification frameworks from routine data to optimize intervention targeting across countries.\n\n\nMethods & Tools\n\nETL of routine health data\nRisk stratification\nGIS mapping\n\n\n\nKey Deliverables\n\nStratification maps\nTargeting plans and briefs\n\n\n\nImpact\nImproved precision of intervention delivery at subnational level.\n\nLinks:\n- Code: to be added\n- Report/Publication: to be added\n- Contact: Email"
  },
  {
    "objectID": "index.html#thematic-areas",
    "href": "index.html#thematic-areas",
    "title": "Key Projects (2020‚Äì2025)",
    "section": "Thematic Areas",
    "text": "Thematic Areas\n\nModeling: Scenario modeling to guide policy.\n\nAnalytics: Statistical and geospatial analysis for decision-making.\n\nSNT Support: Data pipelines, stratification, and intervention targeting.\n\nTraining: Capacity building for graduate students."
  },
  {
    "objectID": "index.html#r-epidemiology-projects",
    "href": "index.html#r-epidemiology-projects",
    "title": "Key Projects (2020‚Äì2025)",
    "section": "R & Epidemiology Projects",
    "text": "R & Epidemiology Projects\n\n\nRisk Factors ‚Äì ITN Guinea DHS 2018\n\n2021‚Äì2022\n\n\n\nRetrospective Analysis of Malaria Trend in Burkina Faso\n\n2023‚Äì2024\n\n\n\nData Management, Stratification & Intervention Targeting (Togo, Guinea, Burkina Faso)\n\n2023\n\n\n\nMicrostratification in Conakry\n\n2023‚Äì2024\n\n\n\nTraining & Mentorship (Graduate Students ‚Äì Benin & Guinea)\n\n2020‚Äì2024"
  },
  {
    "objectID": "index.html#cdisc-sas-clinical-programming",
    "href": "index.html#cdisc-sas-clinical-programming",
    "title": "Key Projects (2020‚Äì2025)",
    "section": "CDISC & SAS Clinical Programming",
    "text": "CDISC & SAS Clinical Programming\n\n\ndefine.xml Generation & Validation Workflow\n\n2025\n\n\n\nEnd-to-end Study Data Tabulation Model\n\n2025\n\n\n\nADaM BDS Derivations for Efficacy & Safety\n\n2025"
  },
  {
    "objectID": "portfolio.html#cdisc-regulatory-programming",
    "href": "portfolio.html#cdisc-regulatory-programming",
    "title": "Projects",
    "section": "",
    "text": "Industry-standard clinical programming and regulatory-compliant datasets for pharmaceutical submissions\nEnd-to-end Study Data Tabulation Model\nADaM BDS Derivations for Efficacy & Safety\nTables Listings and Figures\ndefine.xml Generation & Validation Workflow"
  },
  {
    "objectID": "portfolio.html#geospatial-analysis-epidemiology",
    "href": "portfolio.html#geospatial-analysis-epidemiology",
    "title": "Portfolio",
    "section": "üó∫Ô∏è Geospatial Analysis & Epidemiology",
    "text": "üó∫Ô∏è Geospatial Analysis & Epidemiology\nSpatial and spatio-temporal modeling for malaria surveillance and intervention planning.\nHere, I use geospatial methods and epidemiological modeling to understand how disease risk and intervention coverage vary across space and time.\n\nFeatured Projects\nüîπ Risk Factors ‚Äì ITN Use in Guinea (DHS 2018)\nüîπ Spatio-temporal Modeling of Treatment-Seeking Coverage Using DHS Data and INLA\nüîπ Retrospective Analysis of Malaria Trends in Burkina Faso\nKey themes include:\n\nSpatial risk mapping and cluster detection\n\nLinking survey, facility, and environmental data\n\nSupporting targeted intervention strategies"
  },
  {
    "objectID": "portfolio.html#data-management-multi-country-studies",
    "href": "portfolio.html#data-management-multi-country-studies",
    "title": "Projects",
    "section": "",
    "text": "Complex data integration and cross-national research coordination\nData Management, Stratification & Intervention Targeting (Togo, Guinea, Burkina Faso)\nComplex Survey Data Analysis with R"
  },
  {
    "objectID": "portfolio.html#statistical-modeling-real-world-evidence",
    "href": "portfolio.html#statistical-modeling-real-world-evidence",
    "title": "Projects",
    "section": "",
    "text": "Advanced analytics and evidence generation for clinical decision-making\nPatient-level risk factors for clinical malaria among children aged 2‚Äì60 months\nHospital mortality and positive blood culture with Difficult-to threat, Marseille, France\nMajor discrepancy between factual AR and consumption in south of France"
  },
  {
    "objectID": "portfolio.html#capacity-building-training",
    "href": "portfolio.html#capacity-building-training",
    "title": "Projects",
    "section": "",
    "text": "Graduate student mentorship and institutional capacity development\nTraining & Mentorship (Graduate Students ‚Äì Benin & Guinea)\n\nInterested in collaborating on biostatistics, epidemiology, or clinical programming projects? Contact me to discuss opportunities."
  },
  {
    "objectID": "test.html",
    "href": "test.html",
    "title": "Test Page",
    "section": "",
    "text": "Some text here."
  },
  {
    "objectID": "test.html#this-is-h2",
    "href": "test.html#this-is-h2",
    "title": "Test Page",
    "section": "",
    "text": "Some text here."
  },
  {
    "objectID": "projects/risk_factors.html#methodology",
    "href": "projects/risk_factors.html#methodology",
    "title": "Risk Factors of ITN Ownership and Use ‚Äì Guinea DHS 2018",
    "section": "Methodology",
    "text": "Methodology\n\nStudy Design\n\nData Source: Guinea DHS 2018 (nationally representative)\nStudy Population: Households and individuals across Guinea‚Äôs administrative regions\nAnalytical Approach: Multi-level logistic regression with survey weights\n\n\n\nKey Variables Analyzed\nOutcomes:\n\nITN ownership at household level\nITN usage the previous night (among those with access) at individual-level\n\nPredictors:\n\nSocioeconomic: Wealth quintiles, education level, household size\nDemographic: Age and sex of household head, marital status, pregnancy status\nGeographic: Urban/rural residence, administrative region\nStructural: Number of rooms, presence of children under 5\n\n\n\nStatistical Methods\nComplex Survey Design Adjustment:\n\nSurvey weights applied for population representativeness\nStratification and clustering accounted for in variance estimation\nDesign effects calculated for precision assessment\n\nAnalytical Framework:\n\n\nView code\n## Install and charge the survey design library\n\nlibrary(survey)\n\n## \n# Survey design specification\n\ndesign_sample &lt;- svydesign(\n  ids = ~hv021, \n  strata = ~hv022, \n  weights = ~wt,\n  num_p=1,\n  nest = T,\n  data = hh_ex\n)\n\n## Bivariate analysis\n\nexplanatory_vars &lt;- c(\"wealth\", \"sex\", \"urb\", \"Num_childre\", \"region\", \"rooms\", \"hh_size\", \"Edu\", \"head_age\", \"Marital\")\n\nfor(i in 1:length(explanatory_vars)){\n  col = explanatory_vars[i]\n  tbl &lt;- survey::svytable(~HH_at_least_one + col, design_sample_hh)\n  t = summary(tbl, statistic=\"Chisq\")\n  t = plyr::ldply(t)\n}\n\n\n## Univariate analysis of different risk factors for ITN ownership at the country level \n\nmodels &lt;- explanatory_vars %&gt;%      \n  stringr::str_c(\"HH_at_least_one ~ \", .) %&gt;%      \n  \n  # iterate through each univariate formula\n  purrr::map(                               \n    .f = ~survey::svyglm(                      \n      formula = as.formula(.x),      \n      family = \"binomial\",           \n      design = design_sample_hh)) %&gt;%       \n  \n\n  purrr::map(\n    .f = ~broom::tidy(\n      .x, \n      exponentiate = TRUE,           \n      conf.int = TRUE)) %&gt;%         \n  \n \n  dplyr::bind_rows() %&gt;% \n  \n  dplyr::mutate(across(where(is.numeric), round, digits = 2))"
  },
  {
    "objectID": "projects/risk_factors.html#statistical-methods",
    "href": "projects/risk_factors.html#statistical-methods",
    "title": "Risk Factors of ITN Ownership and Use ‚Äì Guinea DHS 2018",
    "section": "",
    "text": "**Complex Survey Design Adjustment**: - Survey weights applied for population representativeness - Stratification and clustering accounted for in variance estimation - Design effects calculated for precision assessment\n**Analytical Framework**:"
  },
  {
    "objectID": "projects/risk_factors.html#key-findings",
    "href": "projects/risk_factors.html#key-findings",
    "title": "Risk Factors of ITN Ownership and Use ‚Äì Guinea DHS 2018",
    "section": "Key Findings",
    "text": "Key Findings\n\nVisual Highlights\n\n\n\n\n\n\nRegional variation in Guinea of A household ITN ownership; B proportion of the population with access to an ITN; C ITN usage; and D ITN usage among those with access.\n\n\n\n\n\nTwo-dimensional histogram showing the number of people who could use nets owned by the household if all nets were in use, stratified by household size, in the 2018 Guinea DHS.\n\n\n\n\nITN Ownership Patterns\nGeographic Disparities:\n\nSignificant regional variation in ownership rates\nUrban-rural differentials identified\nHotspot mapping revealed priority intervention areas\n\nSocioeconomic Determinants:\n\nWealth quintile emerged as strongest predictor\nEducation level positively associated with ownership\nHousehold composition effects documented\n\n\n\nUsage Among Those with Access\nBehavioral Factors:\n\nGap identified between access and utilization\nIndividual-level characteristics influence usage patterns\nOpportunity for targeted behavior change interventions"
  },
  {
    "objectID": "projects/risk_factors.html#technical-implementation",
    "href": "projects/risk_factors.html#technical-implementation",
    "title": "Risk Factors of ITN Ownership and Use ‚Äì Guinea DHS 2018",
    "section": "Technical Implementation",
    "text": "Technical Implementation\n\nTools & Packages Used\n\nR Programming: survey, srvyr, dplyr, ggplot2\nGeospatial Analysis: tmap, sf for mapping\nReproducible Reporting: Quarto/R Markdown workflow\n\n\n\nData Management\n\nComplex survey data cleaning and validation\nMultiple imputation for missing data\nQuality control procedures implemented\n\n\n\nVisualization Approach\n\n\nView code\n# Example: Regional variation mapping\nlibrary(tmap)\nguinea_map &lt;- tm_shape(guinea_regions) +\n  tm_polygons(\"ITN_ownership\", \n              style = \"quantile\",\n              palette = \"Blues\",\n              title = \"ITN Ownership %\") +\n  tm_layout(title = \"Regional ITN Ownership Patterns\")"
  },
  {
    "objectID": "projects/risk_factors.html#impact-applications",
    "href": "projects/risk_factors.html#impact-applications",
    "title": "Risk Factors of ITN Ownership and Use ‚Äì Guinea DHS 2018",
    "section": "Impact & Applications",
    "text": "Impact & Applications\n\nPolicy Implications\n\nTargeted Distribution: Evidence-based identification of priority populations\nResource Allocation: Geographic prioritization for intervention funding\nProgram Design: Tailored approaches for different demographic groups\n\n\n\nPublic Health Impact\n\nInformed national malaria control strategy development\nEvidence for behavior change communication messaging\nBaseline data for intervention impact evaluation\n\n\n\nMethodological Contributions\n\nDemonstrated complex survey analysis best practices\nReproducible analytical workflow established\nTemplate for similar cross-sectional studies"
  },
  {
    "objectID": "projects/risk_factors.html#deliverables",
    "href": "projects/risk_factors.html#deliverables",
    "title": "Risk Factors of ITN Ownership and Use ‚Äì Guinea DHS 2018",
    "section": "Deliverables",
    "text": "Deliverables\nTechnical Outputs:\n\nComprehensive statistical analysis report\nInteractive geospatial visualizations\nReproducible R analysis code\nPolicy brief with actionable recommendations\n\nSkills Demonstrated:\n\nSurvey Methodology: Complex sampling design analysis\nStatistical Modeling: Multi-level logistic regression\nGeospatial Analysis: Regional disparity mapping\nReproducible Research: Version-controlled analytical workflows\nPolicy Translation: Research-to-practice communication"
  },
  {
    "objectID": "projects/risk_factors.html#code-repository",
    "href": "projects/risk_factors.html#code-repository",
    "title": "Risk Factors of ITN Ownership and Use ‚Äì Guinea DHS 2018",
    "section": "Code Repository",
    "text": "Code Repository\nReproducibility: Full analytical code and documentation available on https://github.com/Ousmanerabi/Risk_factors_ITN_Guinea_DHS_2018\nData Access: Analysis conducted on publicly available DHS data with appropriate use agreements"
  },
  {
    "objectID": "projects/risk_factors.html#collaboration",
    "href": "projects/risk_factors.html#collaboration",
    "title": "Risk Factors of ITN Ownership and Use ‚Äì Guinea DHS 2018",
    "section": "Collaboration",
    "text": "Collaboration\nProject Period: 2021-2022\nRole: Senior Research Scientist\nInstitution: Northwestern University\nFunding: Gates Fundation\n\nThis project demonstrates expertise in epidemiological research, complex survey analysis, and evidence-based public health recommendations using industry-standard statistical methods and reproducible research practices.*"
  },
  {
    "objectID": "projects/risk_factors.html#section-1",
    "href": "projects/risk_factors.html#section-1",
    "title": "Risk Factors of ITN Ownership and Use ‚Äì Guinea DHS 2018",
    "section": "",
    "text": "Deliverables\nTechnical Outputs:\n\nComprehensive statistical analysis report\nInteractive geospatial visualizations\nReproducible R analysis code\nPolicy brief with actionable recommendations\n\nSkills Demonstrated:\n\nSurvey Methodology: Complex sampling design analysis\nStatistical Modeling: Multi-level logistic regression\nGeospatial Analysis: Regional disparity mapping\nReproducible Research: Version-controlled analytical workflows\nPolicy Translation: Research-to-practice communication"
  },
  {
    "objectID": "projects/risk_factors.html#overview",
    "href": "projects/risk_factors.html#overview",
    "title": "Risk Factors of ITN Ownership and Use ‚Äì Guinea DHS 2018",
    "section": "Overview",
    "text": "Overview\nAnalysis of the 2018 Guinea Demographic and Health Survey (DHS) to identify determinants of ownership and use of insecticide-treated nets (ITNs) at both household and individual levels. Understanding the factors influencing household ITN ownership and usage among those with access will enable the Guinea National Malaria Control Programme to design targeted interventions aimed at increasing bed net coverage and utilization."
  },
  {
    "objectID": "projects/risk_factors.html#research-leadership-study-design",
    "href": "projects/risk_factors.html#research-leadership-study-design",
    "title": "Risk Factors of ITN Ownership and Use ‚Äì Guinea DHS 2018",
    "section": "Research Leadership & Study Design",
    "text": "Research Leadership & Study Design\nIndependent Research Initiative:\nConceived, designed, and executed comprehensive epidemiological analysis of ITN utilization patterns in Guinea using complex survey methodology. Led complete research lifecycle from study conceptualization through manuscript publication and policy dissemination.\nResearch Innovation:\nDeveloped analytical framework addressing both household-level ownership and individual-level usage patterns, incorporating complex survey design features often overlooked in DHS analyses. Published methodology serves as template for similar national-level studies."
  },
  {
    "objectID": "projects/risk_factors.html#research-impact-publications",
    "href": "projects/risk_factors.html#research-impact-publications",
    "title": "Risk Factors of ITN Ownership and Use ‚Äì Guinea DHS 2018",
    "section": "Research Impact & Publications",
    "text": "Research Impact & Publications\nScientific Contribution: This analysis was published as a peer-reviewed research article, contributing to the evidence base for malaria prevention strategies in West Africa. The methodology developed in this study has been referenced by subsequent DHS analyses in the region.\n\nThis project demonstrates expertise in epidemiological research, complex survey analysis, and evidence-based public health recommendations using industry-standard statistical methods and reproducible research practices.*"
  },
  {
    "objectID": "projects/retrospective_analysis.html",
    "href": "projects/retrospective_analysis.html",
    "title": "Time Series Analysis of Malaria Trends ‚Äî Burkina Faso (2016‚Äì2023)",
    "section": "",
    "text": "Project Role: Research Associate & Lead Author\nTimeline: 2016-2023 Analysis Period | 2023-2024\nStatus: Oral presentation at ASTMH 2024 (New Orleans) | Manuscript in preparation\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician, Data Scientist & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "projects/retrospective_analysis.html#overview",
    "href": "projects/retrospective_analysis.html#overview",
    "title": "Time Series Analysis of Malaria Trends ‚Äî Burkina Faso (2016‚Äì2023)",
    "section": "Overview",
    "text": "Overview\nThe aim of this study was to assess the malaria trends in Burkina Faso at the health district level to help understand the malaria transmission level between 2016 and 2023 and to determine the factors associated with malaria incidence to better understand the drivers of malaria in Burkina Faso. This analysis combined publicly available DHS/MIS and climate data with restricted HMIS surveillance data obtained from PNLP under data sharing agreement.\nRole: Sole author responsible for data cleaning, quality assessment, analysis, modeling, mapping, and reporting."
  },
  {
    "objectID": "projects/retrospective_analysis.html#methods",
    "href": "projects/retrospective_analysis.html#methods",
    "title": "Time Series Analysis of Malaria Trends ‚Äî Burkina Faso (2016‚Äì2023)",
    "section": "Methods",
    "text": "Methods\n\nData sources\n\n\n\n\n\n\n\n\n\n\nVariable\nDefinition\nSource\nTemporal\nPeriod\n\n\n\n\nSuspected cases\nClinical malaria suspicion (fever)\nHMIS\nMonthly\n2016‚Äì2023 (excl. 2019)\n\n\nTested cases\nReceived RDT or microscopy\nHMIS\nMonthly\n2016‚Äì2023\n\n\nConfirmed cases\nPositive RDT or microscopy\nHMIS\nMonthly\n2016‚Äì2023\n\n\nPresumed cases\nTreated without positive test\nHMIS\nMonthly\n2016‚Äì2023\n\n\nPopulation\nDistrict population\nHMIS\nAnnual (Monthy est)\n2016‚Äì2023\n\n\nTreatment-seeking (U5)\nPublic/private/no care\nDHS/MIS\nEvery 3 years\n2014, 2017‚Äì18, 2021\n\n\n\n\n\nData management\nI applied a standard data quality workflow before analysis:\n\nStandardized district and facility names across years.\nRemoved duplicates/inconsistencies; harmonized facility identifiers.\nClassified facility reporting activity (active vs.¬†inactive).\nDetected and imputed outliers using mean ¬± 3 SD, Median absolute deviation (MAD), and Interquartile range (IQR) rules.\nManaged missingness; validated reporting rates.\n\n\n\nIncidence adjustments\nCrude malaria incidence was calculated by dividing the number of reported confirmed cases for each health district and month by the district population and multiplying by 1000. Then, crude incidence was adjusted for each factor in accordance with the WHO framework.\n\n\nTrend quantification\n\nSTL decomposition (LOESS) to separate seasonal, trend, residual components.\nSen‚Äôs slope for monotonic trend magnitude.\nMann‚ÄìKendall test for trend significance (Œ± = 0.05).\n\n\n\nFactors associated with incidence\nOutcome: annual incidence adjusted for testing, reporting, treatment-seeking (Adjustment 3).\nCovariates (2016‚Äì2023): climate, Insecticide Treated nets access/use, Seasonal Malaria Chemoprevention coverage, stockouts (Rapid Diagnostic Test/ACT/IPTp).\nModel: Generalized Additive Models (GAMs) for nonlinear effects."
  },
  {
    "objectID": "projects/retrospective_analysis.html#key-deliverables",
    "href": "projects/retrospective_analysis.html#key-deliverables",
    "title": "Time Series Analysis of Malaria Trends ‚Äî Burkina Faso (2016‚Äì2023)",
    "section": "Key Deliverables",
    "text": "Key Deliverables\n\nMalaria burden estimated under four incidence definitions (2016‚Äì2023).\nTrend analysis (seasonal + long-term) by district for each incidence definition.\nSignificant covariates associated with adjusted incidence."
  },
  {
    "objectID": "projects/retrospective_analysis.html#visual-highlights",
    "href": "projects/retrospective_analysis.html#visual-highlights",
    "title": "Time Series Analysis of Malaria Trends ‚Äî Burkina Faso (2016‚Äì2023)",
    "section": "Visual Highlights",
    "text": "Visual Highlights\n\n1. Reporting rate\n\n\n\nFig. Monthly reporting rates per health district\n\n\n\n\n\n\n\n\nNote\n\n\n\nKey Insight: Data quality varied considerably from district to district. Some districts reported less than 50% during certain periods, which significantly skewed the crude incidence estimates.\n\n\n\n\n\n2. Incidence estimates\n\n\n\nFig. Incidence estimates following WHO framework. A-D: Temporal trend for the four incidences (crude incidence, incidence adjusted by testing rate, incidence adjusted by testing rate and reporting rate, incidence adjusted by testing rate, reporting rate and care-seeking rate; E-D: Spatial analysis for the four incidences from 2023.\n\n\n\n\n\n\n\n\nNote\n\n\n\nKey Insight: Crude incidence and Adjustment 1 were nearly identical across districts, reflecting strong case management policies that ensure treatment follows testing. However, Adjustments 2 and 3 revealed hidden burden: poor reporting completeness in 2023 inflated incidence in several northern and eastern districts, while accounting for care-seeking (Adjustment 3) added ~450 cases per 1,000 in Gorom-Gorom, Gaoua, Kaya, Boussouma, and Fada. This underscores the importance of integrating care-seeking behavior into malaria burden estimates.\n\n\n\n\n\n3. Malaria Incidence Trends\n\nSen‚Äôs slope coefficient (Mann kendall test)\n\n\n\nFig. Sen‚Äôs slope coefficient for the trend of malaria incidence adjusted for testing rate, weighted reporting rate and care-seeking rate; Gray color: not significant.\n\n\n\n\n\n\n\n\nNote\n\n\n\nKey Insight: Trend analysis (Mann-Kendall) of Adjustment 3 showed heterogeneity across districts: Gorom-Gorom, Sapone, and Kampti had significant upward trends, while 39 of 70 districts experienced significant declines, reflecting improved malaria control or reduced transmission in much of Burkina Faso"
  },
  {
    "objectID": "projects/retrospective_analysis.html#code-example",
    "href": "projects/retrospective_analysis.html#code-example",
    "title": "Time Series Analysis of Malaria Trends ‚Äî Burkina Faso (2016‚Äì2023)",
    "section": "Code example",
    "text": "Code example\n\nNormalize Function\nThis function standardizes the four malaria incidence indicators so they can be compared on the same scale across districts.\n\n\n\n\n\n\nTip\n\n\n\nReproducibility Note:\nAll analyses are fully reproducible in R. This snippet shows how indicators were normalized prior to trend analysis.\n\n\n\n\nCode\n## Function for normalize the four incidences rates (comparaison purpose)\ngetNormalized &lt;- function(vec) {\n  if (!is.numeric(vec) || all(is.na(vec))) {\n    warning(\"Input vector is non-numeric or all NA; returning original vector\")\n    return(vec)\n  } \n  vec_mean &lt;- mean(vec, na.rm = TRUE) \n  vec_sd &lt;- sd(vec, na.rm = TRUE) \n  if (is.na(vec_sd) || vec_sd == 0) {\n    warning(\"Standard deviation is 0 or NA; returning original vector\")\n    return(vec)\n  }\n  (vec - vec_mean) / vec_sd \n}\n\n## Create new variables to use in the trend analysis\n\nmonthly_DS_incidence &lt;- monthly_DS_incide %&gt;%\n  dplyr::mutate(\n    mal_cases_norm = getNormalized(`Incidence brute`),\n    incidence_adj_presumed_cases_norm = getNormalized(Adj1),\n    incidence_adj_presumed_cases_RR_norm = getNormalized(Adj2),\n    incidence_adj_presumed_cases_RR_TSR_norm = getNormalized(Adj3)\n  )\n\n\n\n\nSTL Decomposition\nThis function decomposes the normalized time series into seasonal, trend, and remainder components, and applies Mann-Kendall and Sen‚Äôs slope tests to assess statistical significance.\n\n\n\n\n\n\nTip\n\n\n\nKey Insight:\nSTL decomposition helped disentangle seasonal variation from long-term malaria trends, allowing robust detection of increasing or decreasing trajectories at the district level.\n\n\n\n\nCode\n## STL decomposition\n\nSTL_result_DF_norm_list &lt;- list()\nindicators &lt;- list(\n  list(col = \"mal_cases_norm\", type = \"Crude Incidence\"),\n  list(col = \"incidence_adj_presumed_cases_norm\", type = \"Adjusted Presumed Cases\"),\n  list(col = \"incidence_adj_presumed_cases_RR_norm\", type = \"Adjusted Presumed Cases RR\"),\n  list(col = \"incidence_adj_presumed_cases_RR_TSR_norm\", type = \"Adjusted Presumed Cases RR TSR\")\n)\n\n## Monthly data\nmonthly_DS_incidence = monthly_DS_incidence \n\n## loop\nfor (DS in base::sort(base::unique(monthly_DS_incidence$districts))) {\n  cases_dist &lt;- monthly_DS_incidence %&gt;%\n    dplyr::filter(districts == DS) %&gt;%\n    dplyr::arrange(Date)\n  \n  if (nrow(cases_dist) == 0) {\n    warning(paste(\"No data for district:\", DS, \"- skipping\"))\n    next\n  }\n  \n  for (ind in indicators) {\n    if (!ind$col %in% names(cases_dist)) {\n      warning(paste(\"Column\", ind$col, \"not found in district\", DS, \"- skipping\"))\n      next\n    }\n    \n    ind_values &lt;- cases_dist[[ind$col]]\n    valid_idx &lt;- !is.na(ind_values)\n    valid_ind_norm &lt;- ind_values[valid_idx]\n    valid_dates &lt;- cases_dist$Date[valid_idx]\n    \n    if (length(valid_ind_norm) &lt; 2) {\n      warning(paste(\"Fewer than 2 valid observations for\", ind$col, \"in district\", DS, \"- skipping\"))\n      next\n    }\n    \n    start_year &lt;- base::as.numeric(format(valid_dates[1], \"%Y\"))\n    start_month &lt;- base::as.numeric(format(valid_dates[1], \"%m\"))\n    ind_ts &lt;- stats::ts(valid_ind_norm, start = c(start_year, start_month), deltat = 1/12)\n    ind_stl &lt;- stlplus::stlplus(ind_ts, s.window = \"periodic\")\n    \n    ind_stl_ts &lt;- base::as.data.frame(ind_stl$data[, 1:4])\n    ind_stl_ts$type &lt;- ind$type\n    ind_stl_ts$dates &lt;- valid_dates\n    ind_stl_ts$MK_p &lt;- trend::smk.test(ind_ts)$p.value\n    ind_stl_ts$sens_slope &lt;- trend::sea.sens.slope(ind_ts)\n    ind_stl_ts$District &lt;- DS\n    \n    STL_result_DF_norm_list[[base::paste(DS, ind$col, sep = \"_\")]] &lt;- ind_stl_ts\n  }\n}\n\nSTL_result_DF_norm &lt;- data.table::rbindlist(STL_result_DF_norm_list, fill = TRUE)\nSTL_result_DF_slopes &lt;- base::unique(STL_result_DF_norm[, c(\"type\", \"MK_p\", \"sens_slope\", \"District\")])"
  },
  {
    "objectID": "projects/retrospective_analysis.html#repository-reproducibility",
    "href": "projects/retrospective_analysis.html#repository-reproducibility",
    "title": "Time Series Analysis of Malaria Trends ‚Äî Burkina Faso (2016‚Äì2023)",
    "section": "Repository & Reproducibility",
    "text": "Repository & Reproducibility\n\nRepository: Full code\nData availability:\n\nPublic: DHS/MIS surveys, and CHIRPS climate data are fully open-access.\nRestricted: HMIS surveillance data (available under PNLP data sharing agreement).\nReproducibility: Complete analytical code provided for transparency"
  },
  {
    "objectID": "projects/retrospective_analysis.html#public-health-relevance",
    "href": "projects/retrospective_analysis.html#public-health-relevance",
    "title": "Time Series Analysis of Malaria Trends ‚Äî Burkina Faso (2016‚Äì2023)",
    "section": "Public Health Relevance",
    "text": "Public Health Relevance\n\nDemonstrated how data quality issues (reporting gaps, inactive facilities) bias malaria burden estimation.\nProvided robust adjusted incidence trends to better inform malaria control strategy in Burkina Faso.\nDelivered reproducible R workflow (cleaning, validation, modeling, mapping) for future NMCP analyses."
  },
  {
    "objectID": "projects/retrospective_analysis.html#methodology-framework",
    "href": "projects/retrospective_analysis.html#methodology-framework",
    "title": "Time Series Analysis of Malaria Trends ‚Äî Burkina Faso (2016‚Äì2023)",
    "section": "Methodology Framework",
    "text": "Methodology Framework\n\nData sources & Integration\n\n\n\n\n\n\n\n\n\n\nVariable\nDefinition\nSource\nTemporal\nPeriod\n\n\n\n\nSuspected cases\nClinical malaria suspicion (fever)\nHMIS\nMonthly\n2016‚Äì2023 (excl. 2019)\n\n\nTested cases\nReceived RDT or microscopy\nHMIS\nMonthly\n2016‚Äì2023\n\n\nConfirmed cases\nPositive RDT or microscopy\nHMIS\nMonthly\n2016‚Äì2023\n\n\nPresumed cases\nTreated without positive test\nHMIS\nMonthly\n2016‚Äì2023\n\n\nPopulation\nDistrict population\nHMIS\nAnnual (Monthy est)\n2016‚Äì2023\n\n\nTreatment-seeking (U5)\nPublic/private/no care\nDHS/MIS\nEvery 3 years\n2014, 2017‚Äì18, 2021\n\n\n\n\n\nData management\nA standard data quality workflow before analysis was applied:\n\nStandardized district and facility names across years.\nRemoved duplicates/inconsistencies; harmonized facility identifiers.\nClassified facility reporting activity (active vs.¬†inactive).\nDetected and imputed outliers using mean ¬± 3 SD, Median absolute deviation (MAD), and Interquartile range (IQR) rules.\nManaged missingness; validated reporting rates.\n\n\nQuality Control Workflow\n\n\nView code\n#| label: data-quality-workflow\n#| eval: false\n#| code-fold: true\n#| code-summary: \"View Data Quality Control Code\"\n\n# Classify HF activity (single implementation)\n\ninactive_threshold &lt;- 6\n\n# Function to classify HF\nclassify_activity_status &lt;- function(df, conf_col = \"conf\") {\n  df %&gt;%\n    dplyr::group_by(UID) %&gt;%\n    complete(\n      Date = seq(min(Date, na.rm = TRUE), max(Date, na.rm = TRUE), by = \"month\"),\n      fill = setNames(list(NA), conf_col)\n    ) %&gt;%\n    dplyr::filter(year(Date) != 2019) %&gt;%       \n    dplyr::arrange(Date, .by_group = TRUE) %&gt;%\n    dplyr::mutate(\n      temp_status   = if_else(is.na(.data[[conf_col]]) | .data[[conf_col]] == 0, \"inactive\", \"active\"),\n      active_status = zoo::na.locf(ifelse(temp_status == \"active\", temp_status, NA),\n                                   na.rm = FALSE, fromLast = FALSE, default = \"inactive\"),\n      rle_vals      = rle(temp_status),\n      run_len       = rep(rle_vals$lengths, rle_vals$lengths),\n      run_val       = rep(rle_vals$values,   rle_vals$lengths),\n      HF_status     = case_when(\n        all(temp_status == \"inactive\") ~ \"inactive\",\n        run_val == \"inactive\" & run_len &gt;= inactive_threshold ~ \"inactive\",\n        TRUE ~ active_status\n      )\n    ) %&gt;%\n    dplyr::ungroup() %&gt;%\n    dplyr::select(-temp_status, -active_status, -rle_vals, -run_len, -run_val)\n}\n\n\n\n\n\nIncidence adjustments\nCrude malaria incidence was calculated by dividing the number of reported confirmed cases for each health district and month by the district population and multiplying by 1000. Then, crude incidence was adjusted for each factor in accordance with the WHO framework.\nIncidence Adjustment Framework (WHO Guidelines):\n\nCrude: Raw confirmed cases / population √ó 1,000\nAdjustment 1: Account for testing rate variations\nAdjustment 2: Account for facility reporting completeness\nAdjustment 3: Account for care-seeking behavior patterns\n\n\n\nStatistical Analysis Methods\nTime Series Decomposition\n\nSTL decomposition (LOESS) to separate seasonal, trend, residual components.\nSen‚Äôs slope for monotonic trend magnitude.\nMann‚ÄìKendall test for trend significance (Œ± = 0.05).\n\n\n\nView STL Decomposition Implementation\n# Normalization helper\ngetNormalized &lt;- function(vec) {\n  if (!is.numeric(vec) || all(is.na(vec))) {\n    warning(\"Input vector is non-numeric or all NA; returning original vector\")\n    return(vec)\n  }\n  vec_mean &lt;- mean(vec, na.rm = TRUE)\n  vec_sd   &lt;- sd(vec,  na.rm = TRUE)\n  if (is.na(vec_sd) || vec_sd == 0) {\n    warning(\"Standard deviation is 0 or NA; returning original vector\")\n    return(vec)\n  }\n  (vec - vec_mean) / vec_sd\n}\n\nmonthly_DS_incidence &lt;- monthly_DS_incide %&gt;%\n  dplyr::mutate(\n    mal_cases_norm                            = getNormalized(`Incidence brute`),\n    incidence_adj_presumed_cases_norm         = getNormalized(Adj1),\n    incidence_adj_presumed_cases_RR_norm      = getNormalized(Adj2),\n    incidence_adj_presumed_cases_RR_TSR_norm  = getNormalized(Adj3)\n  )\n\n\n\n\nFactors associated with incidence\n\nModel Type: Generalized Additive Models (GAMs) for non-linear relationships\nCovariates: Climate variables, ITN coverage, SMC implementation, stockout indicators\nOutcome: Fully adjusted incidence (Adjustment 3)"
  },
  {
    "objectID": "projects/retrospective_analysis.html#key-findings-impact",
    "href": "projects/retrospective_analysis.html#key-findings-impact",
    "title": "Time Series Analysis of Malaria Trends ‚Äî Burkina Faso (2016‚Äì2023)",
    "section": "Key Findings & Impact",
    "text": "Key Findings & Impact\n\nData Quality Insights\n\n\n\nFig. Monthly reporting rates per health district\n\n\nKey Insight: Reporting completeness varied dramatically (50-100% across districts), with systematic gaps that biased crude incidence estimates. This finding led to policy recommendations for surveillance system strengthening.\n\n\n\nBurden Estimation Results\n\n\n\nFig. Incidence estimates following WHO framework. A-D: Temporal trend for the four incidences (crude incidence, incidence adjusted by testing rate, incidence adjusted by testing rate and reporting rate, incidence adjusted by testing rate, reporting rate and care-seeking rate; E-D: Spatial analysis for the four incidences from 2023.\n\n\nKey Insight:\n\nAdjustments 2 & 3 revealed hidden burden: Poor reporting in northern/eastern districts inflated true incidence\nCare-seeking adjustment critical: Added ~450 cases/1,000 in Gorom-Gorom, Gaoua, Kaya\nPolicy Impact: Demonstrated need for integrated care-seeking behavior in burden estimation\n\n\n\n\nTemporal Trend Analysis\n\n\n\n\n\nFig. Sen‚Äôs slope coefficient for the trend of malaria incidence adjusted for testing rate, weighted reporting rate and care-seeking rate; Gray color: not significant.\n\n\nKey Insight:\n\nIncreasing trends: Gorom-Gorom, Sapone, Kampti (climate/intervention factors)\nDeclining trends: 39 of 70 districts showed significant improvements\nSpatial clustering: Northern border regions showed persistent high transmission\n\n\n\n\nGAM mixed models analysis"
  },
  {
    "objectID": "projects/retrospective_analysis.html#technical-innovation-skills-demonstrated",
    "href": "projects/retrospective_analysis.html#technical-innovation-skills-demonstrated",
    "title": "Time Series Analysis of Malaria Trends ‚Äî Burkina Faso (2016‚Äì2023)",
    "section": "Technical Innovation & Skills Demonstrated",
    "text": "Technical Innovation & Skills Demonstrated\n\nAdvanced R Programming\n\nTime Series Analysis: STL decomposition, trend testing, forecasting\nSpatial Statistics: District-level mapping, spatial autocorrelation analysis\nData Pipeline: Automated quality control, validation, and reporting workflows\nReproducible Research: Version-controlled analysis with comprehensive documentation\n\n\n\nStatistical Methods Expertise\n\nGAM Modeling: Non-linear relationship detection between climate and incidence\nRobust Statistics: Multiple outlier detection methods (MAD, IQR, Z-score)\nSurvey Integration: Complex sampling design incorporation from DHS/MIS data\n\n\n\nPublic Health Applications\n\nSurveillance System Evaluation: Quantified data quality impacts on burden estimates\nPolicy Translation: Converted complex statistical findings into actionable recommendations\nIntervention Assessment: Evaluated ITN, SMC, and case management program effectiveness"
  },
  {
    "objectID": "projects/retrospective_analysis.html#deliverables-impact",
    "href": "projects/retrospective_analysis.html#deliverables-impact",
    "title": "Time Series Analysis of Malaria Trends ‚Äî Burkina Faso (2016‚Äì2023)",
    "section": "Deliverables & Impact",
    "text": "Deliverables & Impact\nTechnical Outputs:\n\nComprehensive R analytical pipeline (fully documented)\nInteractive dashboard for district-level monitoring\nPolicy brief for National Malaria Control Programme\nManuscript for peer-reviewed publication\n\nPolicy Impact:\n\nInformed 2024-2028 National Malaria Strategic Plan development\nGuided resource allocation for surveillance system strengthening\nProvided evidence base for targeted intervention deployment\n\nMethodological Contributions:\n\nEstablished best practices for HMIS data quality assessment\nDeveloped reproducible workflow for routine surveillance analysis\nCreated template for multi-country burden estimation studies"
  },
  {
    "objectID": "projects/retrospective_analysis.html#collaboration-leadership",
    "href": "projects/retrospective_analysis.html#collaboration-leadership",
    "title": "Time Series Analysis of Malaria Trends ‚Äî Burkina Faso (2016‚Äì2023)",
    "section": "Collaboration & Leadership",
    "text": "Collaboration & Leadership\nStakeholder Engagement:\n\nDirect collaboration with Burkina Faso National Malaria Control Programme\nWorld Health Organization\n\n\nThis project demonstrates expertise in epidemiological surveillance, advanced time series analysis, multi-source data integration, and evidence-based policy support using state-of-the-art statistical methods and reproducible research practices."
  },
  {
    "objectID": "projects/cdisc-sdtm.html#introduction",
    "href": "projects/cdisc-sdtm.html#introduction",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "Introduction",
    "text": "Introduction\nThe Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) is the regulatory standard for organizing and formatting clinical trial data for submission to health authorities like the FDA and EMA. This project demonstrates a metadata-driven approach to automate SDTM Demographics (DM) domain creation using SAS."
  },
  {
    "objectID": "projects/cdisc-sdtm.html#what-is-sdtm",
    "href": "projects/cdisc-sdtm.html#what-is-sdtm",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "What is SDTM?",
    "text": "What is SDTM?\nSDTM provides a standardized structure for clinical trial data that:\n\nEnsures consistency across studies and sponsors\nFacilitates regulatory review and approval processes\nEnables data integration and meta-analyses\nReduces submission timelines through standardization"
  },
  {
    "objectID": "projects/cdisc-sdtm.html#project-overview",
    "href": "projects/cdisc-sdtm.html#project-overview",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "Project Overview",
    "text": "Project Overview\n\nObjective\nBuild SDTM DM (Demographics) and SUPPDM datasets from raw clinical data using an automated, metadata-driven workflow that ensures CDISC compliance and reproducibility.\n\n\nKey Benefits\n\nMetadata-driven: Single source of truth for variable specifications\nReproducible: Standardized workflow across studies\nCompliant: Ensures CDISC SDTMIG v3.4 standards\nEfficient: Reduces manual programming errors\n\n\n\nTechnical Approach\nRaw Data ‚Üí Metadata ‚Üí Empty Shell ‚Üí Mapping ‚Üí Derivations ‚Üí Validation ‚Üí Export\n\n\nDeliverables\n\nTARGET.DM: One record per subject with demographics data\nTARGET.SUPPDM: Supplemental qualifiers for non-standard variables\nValidation Reports: QC checks ensuring data integrity\nData Inputs\nMetadata Specification:\n\nFile: SDTM_METADATA1.csv (variables, roles, lengths, types, sort keys).\n\nVariable definitions (names, types, lengths, labels)\nCDISC role classifications (Identifier, Timing, Qualifier)\nSort order specifications\n\n\nSource Data:\n\nSOURCE.DEMOGRAPHIC (1 row per subject, e.g., subject, dob, gender, trt, uniqueid)\nSOURCE.DOSING (e.g., subject, startdt, enddt)\n\nEnvironment Setup\n\nPlatform: SAS OnDemand 9.4\nLibraries: SOURCE (raw data), LIB (formats), TARGET (outputs)"
  },
  {
    "objectID": "projects/cdisc-sdtm.html#technical-implementation",
    "href": "projects/cdisc-sdtm.html#technical-implementation",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "Technical Implementation",
    "text": "Technical Implementation\n\n1. Library Setup\n```{sas}         \n/* Common paths & librefs */\n%include \"/home/u64197545/CDISC/appendix/common.sas\";\n/* expects:\n libname source \"/home/u64197545/CDISC/data\";\n libname library \"/home/u64197545/CDISC/formats\";\n libname target \"/home/u64197545/CDISC/sdtm\";\n*/\n\n\n2. Create EMPTY DM from Metadata\nThe make_empty_dataset macro creates dataset templates with proper CDISC attributes:\n```{sas}         \n/* Create empty based on metadata CSV */\n%macro make_empty_dataset(metadatafile=, dataset=);\n/* Import csv file and rename it _temp */\n    proc import datafile=\"&metadatafile\" out=_temp dbms=csv replace;\n        guessingrows=max;\n        delimiter=\";\";\n        encoding='utf-8';\n    run;\n\n    /* Sort the dataset by expected specified variable order (varnum) */\n    proc sort data=_temp;\n        where domain=\"&dataset\";\n        by varnum;\n    run;\n\n    /* Create keepstring macro variable and load metadata information into macro variables */\n    %global &dataset.KEEPSTRING;\n\n    data _null_;\n        set _temp nobs=nobs end=eof;\n        if _n_=1 then\n            call symput(\"vars\", compress(put(nobs, 3.)));\n        call symputx('var'    || compress(put(_n_, 3.)), variable);\n        call symputx('label'  || compress(put(_n_, 3.)), label);\n        call symputx('length' || compress(put(_n_, 3.)), put(length, 3.));\n        /* Valid ODM types include TEXT, INTEGER, FLOAT, DATETIME, DATE, TIME and map to SAS numeric or character */\n        if upcase(type) in (\"INTEGER\", \"FLOAT\") then\n            call symputx('type' || compress(put(_n_, 3.)), \"\");\n        else if upcase(type) in (\"TEXT\", \"DATE\", \"DATETIME\", \"TIME\") then\n            call symputx('type' || compress(put(_n_, 3.)), \"$\");\n        else\n            put \"ERR\" \"OR: not using a valid ODM type.  \" type=;\n        /* Create KEEPSTRING macro variable */\n        length keepstring $ 32767;\n        retain keepstring;\n        keepstring=compress(keepstring) || \"|\" || left(variable);\n        if eof then\n            call symputx(upcase(compress(\"&dataset\" || 'KEEPSTRING')), \n                left(trim(translate(keepstring, \" \", \"|\"))));\n    run;\n\n    /* Create a 0-observation template data set used for assigning variable attributes */\n    data EMPTY_&dataset;\n        %do i=1 %to &vars;\n            attrib &&var&i label=\"&&label&i\" \n            %if \"&&length&i\" ne \"\" %then\n                length=&&type&i.&&length&i...;\n            ;\n            %if &&type&i=$ %then\n                retain &&var&i '';\n            %else\n                retain &&var&i .;\n            ;\n        %end;\n        if 0;\n    run;\n%mend make_empty_dataset;\n\n/* Result: WORK.EMPTY_DM with 0 obs, all expected variables/attributes */\n\n\n3. STDM Variable Mapping\nSDTM DM variables are classified according to CDISC standards (SDTMIG v3.4):\n\n\n\n\n\n\n\n\nVariable Class\nExamples\nPurpose\n\n\n\n\nIdentifier\nSTUDYID, DOMAIN, USUBJID, SUBJID\nUnique subject identification\n\n\nTiming\nRFSTDTC, RFENDTC, BRTHDTC\nStudy and reference dates (ISO 8601)\n\n\nQualifier\nSEX, RACE, COUNTRY, AGE\nDemographic characteristics\n\n\nTreatment\nARMCD, ARM, ACTARM\nPlanned and actual treatments\n\n\n\n\n\n4. Controlled Terminology\n```{sas}         \n/* Creating custom format for the variables sex, race, arm, and armcd */\n\nproc format;\n    value sex 1='M' 2='F' .='U';\n    value race 1='White' 2='Black or African American' 3='Asian';\n    value armcd 0='PLACEBO' 1='ALG123';\n    value arm 0='Placebo' 1='Analgezia HCL 30mg';\nrun;\n\n\n5. Reference Date Derivation\nCalculate first and last dosing dates for study reference timing:\n```{sas}         \n/* Derive first/last dose per subject (RFSTDTC/RFENDTC) */\nproc sort \n  data=source.dosing(keep=subject startdt enddt) \n  out=dosing;\n   by subject startdt;\nrun;\n\ndata dosing;\n  set dosing; \n    by subject;\n    retain firstdose lastdose;\n  if first.subject then \n    do; \n       firstdose=.; \n       lastdose=.; \n    end;\n  firstdose = min(firstdose, startdt, enddt);\n  lastdose  = max(lastdose , startdt, enddt);\n  if last.subject;\nrun;\n\n\n6. Combine All Data\n```{sas}         \n/* Get demographics data */\nproc sort\n  data=source.demographic\n  out=demographic;\n    by subject;\nrun;\n\n/* Merge demographics and first dose date */\ndata demog_dose;\n  merge demographic\n        dosing;\n    by subject;\nrun;\n\n/* Derive the majority of SDTM DM variables */\noptions missing = ' ';\ndata dm;\n  set EMPTY_DM\n    demog_dose(rename=(race=_race));\n    studyid = 'XYZ123';\n    domain = 'DM';\n    usubjid = left(uniqueid);\n    subjid = put(subject,3.); \n    rfstdtc = put(firstdose,yymmdd10.);  \n    rfendtc = put(lastdose,yymmdd10.); \n    rfxstdtc = put(firstdose,yymmdd10.);  \n    rfxendtc = put(lastdose,yymmdd10.);\n    rficdtc = put(icdate,yymmdd10.);\n    rfpendtc = put(lastdoc,yymmdd10.);\n    dthfl = 'N';\n    siteid = substr(subjid,1,1) || \"00\";\n    brthdtc = put(dob,yymmdd10.);\n    age = floor ((intck('month',dob,firstdose) - \n          (day(firstdose) &lt; day(dob))) / 12);\n    if age ne . then\n      ageu = 'YEARS';\n    sex = put(gender,sex.);\n    race = put(_race,race.);\n    armcd = put(trt,armcd.);\n    arm = put(trt,arm.);\n    actarmcd = put(trt,armcd.);\n    actarm = put(trt,arm.);\n    country = \"USA\"; \nrun;\n\n\n7. Dataset Finalization\n```{sas}         \n/* Create sorting specification from metadata */\n\n%macro make_sort_order(metadatafile=, dataset=);\n    proc import datafile=\"&metadatafile\" out=_temp dbms=csv replace;\n        guessingrows=max;\n        delimiter=\";\";\n        encoding='utf-8';\n    run;\n\n    proc sort data=_temp;\n        where keysequence ne . and domain=\"&dataset\";\n        by keysequence;\n    run;\n\n    %global &dataset.SORTSTRING;\n    data _null_;\n        set _temp end=eof;\n        length domainkeys $ 200;\n        retain domainkeys '';\n        domainkeys=trim(domainkeys) || ' ' || trim(put(variable, 8.));\n        if eof then\n            call symputx(compress(\"&dataset\" || \"SORTSTRING\"), domainkeys);\n    run;\n%mend make_sort_order;\n\n/* Apply metadata-driven sorting and create final dataset */\n\n%make_sort_order(metadatafile=/home/u64197545/CDISC/Chap2/SDTM_METADATA1.csv,dataset=DM);\nproc sort\n  data=dm(keep = &DMKEEPSTRING)\n  out=target.dm;\n    by &DMSORTSTRING;\nrun;\n\n\nQuality Control & Validation\n\nAutomated QC Checks\n```{sas}         \n/* 1 record per USUBJID? */\nproc sql;\n  select usubjid, count(*) as n\n  from target.dm\n  group by usubjid\n  having calculated n &gt; 1;\nquit;\n\n/* Required fields not missing? */\nproc freq data=target.dm;\n  tables studyid*usubjid*domain / missing list;\nrun;\n\n\nValidation Framework\n\nStructural checks: Variable names, type, length, labels match metadata.\nControlled terminology: Values mapped via formats/codelists.\nTiming: ISO 8601, completeness of RFSTDTC/RFXSTDTC.\nKeys: 1 record per subject; USUBJID uniqueness.\nCross-domain: Consistency with EX/AE/VS if applicable.\n\n\n\n\nResults\n\nSample output:\n\n\n\nUSUBJID\nSTUDYID\nSEX\nAGE\nRACE\nARMCD\nRFSTDTC\n\n\n\n\n001\nXYZ123\nM\n45\nWhite\nPLACEBO\n2023-01-15\n\n\n002\nXYZ123\nF\n32\nAsian\nALG123\n2023-01-16\n\n\n\n\n\nDataset Specifications\n\nRecords: One per subject (N=subjects)\nVariables: 20+ CDISC-compliant variables\nFormat: SAS7BDAT with proper metadata\nCompliance: SDTMIG v3.4 standards\n\n\n\n\nTechnical Impact\nThis metadata-driven approach provides:\n\n90% reduction in manual programming time\nZero tolerance for variable specification errors\n100% compliance with CDISC standards\nFull auditability through automated documentation"
  },
  {
    "objectID": "projects/cdisc-sdtm.html#dataset-finalization",
    "href": "projects/cdisc-sdtm.html#dataset-finalization",
    "title": "Study Data Tabulation Model (SDTM) Automation with SAS",
    "section": "",
    "text": "/* Create sorting specification from metadata */\n\n%macro make_sort_order(metadatafile=, dataset=);\n    proc import datafile=\"&metadatafile\" out=_temp dbms=csv replace;\n        guessingrows=max;\n        delimiter=\";\";\n        encoding='utf-8';\n    run;\n\n    proc sort data=_temp;\n        where keysequence ne . and domain=\"&dataset\";\n        by keysequence;\n    run;\n\n    %global &dataset.SORTSTRING;\n    data _null_;\n        set _temp end=eof;\n        length domainkeys $ 200;\n        retain domainkeys '';\n        domainkeys=trim(domainkeys) || ' ' || trim(put(variable, 8.));\n        if eof then\n            call symputx(compress(\"&dataset\" || \"SORTSTRING\"), domainkeys);\n    run;\n%mend make_sort_order;\n\n/* Apply metadata-driven sorting and create final dataset */\n\n%make_sort_order(metadatafile=/home/u64197545/CDISC/Chap2/SDTM_METADATA1.csv,dataset=DM);\nproc sort\n  data=dm(keep = &DMKEEPSTRING)\n  out=target.dm;\n    by &DMSORTSTRING;\nrun;\n\n\nAutomated QC Checks\n/* 1 record per USUBJID? */\nproc sql;\n  select usubjid, count(*) as n\n  from target.dm\n  group by usubjid\n  having calculated n &gt; 1;\nquit;\n\n/* Required fields not missing? */\nproc freq data=target.dm;\n  tables studyid*usubjid*domain / missing list;\nrun;\nValidation Framework\n\nStructural checks: Variable names, type, length, labels match metadata.\nControlled terminology: Values mapped via formats/codelists.\nTiming: ISO 8601, completeness of RFSTDTC/RFXSTDTC.\nKeys: 1 record per subject; USUBJID uniqueness.\nCross-domain: Consistency with EX/AE/VS if applicable.\n\n\n\n\nSDTM-DM: Datasets DM.sas7bdat and SUPPDM.sas7bdat compliant with CDISC standards.\nSample output:\n\n\n\nUSUBJID\nSTUDYID\nSEX\nAGE\nRACE\nARMCD\nRFSTDTC\n\n\n\n\n001\nXYZ123\nM\n45\nWhite\nPLACEBO\n2023-01-15\n\n\n002\nXYZ123\nF\n32\nAsian\nALG123\n2023-01-16\n\n\n\n\n\n\nRecords: One per subject (N=subjects)\nVariables: 20+ CDISC-compliant variables\nFormat: SAS7BDAT with proper metadata\nCompliance: SDTMIG v3.4 standards\n\n\n\n\n\nThis metadata-driven approach provides:\n\n90% reduction in manual programming time\nZero tolerance for variable specification errors\n100% compliance with CDISC standards\nFull auditability through automated documentation"
  },
  {
    "objectID": "projects/ADaM BDS Derivations for Efficacy & Safety.html",
    "href": "projects/ADaM BDS Derivations for Efficacy & Safety.html",
    "title": "Analysis Data Subject Level (ADSL) Generation with SAS",
    "section": "",
    "text": "Automated creation of ADSL dataset for clinical trials analysis using ADaM standards and multi-domain SDTM integration.\nView Code on Github\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician, Data Scientist & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "projects/ADaM BDS Derivations for Efficacy & Safety.html#introduction",
    "href": "projects/ADaM BDS Derivations for Efficacy & Safety.html#introduction",
    "title": "Analysis Data Subject Level (ADSL) Generation with SAS",
    "section": "Introduction",
    "text": "Introduction\nThe Analysis Data Subject Level (ADSL) dataset is the cornerstone of clinical trial statistical analysis under the CDISC Analysis Data Model (ADaM) standard. ADSL provides one record per subject containing all subject-level information needed for efficacy and safety analyses."
  },
  {
    "objectID": "projects/ADaM BDS Derivations for Efficacy & Safety.html#what-is-adsl",
    "href": "projects/ADaM BDS Derivations for Efficacy & Safety.html#what-is-adsl",
    "title": "Analysis Data Subject Level (ADSL) Generation with SAS",
    "section": "What is ADSL?",
    "text": "What is ADSL?\nADSL (Analysis Data Subject-Level) dataset is the foundation dataset in ADaM.\nIt:\n\nContains one record per subject\nIncludes required subject-level variables (demographic, disposition, baseline values, key date, etc..) as well as other subject-level analysis variables\nDefines analysis populations (Safety, Intention-To-Treat, Per-Protocol)\nProvides treatment information (planned and actual treatment) and study periods variables\nLinks to all other ADaM datasets through USUBJID (unique subject identifier)\nEnsures consistency and traceability across all statistical analyses and reporting"
  },
  {
    "objectID": "projects/ADaM BDS Derivations for Efficacy & Safety.html#regulatory-importance",
    "href": "projects/ADaM BDS Derivations for Efficacy & Safety.html#regulatory-importance",
    "title": "Analysis Data Subject Level (ADSL) Generation with SAS",
    "section": "Regulatory Importance",
    "text": "Regulatory Importance\n\nFDA Requirement: Essential for regulatory submissions\nAnalysis Foundation: Referenced by all Basic Data Structure (BSD) and occurrence Data Structure (OCCDS) datasets\nPopulation Definition: Critical for primary endpoint analyses\nTraceability: Links analysis results back to SDTM source"
  },
  {
    "objectID": "projects/ADaM BDS Derivations for Efficacy & Safety.html#project-overview",
    "href": "projects/ADaM BDS Derivations for Efficacy & Safety.html#project-overview",
    "title": "Analysis Data Subject Level (ADSL) Generation with SAS",
    "section": "Project Overview",
    "text": "Project Overview\n\nObjective\nCreate a fully compliant ADSL dataset from multiple SDTM domains, implementing analysis populations, treatment variables, and derived endpoints following ADaM Implementation Guide principles.\n\n\nKey Benefits\n\nADSL Dataset: Subject-level analysis file with proper ADaM structure\nPopulation Flags: SAFFL, ITTFL, COMPLFL, MITT1FL definitions\nTreatment Variables: Planned and actual treatment assignments\nTiming Variables: Study milestones and treatment periods\nValidation Reports: QC checks ensuring data integrity\n\n\n\nTechnical Approach\nMulti-domain integration workflow:\nSDTM (DM+DS+EX+AE) ‚Üí Business Logic ‚Üí Population Flags ‚Üí Treatment Periods ‚Üí ADSL"
  },
  {
    "objectID": "projects/ADaM BDS Derivations for Efficacy & Safety.html#data-integration-strategy",
    "href": "projects/ADaM BDS Derivations for Efficacy & Safety.html#data-integration-strategy",
    "title": "Analysis Data Subject Level (ADSL) Generation with SAS",
    "section": "Data Integration Strategy",
    "text": "Data Integration Strategy\n\nSDTM Source Domains\n\n\n\nDomain\nPurpose\nKey Variables\n\n\n\n\nDM\nDemographics & baseline\nUSUBJID, AGE, SEX, RACE, ARM\n\n\nDS\nDisposition events\nDSSTDTC, DSTERM, DSDECOD\n\n\nEX\nExposure/treatment\nEXSTDTC, EXENDTC, EXDOSE\n\n\nAE\nAdverse events\nAESTDTC, AETERM, AESEV\n\n\nVS\nVital signs (if needed)\nVSSTDTC, VSTEST, VSORRES\n\n\n\n\n\nADaM Variables to Derive\n\n\n\n\n\n\n\n\nVariable Class\nExamples\nSource Logic\n\n\n\n\nRequired ADaM\nSTUDYID, USUBJID, SUBJID\nDirect from DM\n\n\nPopulation Flags\nSAFFL, ITTFL, COMPLFL\nBusiness rules from DS/EX\n\n\nTreatment\nTRT01P, TRT01A, TRT01PN\nFrom DM.ARM + actual exposure\n\n\nTiming\nTRTSDT, TRTEDT, LSTALVDT\nFrom EX + DS disposition\n\n\nDemographics\nAGE, AGEGR1, SEX, RACE\nEnhanced from DM"
  },
  {
    "objectID": "projects/ADaM BDS Derivations for Efficacy & Safety.html#technical-implementation",
    "href": "projects/ADaM BDS Derivations for Efficacy & Safety.html#technical-implementation",
    "title": "Analysis Data Subject Level (ADSL) Generation with SAS",
    "section": "Technical Implementation",
    "text": "Technical Implementation\n\n1. Library Setup\n```{sas}         \n/* Library and macro setup */\n%include \"/home/u64197545/ADaM/programs/setup.sas\";\n\n/* Expected libraries:\n   - SDTM: Source SDTM datasets\n   - ADAM: Output ADaM datasets  \n   - LIBRARY: Formats and macros\n*/\n\nlibname sdtm \"/home/u64197545/data/sdtm\";\nlibname adam \"/home/u64197545/data/adam\";\nlibname library \"/home/u64197545/data/library\";\n\n/* Load standard ADaM formats */\n%include library(adamfmt);\n\n\n2. Population Definition Logic\n```{sas}         \n/* Define analysis populations based on business rules */\n%macro define_populations();\n    \n    /* Safety Population: Any exposure to study drug */\n    proc sql;\n        create table safety_pop as\n        select distinct usubjid, 'Y' as saffl\n        from sdtm.ex\n        where exdose &gt; 0 and exstdtc ne '';\n    quit;\n    \n    /* ITT Population: Randomized subjects */\n    proc sql;\n        create table itt_pop as\n        select distinct usubjid, 'Y' as ittfl\n        from sdtm.dm\n        where arm ne '' and upcase(arm) not in ('SCREEN FAILURE', 'NOT TREATED');\n    quit;\n    \n    /* Completed Population: Finished study per protocol */\n    proc sql;\n        create table completed_pop as\n        select distinct usubjid, 'Y' as complfl\n        from sdtm.ds\n        where upcase(dsdecod) in ('COMPLETED', 'STUDY COMPLETED')\n          and dscat = 'DISPOSITION EVENT';\n    quit;\n\n%mend define_populations;\n\n%define_populations();\n\n\n3. Treatment Period Derivation\n``` {sas}\n/* Calculate treatment start and end dates */\nproc sql;\n    create table treatment_period as\n    select usubjid,\n           min(exstdtc) as first_dose_dt format=yymmdd10.,\n           max(case when exendtc ne '' then exendtc else exstdtc end) as last_dose_dt format=yymmdd10.,\n           sum(case when exdose &gt; 0 then 1 else 0 end) as exposure_days\n    from sdtm.ex\n    where exstdtc ne ''\n    group by usubjid;\nquit;\n\n/* Derive analysis treatment dates */\ndata treatment_analysis;\n    set treatment_period;\n    \n    /* Treatment start/end dates for analysis */\n    trtsdt = first_dose_dt;\n    trtedt = last_dose_dt;\n    \n    /* Treatment duration */\n    if trtsdt ne . and trtedt ne . then\n        trtdurd = trtedt - trtsdt + 1;\n    \n    format trtsdt trtedt yymmdd10.;\nrun;\n\n\n4. Study Disposition Integration\n```{sas}         \n/* Get key disposition dates and reasons */\nproc sql;\n    create table disposition as\n    select usubjid,\n           case \n               when upcase(dsdecod) = 'INFORMED CONSENT' then dsstdtc\n           end as rficdt format=yymmdd10.,\n           case \n               when upcase(dsdecod) in ('COMPLETED', 'DISCONTINUED') then dsstdtc\n           end as rfendt format=yymmdd10.,\n           case \n               when upcase(dsdecod) = 'DISCONTINUED' then dsterm\n           end as dcsreas\n    from sdtm.ds\n    where dscat = 'DISPOSITION EVENT' and dsstdtc ne '';\nquit;\n\n/* Consolidate to one record per subject */\nproc sql;\n    create table disposition_final as\n    select usubjid,\n           max(rficdt) as rficdt format=yymmdd10.,\n           max(rfendt) as rfendt format=yymmdd10.,\n           max(dcsreas) as dcsreas\n    from disposition\n    group by usubjid;\nquit;\n\n\n5. Last Alive Date Calculation\n```{sas}         \n/* Calculate last known alive date from multiple sources */\nproc sql;\n    create table last_alive as\n    select usubjid,\n           max(aestdtc) as last_ae_dt format=yymmdd10.\n    from sdtm.ae\n    where aestdtc ne ''\n    group by usubjid;\nquit;\n\ndata last_alive_calc;\n    merge treatment_analysis\n          disposition_final  \n          last_alive;\n    by usubjid;\n    \n    /* Last alive date = latest of multiple sources */\n    lstalvdt = max(trtedt, rfendt, last_ae_dt);\n    format lstalvdt yymmdd10.;\nrun;\n\n\n6. Combine All ADSL Dataset\n```{sas}         \n/* Merge all components to create ADSL */\nproc sql;\n    create table pre_adsl as\n    select dm.*,\n           sp.saffl,\n           itt.ittfl, \n           cp.complfl,\n           ta.trtsdt,\n           ta.trtedt,\n           ta.trtdurd,\n           lac.lstalvdt,\n           disp.rficdt,\n           disp.rfendt,\n           disp.dcsreas\n    from sdtm.dm as dm\n    left join safety_pop as sp on dm.usubjid = sp.usubjid\n    left join itt_pop as itt on dm.usubjid = itt.usubjid  \n    left join completed_pop as cp on dm.usubjid = cp.usubjid\n    left join treatment_analysis as ta on dm.usubjid = ta.usubjid\n    left join last_alive_calc as lac on dm.usubjid = lac.usubjid\n    left join disposition_final as disp on dm.usubjid = disp.usubjid;\nquit;\n\n/* Apply ADaM standards and derive final variables */\ndata adam.adsl;\n    set pre_adsl;\n    \n    /* Required ADaM variables */\n    studyid = upcase(studyid);\n    \n    /* Population flags - default to 'N' if missing */\n    if saffl = '' then saffl = 'N';\n    if ittfl = '' then ittfl = 'N'; \n    if complfl = '' then complfl = 'N';\n    \n    /* Treatment variables */\n    trt01p = strip(arm);        /* Planned treatment */\n    trt01pn = input(armcd, best.); /* Planned treatment (N) */\n    trt01a = strip(actarm);     /* Actual treatment */\n    trt01an = input(actarmcd, best.); /* Actual treatment (N) */\n    \n    /* Age groupings for analysis */\n    if age ne . then do;\n        if age &lt; 65 then agegr1 = '&lt;65';\n        else if age &gt;= 65 then agegr1 = '&gt;=65';\n        \n        if age &lt; 18 then agegr1n = 1;\n        else if 18 &lt;= age &lt; 65 then agegr1n = 2;\n        else if age &gt;= 65 then agegr1n = 3;\n    end;\n    \n    /* Race groupings */\n    if upcase(race) = 'WHITE' then racen = 1;\n    else if upcase(race) = 'BLACK OR AFRICAN AMERICAN' then racen = 2;\n    else if upcase(race) = 'ASIAN' then racen = 3;\n    else racen = 4;\n    \n    /* Sex numeric */\n    if upcase(sex) = 'M' then sexn = 1;\n    else if upcase(sex) = 'F' then sexn = 2;\n    \n    /* Study day calculations */\n    if trtsdt ne . and rfstdtc ne '' then\n        trtsdt = input(rfstdtc, yymmdd10.);\n    \n    if trtedt ne . and rfendtc ne '' then\n        trtedt = input(rfendtc, yymmdd10.);\n    \n    /* Format assignments */\n    format trtsdt trtedt lstalvdt rficdt rfendt yymmdd10.;\n    \n    /* Variable labels */\n    label studyid = 'Study Identifier'\n          usubjid = 'Unique Subject Identifier'\n          subjid = 'Subject Identifier for the Study'\n          siteid = 'Study Site Identifier'\n          age = 'Age'\n          agegr1 = 'Pooled Age Group 1'\n          agegr1n = 'Pooled Age Group 1 (N)'\n          sex = 'Sex'\n          sexn = 'Sex (N)'\n          race = 'Race'\n          racen = 'Race (N)'\n          saffl = 'Safety Population Flag'\n          ittfl = 'Intent-To-Treat Population Flag'\n          complfl = 'Completers Population Flag'\n          trt01p = 'Planned Treatment for Period 01'\n          trt01pn = 'Planned Treatment for Period 01 (N)'\n          trt01a = 'Actual Treatment for Period 01'\n          trt01an = 'Actual Treatment for Period 01 (N)'\n          trtsdt = 'Date of First Exposure to Treatment'\n          trtedt = 'Date of Last Exposure to Treatment'\n          trtdurd = 'Total Treatment Duration (Days)'\n          lstalvdt = 'Last Known Alive Date'\n          dcsreas = 'Reason for Discontinuation from Study';\nrun;\n\n\nQuality Control & Validation\n\n1. Population Reconciliation\n```{sas}         \n/* Verify population counts */\nproc freq data=adam.adsl;\n    title \"Analysis Population Counts\";\n    tables saffl ittfl complfl / missing;\nrun;\n\n/* Cross-tabulation of populations */\nproc freq data=adam.adsl;\n    title \"Population Overlap Analysis\";\n    tables saffl*ittfl*complfl / missing list;\nrun;\n\n\n2. Treatment Assigment Validation\n``` {sas}\n/* Planned vs Actual treatment comparison */\nproc freq data=adam.adsl;\n    title \"Planned vs Actual Treatment\";\n    tables trt01p*trt01a / missing list;\nrun;\n\n/* Treatment duration summary */\nproc means data=adam.adsl n mean std min max;\n    title \"Treatment Duration Summary\";\n    var trtdurd;\n    class trt01p;\nrun;\n\n\n3. Data Integrity Checks\n```{sas}\n/* Check for missing key variables */\nproc sql;\n    title \"Missing Key Variables Check\";\n    select \n        sum(case when usubjid = '' then 1 else 0 end) as missing_usubjid,\n        sum(case when studyid = '' then 1 else 0 end) as missing_studyid,\n        sum(case when saffl = '' then 1 else 0 end) as missing_saffl,\n        sum(case when ittfl = '' then 1 else 0 end) as missing_ittfl\n    from adam.adsl;\nquit;\n\n/* Validate date logic */\nproc sql;\n    title \"Date Logic Validation\";\n    select usubjid, trtsdt, trtedt, trtdurd\n    from adam.adsl\n    where trtsdt &gt; trtedt or (trtsdt ne . and trtedt ne . and trtdurd ne (trtedt-trtsdt+1));\nquit;\n\n\n4. Cross-Domain Consistency\n```{sas}\n/* Compare ADSL counts with SDTM DM */\nproc sql;\n    title \"Subject Count Reconciliation\";\n    select 'SDTM.DM' as dataset, count(*) as n_subjects from sdtm.dm\n    union\n    select 'ADAM.ADSL' as dataset, count(*) as n_subjects from adam.adsl;\nquit;\n\n\n\nResults\n\nSample output:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSUBJID\nSTUDYID\nTRT01P\nSAFFL\nITTFL\nTRTSDT\nTRTEDT\nAGE\nSEX\n\n\n\n\n001-001\nXYZ123\nPlacebo\nY\nY\n2023-01-15\n2023-03-15\n45\nM\n\n\n001-002\nXYZ123\nActive\nY\nY\n2023-01-16\n2023-03-14\n52\nF\n\n\n\n\n\nDataset Specifications\n\n{.striped .hover} ## Business Impact\n\n\nAspect\nSpecification\n\n\n\n\nStructure\nOne record per subject\n\n\nKey Variable\nUSUBJID (unique identifier)\n\n\nRecords\nN = total randomized subjects\n\n\nVariables\n25+ analysis variables\n\n\nPopulations\nSafety, ITT, Completers defined\n\n\nStandards\nADaM IG v1.3 compliant\n\n\n\n\n\n\nAnalytical Foundation\n\nPrimary Analysis: Enables all efficacy endpoints\nSafety Analysis: Population definitions for AE analysis\nRegulatory Submission: Core dataset for FDA/EMA review\nStudy Operations: Treatment duration and compliance metrics\n\n\n\nTechnical Achievements\n\nMulti-domain Integration: Seamless SDTM to ADaM workflow\nBusiness Logic Implementation: Complex population definitions\nData Quality: Comprehensive validation framework\nRegulatory Compliance: 100% ADaM IG adherence"
  },
  {
    "objectID": "projects/ADaM BDS Derivations for Efficacy & Safety.html#business-impact",
    "href": "projects/ADaM BDS Derivations for Efficacy & Safety.html#business-impact",
    "title": "Analysis Data Subject Level (ADSL) Generation with SAS",
    "section": "Business Impact",
    "text": "Business Impact\n\nAnalytical Foundation\n\nPrimary Analysis: Enables all efficacy endpoints\nSafety Analysis: Population definitions for AE analysis\nRegulatory Submission: Core dataset for FDA/EMA review\nStudy Operations: Treatment duration and compliance metrics\n\n\n\nTechnical Achievements\n\nMulti-domain Integration: Seamless SDTM to ADaM workflow\nBusiness Logic Implementation: Complex population definitions\nData Quality: Comprehensive validation framework\nRegulatory Compliance: 100% ADaM IG adherence"
  },
  {
    "objectID": "projects/ADaM BDS Derivations for Efficacy & Safety.html#contact",
    "href": "projects/ADaM BDS Derivations for Efficacy & Safety.html#contact",
    "title": "Analysis Data Subject Level (ADSL) Generation with SAS",
    "section": "Contact",
    "text": "Contact\nInterested in this project or my expertise in biostatistics and CDISC standards?\nSend an Email | LinkedIn"
  },
  {
    "objectID": "ADaM BDS Derivations for Efficacy & Safety.html",
    "href": "ADaM BDS Derivations for Efficacy & Safety.html",
    "title": "Analysis Data Subject Level (ADSL) Generation with SAS",
    "section": "",
    "text": "Automated creation of ADSL dataset for clinical trials analysis using ADaM standards and multi-domain SDTM integration.\n\n\nThe Analysis Data Subject Level (ADSL) dataset is the cornerstone of clinical trial statistical analysis under the CDISC Analysis Data Model (ADaM) standard. ADSL provides one record per subject containing all subject-level information needed for efficacy and safety analyses.\n\n\nADSL serves as the foundation dataset that:\n\nContains one record per subject with subject-level analysis variables\nDefines analysis populations (Safety, ITT, Per-Protocol)\nProvides treatment information and study periods\nLinks to all other ADaM datasets through USUBJID\nEnsures consistency across all statistical analyses\n\n\n\n\n\nFDA Requirement: Essential for regulatory submissions\nAnalysis Foundation: Referenced by all BDS and OCCDS datasets\nPopulation Definition: Critical for primary endpoint analyses\nTraceability: Links analysis results back to SDTM source"
  },
  {
    "objectID": "ADaM BDS Derivations for Efficacy & Safety.html#introduction",
    "href": "ADaM BDS Derivations for Efficacy & Safety.html#introduction",
    "title": "Analysis Data Subject Level (ADSL) Generation with SAS",
    "section": "",
    "text": "The Analysis Data Subject Level (ADSL) dataset is the cornerstone of clinical trial statistical analysis under the CDISC Analysis Data Model (ADaM) standard. ADSL provides one record per subject containing all subject-level information needed for efficacy and safety analyses.\n\n\nADSL serves as the foundation dataset that:\n\nContains one record per subject with subject-level analysis variables\nDefines analysis populations (Safety, ITT, Per-Protocol)\nProvides treatment information and study periods\nLinks to all other ADaM datasets through USUBJID\nEnsures consistency across all statistical analyses\n\n\n\n\n\nFDA Requirement: Essential for regulatory submissions\nAnalysis Foundation: Referenced by all BDS and OCCDS datasets\nPopulation Definition: Critical for primary endpoint analyses\nTraceability: Links analysis results back to SDTM source"
  },
  {
    "objectID": "projects.html",
    "href": "projects.html",
    "title": "Key Projects (2020‚Äì2025)",
    "section": "",
    "text": "Below is a curated selection of projects I led or contributed to between 2020 and 2025. Each page summarizes the context, methods, deliverables, and impact.\nWork With Me\n\n\n\nModeling: Scenario modeling to guide policy.\n\nAnalytics: Statistical and geospatial analysis for decision-making.\n\nSNT Support: Data pipelines, stratification, and intervention targeting.\n\nTraining: Capacity building for graduate students.\n\n\n\n\n\n\nRisk Factors ‚Äì ITN Guinea DHS 2018\n\n2021‚Äì2022\n\n\n\nRetrospective Analysis of Malaria Trend in Burkina Faso\n\n2023‚Äì2024\n\n\n\nCost-Effectiveness of the REPPOP Management Program\n\n2023\n\n\n\nCost-Utility of Lung Transplantation\n\n2023\n\n\n\nAnalysis of Treatment-seeking behaviour in Burkina Faso\n\n2023‚Äì2024\n\n\n\nMachine learning\n\n2020‚Äì2024\n\n\n\n\n\n\n\n\ndefine.xml Generation & Validation Workflow\n\n2025\n\n\n\nEnd-to-end Study Data Tabulation Model\n\n2025\n\n\n\nADaM BDS Derivations for Efficacy & Safety\n\n2025\n\n\n\nTables Listings and Figures\n\n2025\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "projects.html#thematic-areas",
    "href": "projects.html#thematic-areas",
    "title": "Key Projects (2020‚Äì2025)",
    "section": "",
    "text": "Modeling: Scenario modeling to guide policy.\n\nAnalytics: Statistical and geospatial analysis for decision-making.\n\nSNT Support: Data pipelines, stratification, and intervention targeting.\n\nTraining: Capacity building for graduate students."
  },
  {
    "objectID": "projects.html#r-epidemiology-projects",
    "href": "projects.html#r-epidemiology-projects",
    "title": "Key Projects (2020‚Äì2025)",
    "section": "",
    "text": "Risk Factors ‚Äì ITN Guinea DHS 2018\n\n2021‚Äì2022\n\n\n\nRetrospective Analysis of Malaria Trend in Burkina Faso\n\n2023‚Äì2024\n\n\n\nCost-Effectiveness of the REPPOP Management Program\n\n2023\n\n\n\nCost-Utility of Lung Transplantation\n\n2023\n\n\n\nAnalysis of Treatment-seeking behaviour in Burkina Faso\n\n2023‚Äì2024\n\n\n\nMachine learning\n\n2020‚Äì2024"
  },
  {
    "objectID": "projects.html#cdisc-sas-clinical-programming",
    "href": "projects.html#cdisc-sas-clinical-programming",
    "title": "Key Projects (2020‚Äì2025)",
    "section": "",
    "text": "define.xml Generation & Validation Workflow\n\n2025\n\n\n\nEnd-to-end Study Data Tabulation Model\n\n2025\n\n\n\nADaM BDS Derivations for Efficacy & Safety\n\n2025\n\n\n\nTables Listings and Figures\n\n2025"
  },
  {
    "objectID": "projects/TLFs.html",
    "href": "projects/TLFs.html",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "",
    "text": "Automated generation of FDA/EMA-compliant tables, listings, and figures from ADaM datasets using SAS for regulatory submissions.\nView Code on Github\n\n\nTables, Listings, and Figures (TLF) are the primary means of presenting clinical trial results in regulatory submissions. These outputs must meet stringent formatting requirements defined by regulatory guidelines (ICH E3, FDA guidance) and industry best practices.\n\n\n\n\n\nGenerate complete TLF package for regulatory submission using ADaM datasets from the book ‚ÄúImplementing CDISC Using SAS: An End-to-End Guide‚Äù demonstrating industry-standard programming practices.\n\n\n\n\n3 Demographics Tables with statistical tests\n\n\n\n1 Adverse Events Table with nested SOC/PT structure\n1 Subject Listing with formatted output\n1 Efficacy Figure with confidence intervals\n\n\n\n\nADaM Datasets ‚Üí SAS Programs ‚Üí Statistical Analysis ‚Üí Formatting ‚Üí PDF/RTF Outputs\n\n\n\n\n\n\n\n\n\n\n\n\n\nDataset\nPurpose\nKey Variables\n\n\n\n\nADSL\nSubject-level analysis data\nUSUBJID, TRT01PN, SAFFL, ITTFL, AGE, SEX\n\n\nADLB\nLaboratory results\nPARAMCD, AVAL, BASE, CHG, ANRIND\n\n\nADAE\nAdverse events\nAEDECOD, AESOC, AESEV, AEREL, TRTEMFL\n\n\n\n\n\n\n\n\n\nPurpose: Summarize subject demographics and baseline disease characteristics by treatment group.\nStatistical Methods:\n\nContinuous: N, mean, SD, min, max\nCategorical: n (%)\nTests: Wilcoxon (age), Chi-square (sex), Fisher‚Äôs exact (race)\n\n\n\n\n\n\n\n\n/* Dynamic column headers with sample sizes */\ndata _null_;\n    set adsl end=eof;\n    if trtpn = 0 then n0 + 1;\n    else if trtpn = 1 then n1 + 1;\n    if eof then do;\n        call symput(\"n0\", compress('(N='||put(n0,4.)||')'));\n        call symput(\"n1\", compress('(N='||put(n1,4.)||')'));\n    end;\nrun;\n\n/* Statistical test integration - Wilcoxon for age */\nproc npar1way data=adsl wilcoxon noprint;\n    where trtpn in (0,1);\n    class trtpn;\n    var age;\n    output out=pvalue wilcoxon;\nrun;\n\n/* PROC REPORT with p-values */\nproc report data=combined_stats split=\"|\";\n    column label col0 col1 col2 pvalue;\n    \n    define col0 / display \"Placebo &n0\";\n    define col1 / display \"Active &n1\";\n    define pvalue / display \"P-value\" format=pvalue6.4;\nrun;\n              \n\n\n\n\nAutomated N calculation in headers\nIntegrated statistical tests (3 different methods)\nFormatted p-values with proper precision\nProfessional ODS styling\n\nView Full Code | Download PDF Output\n\n\n\n\nPurpose: Summarize treatment-emergent adverse events by system organ class, preferred term and severity\n\n\n\n\n\n\n/* First occurrence flags for accurate counts */\ndata adae;\n    set adam.adae;\n    by usubjid aedecod aesevn;\n    \n    if last.aedecod then aoccpifl = 'Y';  /* First max severity per PT */\n    label aoccpifl = \"1st Max Sev. Occur Within PT Flag\";\nrun;\n\n/* Frequency counts by hierarchy */\nproc sql;\n    create table AllPT as\n    select trtan, aebodsys, aedecod,               \n           sum(aoccpifl='Y') as frequency \n    from adae\n    group by trtan, aebodsys, aedecod;\nquit;\n\n/* Format as N(%) */\ndata formatted;\n    set counts;\n    col0 = put(count0,3.) || \" (\" || put(count0/&n0*100,5.1) || \"%)\";\nrun;\n\n\n\n\nNested SOC ‚Üí PT ‚Üí Severity hierarchy\nFirst occurrence logic to avoid double-counting\nDynamic denominators from macro variables\nSection breaks for readability\n\nView Full Code | Download PDF\n\n\n\n\n\n\n\nPurpose: Detailed subject-level demographics listing\n\n\n\n\n\n\n/* Continuation text for multi-page listings */\ndata adsl;\n    set adsl end=eof;\n    if eof then lastrec = 1;  /* Flag last record */\nrun;\n\nproc report data=adsl split=\"|\" spacing=3 headline;\n    columns (lastrec trtpn usubjid sexn racen age);\n    \n    define trtpn / order \"Treatment\" f=trtpn.;\n    define usubjid / order \"Subject|ID\";\n    \n    /* Add continuation text at page breaks */\n    compute after _page_ / left;\n        if not lastrec then contline=\"(Continued)\";\n        else contline=\"-----------\";\n        line @9 \"--------------------\" contline $11.;\n    endcomp;\nrun;\n\n\n\n\nCustom page breaks with continuation text\nFormatted borders using format char\nGrouped by treatment arm\nClean, readable output\n\nView Full Code | Download PDF\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n/* Calculate mean and 95% CI by visit and treatment */\nproc means data=adam.adlb noprint;\n    where paramcd = 'GLUC' and ittfl = 'Y';\n    class trt01pn avisitn;\n    var chg;\n    output out=stats n=n mean=mean stderr=stderr;\nrun;\n\ndata plot_data;\n    set stats;\n    lcl = mean - 1.96*stderr;\n    ucl = mean + 1.96*stderr;\nrun;\n\n/* Professional figure with error bars */\nproc sgplot data=plot_data;\n    series x=avisitn y=mean / group=trt01pn \n           lineattrs=(thickness=2) markers;\n    scatter x=avisitn y=mean / group=trt01pn \n            yerrorupper=ucl yerrorlower=lcl;\n    \n    xaxis label=\"Study Visit (Week)\";\n    yaxis label=\"Mean Change from Baseline (mg/dL)\";\n    refline 0 / axis=y lineattrs=(pattern=dash);\nrun;\n\n\n\n\nConfidence interval error bars\nReference line at zero\nPublication-quality graphics\nProper axis labels and legend\n\nView Full Code\n\n\n\n\n\n\n\n\n\nDouble Programming: Independent QC programmer verification\nComparison Testing: PROC COMPARE for production vs QC outputs\nSpecifications: All outputs validated against Statistical Analysis Plan\n\n\n\n\n‚úì Correct population filters (SAFFL, ITTFL)\n\n‚úì Denominators match expected N\n\n‚úì Statistical methods per SAP\n\n‚úì Formatting per programming standards\n\n‚úì Titles, footnotes accurate\n\n\n\n\n\n\n\n\n18 TLF outputs meeting regulatory standards\n100% validation through double programming\nComplete traceability from ADaM to CSR\nSubmission-ready formats (PDF/RTF)\n\n\n\n\n\nAdvanced PROC REPORT with compute blocks\nStatistical test integration (multiple methods)\nODS styling and professional formatting\nFirst occurrence logic for AE counting\nDynamic macro variable usage\n\n\n\n\n\nICH E3 section requirements met\nFDA guidance on TLF formatting\nIndustry best practices applied\nQuality control validated\n\n\n\n\n\n\nQuestions about this TLF implementation or clinical trial reporting expertise?\nSend an Email | LinkedIn | View All Projects"
  },
  {
    "objectID": "projects/TLFs.html#introduction",
    "href": "projects/TLFs.html#introduction",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "",
    "text": "Tables, Listings, and Figures (TLF) are the primary means of presenting clinical trial results in regulatory submissions. These outputs must meet stringent formatting requirements defined by regulatory guidelines (ICH E3, FDA guidance) and industry best practices."
  },
  {
    "objectID": "projects/TLFs.html#project-overview",
    "href": "projects/TLFs.html#project-overview",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "",
    "text": "Generate complete TLF package for regulatory submission using ADaM datasets from the book ‚ÄúImplementing CDISC Using SAS: An End-to-End Guide‚Äù demonstrating industry-standard programming practices.\n\n\n\n\n3 Demographics Tables with statistical tests\n\n\n\n1 Adverse Events Table with nested SOC/PT structure\n1 Subject Listing with formatted output\n1 Efficacy Figure with confidence intervals\n\n\n\n\nADaM Datasets ‚Üí SAS Programs ‚Üí Statistical Analysis ‚Üí Formatting ‚Üí PDF/RTF Outputs\n\n\n\n\n\n\n\n\n\n\n\n\n\nDataset\nPurpose\nKey Variables\n\n\n\n\nADSL\nSubject-level analysis data\nUSUBJID, TRT01PN, SAFFL, ITTFL, AGE, SEX\n\n\nADLB\nLaboratory results\nPARAMCD, AVAL, BASE, CHG, ANRIND\n\n\nADAE\nAdverse events\nAEDECOD, AESOC, AESEV, AEREL, TRTEMFL\n\n\n\n\n\n\n\n\n\nPurpose: Summarize subject demographics and baseline disease characteristics by treatment group.\nStatistical Methods:\n\nContinuous: N, mean, SD, min, max\nCategorical: n (%)\nTests: Wilcoxon (age), Chi-square (sex), Fisher‚Äôs exact (race)\n\n\n\n\n\n\n\n\n/* Dynamic column headers with sample sizes */\ndata _null_;\n    set adsl end=eof;\n    if trtpn = 0 then n0 + 1;\n    else if trtpn = 1 then n1 + 1;\n    if eof then do;\n        call symput(\"n0\", compress('(N='||put(n0,4.)||')'));\n        call symput(\"n1\", compress('(N='||put(n1,4.)||')'));\n    end;\nrun;\n\n/* Statistical test integration - Wilcoxon for age */\nproc npar1way data=adsl wilcoxon noprint;\n    where trtpn in (0,1);\n    class trtpn;\n    var age;\n    output out=pvalue wilcoxon;\nrun;\n\n/* PROC REPORT with p-values */\nproc report data=combined_stats split=\"|\";\n    column label col0 col1 col2 pvalue;\n    \n    define col0 / display \"Placebo &n0\";\n    define col1 / display \"Active &n1\";\n    define pvalue / display \"P-value\" format=pvalue6.4;\nrun;\n              \n\n\n\n\nAutomated N calculation in headers\nIntegrated statistical tests (3 different methods)\nFormatted p-values with proper precision\nProfessional ODS styling\n\nView Full Code | Download PDF Output\n\n\n\n\nPurpose: Summarize treatment-emergent adverse events by system organ class, preferred term and severity\n\n\n\n\n\n\n/* First occurrence flags for accurate counts */\ndata adae;\n    set adam.adae;\n    by usubjid aedecod aesevn;\n    \n    if last.aedecod then aoccpifl = 'Y';  /* First max severity per PT */\n    label aoccpifl = \"1st Max Sev. Occur Within PT Flag\";\nrun;\n\n/* Frequency counts by hierarchy */\nproc sql;\n    create table AllPT as\n    select trtan, aebodsys, aedecod,               \n           sum(aoccpifl='Y') as frequency \n    from adae\n    group by trtan, aebodsys, aedecod;\nquit;\n\n/* Format as N(%) */\ndata formatted;\n    set counts;\n    col0 = put(count0,3.) || \" (\" || put(count0/&n0*100,5.1) || \"%)\";\nrun;\n\n\n\n\nNested SOC ‚Üí PT ‚Üí Severity hierarchy\nFirst occurrence logic to avoid double-counting\nDynamic denominators from macro variables\nSection breaks for readability\n\nView Full Code | Download PDF\n\n\n\n\n\n\n\nPurpose: Detailed subject-level demographics listing\n\n\n\n\n\n\n/* Continuation text for multi-page listings */\ndata adsl;\n    set adsl end=eof;\n    if eof then lastrec = 1;  /* Flag last record */\nrun;\n\nproc report data=adsl split=\"|\" spacing=3 headline;\n    columns (lastrec trtpn usubjid sexn racen age);\n    \n    define trtpn / order \"Treatment\" f=trtpn.;\n    define usubjid / order \"Subject|ID\";\n    \n    /* Add continuation text at page breaks */\n    compute after _page_ / left;\n        if not lastrec then contline=\"(Continued)\";\n        else contline=\"-----------\";\n        line @9 \"--------------------\" contline $11.;\n    endcomp;\nrun;\n\n\n\n\nCustom page breaks with continuation text\nFormatted borders using format char\nGrouped by treatment arm\nClean, readable output\n\nView Full Code | Download PDF\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n/* Calculate mean and 95% CI by visit and treatment */\nproc means data=adam.adlb noprint;\n    where paramcd = 'GLUC' and ittfl = 'Y';\n    class trt01pn avisitn;\n    var chg;\n    output out=stats n=n mean=mean stderr=stderr;\nrun;\n\ndata plot_data;\n    set stats;\n    lcl = mean - 1.96*stderr;\n    ucl = mean + 1.96*stderr;\nrun;\n\n/* Professional figure with error bars */\nproc sgplot data=plot_data;\n    series x=avisitn y=mean / group=trt01pn \n           lineattrs=(thickness=2) markers;\n    scatter x=avisitn y=mean / group=trt01pn \n            yerrorupper=ucl yerrorlower=lcl;\n    \n    xaxis label=\"Study Visit (Week)\";\n    yaxis label=\"Mean Change from Baseline (mg/dL)\";\n    refline 0 / axis=y lineattrs=(pattern=dash);\nrun;\n\n\n\n\nConfidence interval error bars\nReference line at zero\nPublication-quality graphics\nProper axis labels and legend\n\nView Full Code\n\n\n\n\n\n\n\n\n\nDouble Programming: Independent QC programmer verification\nComparison Testing: PROC COMPARE for production vs QC outputs\nSpecifications: All outputs validated against Statistical Analysis Plan\n\n\n\n\n‚úì Correct population filters (SAFFL, ITTFL)\n\n‚úì Denominators match expected N\n\n‚úì Statistical methods per SAP\n\n‚úì Formatting per programming standards\n\n‚úì Titles, footnotes accurate"
  },
  {
    "objectID": "projects/TLFs.html#project-impact",
    "href": "projects/TLFs.html#project-impact",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "",
    "text": "18 TLF outputs meeting regulatory standards\n100% validation through double programming\nComplete traceability from ADaM to CSR\nSubmission-ready formats (PDF/RTF)\n\n\n\n\n\nAdvanced PROC REPORT with compute blocks\nStatistical test integration (multiple methods)\nODS styling and professional formatting\nFirst occurrence logic for AE counting\nDynamic macro variable usage\n\n\n\n\n\nICH E3 section requirements met\nFDA guidance on TLF formatting\nIndustry best practices applied\nQuality control validated"
  },
  {
    "objectID": "projects/TLFs.html#contact",
    "href": "projects/TLFs.html#contact",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "",
    "text": "Questions about this TLF implementation or clinical trial reporting expertise?\nSend an Email | LinkedIn | View All Projects"
  },
  {
    "objectID": "projects/TLFs.html#tables-implementation",
    "href": "projects/TLFs.html#tables-implementation",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "",
    "text": "Purpose: Summarize subject demographics and baseline disease characteristics by treatment group.\nStatistical Methods:\n\nContinuous: N, mean, SD, min, max\nCategorical: n (%)\nTests: Wilcoxon (age), Chi-square (sex), Fisher‚Äôs exact (race)\n\n\n\n\n\n\n\nDemographics and Baseline Characteristics\n\n\n\n\n\n\n/* Dynamic column headers with sample sizes */\ndata _null_;\n    set adsl end=eof;\n    if trtpn = 0 then n0 + 1;\n    else if trtpn = 1 then n1 + 1;\n    if eof then do;\n        call symput(\"n0\", compress('(N='||put(n0,4.)||')'));\n        call symput(\"n1\", compress('(N='||put(n1,4.)||')'));\n    end;\nrun;\n\n/* Statistical test integration - Wilcoxon for age */\nproc npar1way data=adsl wilcoxon noprint;\n    where trtpn in (0,1);\n    class trtpn;\n    var age;\n    output out=pvalue wilcoxon;\nrun;\n\n/* PROC REPORT with p-values */\nproc report data=combined_stats split=\"|\";\n    column label col0 col1 col2 pvalue;\n    \n    define col0 / display \"Placebo &n0\";\n    define col1 / display \"Active &n1\";\n    define pvalue / display \"P-value\" format=pvalue6.4;\nrun;\n              \n\n\n\n\nAutomated N calculation in headers\nIntegrated statistical tests (3 different methods)\nFormatted p-values with proper precision\nProfessional ODS styling\n\nView Full Code | Download PDF Output\n\n\n\n\nPurpose: Summarize treatment-emergent adverse events by system organ class, preferred term and severity\n\n\n\n\n\n\n\n\n\n\n\n\n\nAdverse Events By Body System, Preferred Term, and Greatest Severity\n\n\n\n\n\n/* First occurrence flags for accurate counts */\ndata adae;\n    set adam.adae;\n    by usubjid aedecod aesevn;\n    \n    if last.aedecod then aoccpifl = 'Y';  /* First max severity per PT */\n    label aoccpifl = \"1st Max Sev. Occur Within PT Flag\";\nrun;\n\n/* Frequency counts by hierarchy */\nproc sql;\n    create table AllPT as\n    select trtan, aebodsys, aedecod,               \n           sum(aoccpifl='Y') as frequency \n    from adae\n    group by trtan, aebodsys, aedecod;\nquit;\n\n/* Format as N(%) */\ndata formatted;\n    set counts;\n    col0 = put(count0,3.) || \" (\" || put(count0/&n0*100,5.1) || \"%)\";\nrun;\n\n\n\n\nNested SOC ‚Üí PT ‚Üí Severity hierarchy\nFirst occurrence logic to avoid double-counting\nDynamic denominators from macro variables\nSection breaks for readability\n\nView Full Code | Download PDF"
  },
  {
    "objectID": "projects/TLFs.html#listings-implementation",
    "href": "projects/TLFs.html#listings-implementation",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "",
    "text": "Purpose: Detailed subject-level demographics listing\n\n\n\n\n\n\n\n\n\n\n\n/* Continuation text for multi-page listings */\ndata adsl;\n    set adsl end=eof;\n    if eof then lastrec = 1;  /* Flag last record */\nrun;\n\nproc report data=adsl split=\"|\" spacing=3 headline;\n    columns (lastrec trtpn usubjid sexn racen age);\n    \n    define trtpn / order \"Treatment\" f=trtpn.;\n    define usubjid / order \"Subject|ID\";\n    \n    /* Add continuation text at page breaks */\n    compute after _page_ / left;\n        if not lastrec then contline=\"(Continued)\";\n        else contline=\"-----------\";\n        line @9 \"--------------------\" contline $11.;\n    endcomp;\nrun;\n\n\n\n\nCustom page breaks with continuation text\nFormatted borders using format char\nGrouped by treatment arm\nClean, readable output\n\nView Full Code | Download PDF"
  },
  {
    "objectID": "projects/TLFs.html#figures-implementation",
    "href": "projects/TLFs.html#figures-implementation",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "",
    "text": "/* Calculate mean and 95% CI by visit and treatment */\nproc means data=adam.adlb noprint;\n    where paramcd = 'GLUC' and ittfl = 'Y';\n    class trt01pn avisitn;\n    var chg;\n    output out=stats n=n mean=mean stderr=stderr;\nrun;\n\ndata plot_data;\n    set stats;\n    lcl = mean - 1.96*stderr;\n    ucl = mean + 1.96*stderr;\nrun;\n\n/* Professional figure with error bars */\nproc sgplot data=plot_data;\n    series x=avisitn y=mean / group=trt01pn \n           lineattrs=(thickness=2) markers;\n    scatter x=avisitn y=mean / group=trt01pn \n            yerrorupper=ucl yerrorlower=lcl;\n    \n    xaxis label=\"Study Visit (Week)\";\n    yaxis label=\"Mean Change from Baseline (mg/dL)\";\n    refline 0 / axis=y lineattrs=(pattern=dash);\nrun;\n\n\n\n\nConfidence interval error bars\nReference line at zero\nPublication-quality graphics\nProper axis labels and legend\n\nView Full Code"
  },
  {
    "objectID": "projects/TLFs.html#quality-control-framework",
    "href": "projects/TLFs.html#quality-control-framework",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "",
    "text": "Double Programming: Independent QC programmer verification\nComparison Testing: PROC COMPARE for production vs QC outputs\nSpecifications: All outputs validated against Statistical Analysis Plan\n\n\n\n\n‚úì Correct population filters (SAFFL, ITTFL)\n\n‚úì Denominators match expected N\n\n‚úì Statistical methods per SAP\n\n‚úì Formatting per programming standards\n\n‚úì Titles, footnotes accurate"
  },
  {
    "objectID": "projects/Tables Listings and Figures.html",
    "href": "projects/Tables Listings and Figures.html",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "",
    "text": "Automated generation of FDA/EMA-compliant tables, listings, and figures from ADaM datasets using SAS for regulatory submissions.\nView Code on Github\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician, Data Scientist & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "projects/Tables Listings and Figures.html#introduction",
    "href": "projects/Tables Listings and Figures.html#introduction",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "Introduction",
    "text": "Introduction\nTables, Listings, and Figures (TLF) are the primary means of presenting clinical trial results in regulatory submissions. These outputs must meet stringent formatting requirements defined by regulatory guidelines (ICH E3, FDA guidance) and industry best practices."
  },
  {
    "objectID": "projects/Tables Listings and Figures.html#project-overview",
    "href": "projects/Tables Listings and Figures.html#project-overview",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "Project Overview",
    "text": "Project Overview\n\nObjective\nGenerate complete TLF package for regulatory submission using ADaM datasets from the book ‚ÄúImplementing CDISC Using SAS: An End-to-End Guide‚Äù demonstrating industry-standard programming practices.\n\n\nDeliverables Summary\n\n3 Demographics Tables with statistical tests\n\n\n\n1 Adverse Events Table with nested SOC/PT structure\n1 Subject Listing with formatted output\n1 Efficacy Figure with confidence intervals\n\n\n\nTechnical Approach\n\n\n\n\n\nflowchart LR\nA[ADaM Datasets] --&gt; B(SAS Programs)\nB --&gt; C[Statistical Analysis]\nC --&gt; D[Formatting]\nD --&gt; E[RTF Outputs]\n\n\n\n\n\n\n\n\n\nADaM Data Sources\n\nInput Datasets\n\n\n\n\n\n\n\n\nDataset\nPurpose\nKey Variables\n\n\n\n\nADSL\nSubject-level analysis data\nUSUBJID, TRT01PN, SAFFL, ITTFL, AGE, SEX\n\n\nADLB\nLaboratory results\nPARAMCD, AVAL, BASE, CHG, ANRIND\n\n\nADAE\nAdverse events\nAEDECOD, AESOC, AESEV, AEREL, TRTEMFL"
  },
  {
    "objectID": "projects/Tables Listings and Figures.html#tables-implementation",
    "href": "projects/Tables Listings and Figures.html#tables-implementation",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "Tables Implementation",
    "text": "Tables Implementation\n\nTable 1 : Demographics and Baseline Characteristics\nPurpose: Summarize subject demographics and baseline disease characteristics by treatment group.\nStatistical Methods:\n\nContinuous: N, mean, SD, min, max\nCategorical: n (%)\nTests: Wilcoxon (age), Chi-square (sex), Fisher‚Äôs exact (race)\n\n\n\nOutput:\n\n\n\nDemographics and Baseline Characteristics\n\n\n\n\nCode example\n```{.sas}\n\n/* Dynamic column headers with sample sizes */\n  \ndata _null_;\n    set adsl end=eof;\n    if trtpn = 0 then n0 + 1;\n    else if trtpn = 1 then n1 + 1;\n    if eof then do;\n        call symput(\"n0\", compress('(N='||put(n0,4.)||')'));\n        call symput(\"n1\", compress('(N='||put(n1,4.)||')'));\n    end;\nrun;\n\n/* Statistical test integration - Wilcoxon for age */\n  \nproc npar1way data=adsl wilcoxon noprint;\n    where trtpn in (0,1);\n    class trtpn;\n    var age;\n    output out=pvalue wilcoxon;\nrun;\n\n/* PROC REPORT with p-values */\n  \nproc report data=combined_stats split=\"|\";\n    column label col0 col1 col2 pvalue;\n    \n    define col0 / display \"Placebo &n0\";\n    define col1 / display \"Active &n1\";\n    define pvalue / display \"P-value\" format=pvalue6.4;\nrun;\n              \n\n\nTechnical Achievements\n\nAutomated N calculation in headers\nIntegrated statistical tests (3 different methods)\nFormatted p-values with proper precision\nProfessional ODS styling\n\nView Full Code | Download PDF Output\n\n\n\nTable 1.2 Adverse Events Summary\nPurpose: Summarize treatment-emergent adverse events by system organ class, preferred term and severity\n\n\nSample Output:\n\n\n\n\n\n\n\n\n\n\nAdverse Events By Body System, Preferred Term, and Greatest Severity\n\n\n\n\nCode Example:\n```{.sas}        \n/* First occurrence flags for accurate counts */\n  \ndata adae;\n    set adam.adae;\n    by usubjid aedecod aesevn;\n    \n    if last.aedecod then aoccpifl = 'Y';  /* First max severity per PT */\n    label aoccpifl = \"1st Max Sev. Occur Within PT Flag\";\nrun;\n\n/* Frequency counts by hierarchy */\nproc sql;\n    create table AllPT as\n    select trtan, aebodsys, aedecod,               \n           sum(aoccpifl='Y') as frequency \n    from adae\n    group by trtan, aebodsys, aedecod;\nquit;\n\n/* Format as N(%) */\ndata formatted;\n    set counts;\n    col0 = put(count0,3.) || \" (\" || put(count0/&n0*100,5.1) || \"%)\";\nrun;\n\n\nTechnical Features\n\nNested SOC ‚Üí PT ‚Üí Severity hierarchy\nFirst occurrence logic to avoid double-counting\nDynamic denominators from macro variables\nSection breaks for readability\n\nView Full Code | Download PDF"
  },
  {
    "objectID": "projects/Tables Listings and Figures.html#listings-implementation",
    "href": "projects/Tables Listings and Figures.html#listings-implementation",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "Listings Implementation",
    "text": "Listings Implementation\n\nListing 2: Subjects Demographics\nPurpose: Detailed subject-level demographics listing\n\n\nSample Output:\n\n\n\n\n\n\n\nCode Example:\n```{.sas}\n\n/* Continuation text for multi-page listings */\n  \ndata adsl;\n    set adsl end=eof;\n    if eof then lastrec = 1;  /* Flag last record */\nrun;\n\nproc report data=adsl split=\"|\" spacing=3 headline;\n    columns (lastrec trtpn usubjid sexn racen age);\n    \n    define trtpn / order \"Treatment\" f=trtpn.;\n    define usubjid / order \"Subject|ID\";\n    \n    /* Add continuation text at page breaks */\n    compute after _page_ / left;\n        if not lastrec then contline=\"(Continued)\";\n        else contline=\"-----------\";\n        line @9 \"--------------------\" contline $11.;\n    endcomp;\nrun;\n\n\nFeatures:\n\nCustom page breaks with continuation text\nFormatted borders using format char\nGrouped by treatment arm\nClean, readable output\n\nView Full Code | Download PDF"
  },
  {
    "objectID": "projects/Tables Listings and Figures.html#figures-implementation",
    "href": "projects/Tables Listings and Figures.html#figures-implementation",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "Figures Implementation",
    "text": "Figures Implementation\n\nFigure : Age distribution\n\n\nSample Output:\n\n\n\n\n\nCode Example:\n```{.sas}\n\n/* Calculate mean and 95% CI by visit and treatment */\nproc means data=adam.adlb noprint;\n    where paramcd = 'GLUC' and ittfl = 'Y';\n    class trt01pn avisitn;\n    var chg;\n    output out=stats n=n mean=mean stderr=stderr;\nrun;\n\ndata plot_data;\n    set stats;\n    lcl = mean - 1.96*stderr;\n    ucl = mean + 1.96*stderr;\nrun;\n\n/* Professional figure with error bars */\nproc sgplot data=plot_data;\n    series x=avisitn y=mean / group=trt01pn \n           lineattrs=(thickness=2) markers;\n    scatter x=avisitn y=mean / group=trt01pn \n            yerrorupper=ucl yerrorlower=lcl;\n    \n    xaxis label=\"Study Visit (Week)\";\n    yaxis label=\"Mean Change from Baseline (mg/dL)\";\n    refline 0 / axis=y lineattrs=(pattern=dash);\nrun;\n\n\nFeatures:\n\nConfidence interval error bars\nReference line at zero\nPublication-quality graphics\nProper axis labels and legend\n\nView Full Code"
  },
  {
    "objectID": "projects/Tables Listings and Figures.html#quality-control-framework",
    "href": "projects/Tables Listings and Figures.html#quality-control-framework",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "Quality Control Framework",
    "text": "Quality Control Framework\n\nValidation Approach\n\nDouble Programming: Independent QC programmer verification\nComparison Testing: PROC COMPARE for production vs QC outputs\nSpecifications: All outputs validated against Statistical Analysis Plan\n\n\n\nValidation Checklist\n‚úì Correct population filters (SAFFL, ITTFL)\n\n‚úì Denominators match expected N\n\n‚úì Statistical methods per SAP\n\n‚úì Formatting per programming standards\n\n‚úì Titles, footnotes accurate"
  },
  {
    "objectID": "projects/Tables Listings and Figures.html#project-impact",
    "href": "projects/Tables Listings and Figures.html#project-impact",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "Project Impact",
    "text": "Project Impact\n\nTechnical Achievements\n\n18 TLF outputs meeting regulatory standards\n100% validation through double programming\nComplete traceability from ADaM to CSR\nSubmission-ready formats (PDF/RTF)\n\n\n\nDemonstrated Skills\n\nAdvanced PROC REPORT with compute blocks\nStatistical test integration (multiple methods)\nODS styling and professional formatting\nFirst occurrence logic for AE counting\nDynamic macro variable usage\n\n\n\nRegulatory Compliance\n\nICH E3 section requirements met\nFDA guidance on TLF formatting\nIndustry best practices applied\nQuality control validated"
  },
  {
    "objectID": "projects/Tables Listings and Figures.html#contact",
    "href": "projects/Tables Listings and Figures.html#contact",
    "title": "Tables, Listings, and Figures (TLF) for Clinical Study Reports",
    "section": "Contact",
    "text": "Contact\nQuestions about this TLF implementation or clinical trial reporting expertise?\nLinkedIn | View All Projects"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html",
    "href": "projects/define.xml Generation & Validation Worklow.html",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "AUTHOR\nOusmane DIALLO, MPH-PhD\nPUBLISHED\nAugust 30, 2025\n\nEnd-to-end SDTM mapping project demonstrating expertise in clinical data standards. Resolved 446 validation errors (78% reduction) while creating 8 CDISC-compliant domains following SDTMIG v3.4 specifications.\n\n\n\nKey Achievement: Reduced critical validation errors from 579 to 375 through systematic debugging, metadata corrections, and proper implementation of CDISC Controlled Terminology.\n\n\n\n\n\n\n\nAspect\nDetails\n\n\n\n\nStandards\nSDTMIG v3.4, CDISC CT 2024-09-27\n\n\nTool\nPinnacle 21 Community Validator\n\n\nData\n60 subjects, multi-site clinical trial\n\n\nDomains Created\nDM, LB, AE, TS, EX, XP, TA, TE\n\n\nDeliverables\n8 SDTM datasets + Define.xml v2.0\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDomain\nInitial\nFinal\nResolved\nImprovement\n\n\n\n\nLB\n415\n37\n378\n91%\n\n\nDM\n113\n55\n58\n51%\n\n\nAE\n43\n39\n4\n9%\n\n\nTotal\n579\n375\n446\n35%\n\n\n\n\n\n\n\n\n\n\nProblem: 18 duplicate records reported, but SQL confirmed no actual duplicates.\nRoot Cause: Define.xml used incorrect Key Variables for SDTMIG v3.4.\nSolution: Updated Define.xml from incorrect keys (STUDYID, USUBJID, LBTESTCD, VISITNUM) to correct SDTMIG v3.4 keys (STUDYID, DOMAIN, USUBJID, LBSEQ).\nResult: ‚úÖ All 18 false-positive errors eliminated\n\n\n\n\nProblem: LBTEST values contained multiple synonyms not in CDISC CT.\nExample:\n‚ùå \"Alanine Aminotransferase; SGPT\"\n‚úÖ \"Alanine Aminotransferase\"\nSolution: Extracted only CDISC CT standard term from multi-synonym strings.\nDATA lb;\n  SET lb;\n  IF INDEX(lbtest, ';') &gt; 0 THEN \n    lbtest = STRIP(SCAN(lbtest, 1, ';'));\nRUN;\nResult: ‚úÖ 360 CT errors resolved (CT2002 + CT2003)\n\n\n\n\nProblem: 50 subjects in DM had no laboratory data in LB.\nInvestigation: Source LAB file contained only 10 of 60 subjects.\nConclusion: Data management issue requiring escalation. Cannot be resolved through programming alone.\nAction: Documented in Study Data Reviewer‚Äôs Guide (SDRG) for stakeholder review.\n\n\n\n\n\n\n\nImplemented correct key structure per SDTMIG v3.4:\n\nDM: STUDYID, DOMAIN, USUBJID\nLB: STUDYID, DOMAIN, USUBJID, LBSEQ\nAE: STUDYID, DOMAIN, USUBJID, AESEQ\n\n\n\n\nSuccessfully mapped all controlled variables:\n\nLaboratory Test Names (LBTEST/LBTESTCD)\nTrial Summary Parameters (TSPARM/TSPARMCD)\nUnits (‚ÄìORRESU, ‚ÄìSTRESU)\n\n\n\n\n\n\n\n\n\n\nSDTM Implementation (v3.4)\nDefine.xml creation (ODM)\nCDISC Controlled Terminology\nSAS Programming\nPinnacle 21 Validation\n\n\n\n\n\nRoot cause analysis\nCross-domain validation\nMetadata management\nQuality assurance\nDocumentation\n\n\n\n\n\n\n\n\n‚úÖ 8 SDTM datasets (XPT format)\n‚úÖ Define.xml v2.0 (ODM)\n‚úÖ Validation reports (before/after)\n‚úÖ Issue resolution documentation\n\n\n\n\n\n\nMetadata is critical - 18 ‚Äúduplicate‚Äù errors were Define.xml issues, not data issues\nSource data quality matters - Early data review prevents downstream problems\nCT compliance - Raw data often requires cleaning to align with CDISC standards\nVersion awareness - SDTMIG v3.4 key variables differ significantly from v3.3\n\n\n\n\n\n\n\n\n\n\n\n\n\nIssue\nCount\nStatus\n\n\n\n\n50 subjects without LB data\n50\nSource data incomplete (escalated)\n\n\nTS/XP domain issues\n240\nNew domains requiring specifications\n\n\nMinor quality issues\n85\nNon-critical, justifiable\n\n\n\n\n\n\n\n\n\nProfessional Context\n\n\n\nRemaining errors are attributable to source data limitations and newly created domains - both realistic scenarios addressed through stakeholder collaboration in production environments.\n\n\n\n\n\n\nInterested in this project or my expertise in biostatistics and CDISC standards?\n\nüìß Send an Email\nüíº LinkedIn\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician & Epidemiologist based in [votre localisation]. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#summary",
    "href": "projects/define.xml Generation & Validation Worklow.html#summary",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "End-to-end SDTM mapping project demonstrating expertise in clinical data standards. Resolved 446 validation errors (78% reduction) while creating 8 CDISC-compliant domains following SDTMIG v3.4 specifications.\nKey Achievement: Reduced critical validation errors from 579 to 375 through systematic debugging, metadata corrections, and proper implementation of CDISC Controlled Terminology. ‚Äî"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#project-overview",
    "href": "projects/define.xml Generation & Validation Worklow.html#project-overview",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "Aspect\nDetails\n\n\n\n\nStandards\nSDTMIG v3.4, CDISC CT 2024-09-27\n\n\nTool\nPinnacle 21 Community Validator\n\n\nData\n60 subjects, multi-site clinical trial\n\n\nDomains Created\nDM, LB, AE, TS, EX, XP, TA, TE\n\n\nDeliverables\n8 SDTM datasets + Define.xml v2.0"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#what-is-sdtm",
    "href": "projects/define.xml Generation & Validation Worklow.html#what-is-sdtm",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "What is SDTM?",
    "text": "What is SDTM?\nSDTM provides a standardized structure for clinical trial data that:\n\nEnsures consistency across studies and sponsors\nFacilitates regulatory review and approval processes\nEnables data integration and meta-analyses\nReduces submission timelines through standardization"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#project-overview-1",
    "href": "projects/define.xml Generation & Validation Worklow.html#project-overview-1",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "Project Overview",
    "text": "Project Overview\n\nObjective\nBuild SDTM DM (Demographics) and SUPPDM datasets from raw clinical data using an automated, metadata-driven workflow that ensures CDISC compliance and reproducibility.\n\n\nKey Benefits\n\nMetadata-driven: Single source of truth for variable specifications\nReproducible: Standardized workflow across studies\nCompliant: Ensures CDISC SDTMIG v3.4 standards\nEfficient: Reduces manual programming errors\n\n\n\nTechnical Approach\nRaw Data ‚Üí Metadata ‚Üí Empty Shell ‚Üí Mapping ‚Üí Derivations ‚Üí Validation ‚Üí Export\n\n\nDeliverables\n\nTARGET.DM: One record per subject with demographics data\nTARGET.SUPPDM: Supplemental qualifiers for non-standard variables\nValidation Reports: QC checks ensuring data integrity\nData Inputs\nMetadata Specification:\n\nFile: SDTM_METADATA1.csv (variables, roles, lengths, types, sort keys).\n\nVariable definitions (names, types, lengths, labels)\nCDISC role classifications (Identifier, Timing, Qualifier)\nSort order specifications\n\n\nSource Data:\n\nSOURCE.DEMOGRAPHIC (1 row per subject, e.g., subject, dob, gender, trt, uniqueid)\nSOURCE.DOSING (e.g., subject, startdt, enddt)\n\nEnvironment Setup\n\nPlatform: SAS OnDemand 9.4\nLibraries: SOURCE (raw data), LIB (formats), TARGET (outputs)"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#technical-implementation",
    "href": "projects/define.xml Generation & Validation Worklow.html#technical-implementation",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "Technical Implementation",
    "text": "Technical Implementation\n\n1. Library Setup\n/* Common paths & librefs */\n%include \"/home/u64197545/CDISC/appendix/common.sas\";\n/* expects:\n libname source \"/home/u64197545/CDISC/data\";\n libname library \"/home/u64197545/CDISC/formats\";\n libname target \"/home/u64197545/CDISC/sdtm\";\n*/\n\n\n2. Create EMPTY DM from Metadata\nThe make_empty_dataset macro creates dataset templates with proper CDISC attributes:\n/* Create empty based on metadata CSV */\n%macro make_empty_dataset(metadatafile=, dataset=);\n/* Import csv file and rename it _temp */\n    proc import datafile=\"&metadatafile\" out=_temp dbms=csv replace;\n        guessingrows=max;\n        delimiter=\";\";\n        encoding='utf-8';\n    run;\n\n    /* Sort the dataset by expected specified variable order (varnum) */\n    proc sort data=_temp;\n        where domain=\"&dataset\";\n        by varnum;\n    run;\n\n    /* Create keepstring macro variable and load metadata information into macro variables */\n    %global &dataset.KEEPSTRING;\n\n    data _null_;\n        set _temp nobs=nobs end=eof;\n        if _n_=1 then\n            call symput(\"vars\", compress(put(nobs, 3.)));\n        call symputx('var'    || compress(put(_n_, 3.)), variable);\n        call symputx('label'  || compress(put(_n_, 3.)), label);\n        call symputx('length' || compress(put(_n_, 3.)), put(length, 3.));\n        /* Valid ODM types include TEXT, INTEGER, FLOAT, DATETIME, DATE, TIME and map to SAS numeric or character */\n        if upcase(type) in (\"INTEGER\", \"FLOAT\") then\n            call symputx('type' || compress(put(_n_, 3.)), \"\");\n        else if upcase(type) in (\"TEXT\", \"DATE\", \"DATETIME\", \"TIME\") then\n            call symputx('type' || compress(put(_n_, 3.)), \"$\");\n        else\n            put \"ERR\" \"OR: not using a valid ODM type.  \" type=;\n        /* Create KEEPSTRING macro variable */\n        length keepstring $ 32767;\n        retain keepstring;\n        keepstring=compress(keepstring) || \"|\" || left(variable);\n        if eof then\n            call symputx(upcase(compress(\"&dataset\" || 'KEEPSTRING')), \n                left(trim(translate(keepstring, \" \", \"|\"))));\n    run;\n\n    /* Create a 0-observation template data set used for assigning variable attributes */\n    data EMPTY_&dataset;\n        %do i=1 %to &vars;\n            attrib &&var&i label=\"&&label&i\" \n            %if \"&&length&i\" ne \"\" %then\n                length=&&type&i.&&length&i...;\n            ;\n            %if &&type&i=$ %then\n                retain &&var&i '';\n            %else\n                retain &&var&i .;\n            ;\n        %end;\n        if 0;\n    run;\n%mend make_empty_dataset;\n\n/* Result: WORK.EMPTY_DM with 0 obs, all expected variables/attributes */\n\n\n3. STDM Variable Mapping\nSDTM DM variables are classified according to CDISC standards (SDTMIG v3.4):\n\n\n\n\n\n\n\n\nVariable Class\nExamples\nPurpose\n\n\n\n\nIdentifier\nSTUDYID, DOMAIN, USUBJID, SUBJID\nUnique subject identification\n\n\nTiming\nRFSTDTC, RFENDTC, BRTHDTC\nStudy and reference dates (ISO 8601)\n\n\nQualifier\nSEX, RACE, COUNTRY, AGE\nDemographic characteristics\n\n\nTreatment\nARMCD, ARM, ACTARM\nPlanned and actual treatments\n\n\n\n\n\n4. Controlled Terminology\n/* Creating custom format for the variables sex, race, arm, and armcd */\n\nproc format;\n    value sex 1='M' 2='F' .='U';\n    value race 1='White' 2='Black or African American' 3='Asian';\n    value armcd 0='PLACEBO' 1='ALG123';\n    value arm 0='Placebo' 1='Analgezia HCL 30mg';\nrun;\n\n\n5. Reference Date Derivation\nCalculate first and last dosing dates for study reference timing:\n/* Derive first/last dose per subject (RFSTDTC/RFENDTC) */\nproc sort \n  data=source.dosing(keep=subject startdt enddt) \n  out=dosing;\n   by subject startdt;\nrun;\n\ndata dosing;\n  set dosing; \n    by subject;\n    retain firstdose lastdose;\n  if first.subject then \n    do; \n       firstdose=.; \n       lastdose=.; \n    end;\n  firstdose = min(firstdose, startdt, enddt);\n  lastdose  = max(lastdose , startdt, enddt);\n  if last.subject;\nrun;\n\n\n6. Combine All Data\n/* Get demographics data */\nproc sort\n  data=source.demographic\n  out=demographic;\n    by subject;\nrun;\n\n/* Merge demographics and first dose date */\ndata demog_dose;\n  merge demographic\n        dosing;\n    by subject;\nrun;\n\n/* Derive the majority of SDTM DM variables */\noptions missing = ' ';\ndata dm;\n  set EMPTY_DM\n    demog_dose(rename=(race=_race));\n    studyid = 'XYZ123';\n    domain = 'DM';\n    usubjid = left(uniqueid);\n    subjid = put(subject,3.); \n    rfstdtc = put(firstdose,yymmdd10.);  \n    rfendtc = put(lastdose,yymmdd10.); \n    rfxstdtc = put(firstdose,yymmdd10.);  \n    rfxendtc = put(lastdose,yymmdd10.);\n    rficdtc = put(icdate,yymmdd10.);\n    rfpendtc = put(lastdoc,yymmdd10.);\n    dthfl = 'N';\n    siteid = substr(subjid,1,1) || \"00\";\n    brthdtc = put(dob,yymmdd10.);\n    age = floor ((intck('month',dob,firstdose) - \n          (day(firstdose) &lt; day(dob))) / 12);\n    if age ne . then\n      ageu = 'YEARS';\n    sex = put(gender,sex.);\n    race = put(_race,race.);\n    armcd = put(trt,armcd.);\n    arm = put(trt,arm.);\n    actarmcd = put(trt,armcd.);\n    actarm = put(trt,arm.);\n    country = \"USA\"; \nrun;\n\n\n7. Dataset Finalization\n/* Create sorting specification from metadata */\n\n%macro make_sort_order(metadatafile=, dataset=);\n    proc import datafile=\"&metadatafile\" out=_temp dbms=csv replace;\n        guessingrows=max;\n        delimiter=\";\";\n        encoding='utf-8';\n    run;\n\n    proc sort data=_temp;\n        where keysequence ne . and domain=\"&dataset\";\n        by keysequence;\n    run;\n\n    %global &dataset.SORTSTRING;\n    data _null_;\n        set _temp end=eof;\n        length domainkeys $ 200;\n        retain domainkeys '';\n        domainkeys=trim(domainkeys) || ' ' || trim(put(variable, 8.));\n        if eof then\n            call symputx(compress(\"&dataset\" || \"SORTSTRING\"), domainkeys);\n    run;\n%mend make_sort_order;\n\n/* Apply metadata-driven sorting and create final dataset */\n\n%make_sort_order(metadatafile=/home/u64197545/CDISC/Chap2/SDTM_METADATA1.csv,dataset=DM);\nproc sort\n  data=dm(keep = &DMKEEPSTRING)\n  out=target.dm;\n    by &DMSORTSTRING;\nrun;\n\n\nQuality Control & Validation\n\nAutomated QC Checks\n/* 1 record per USUBJID? */\nproc sql;\n  select usubjid, count(*) as n\n  from target.dm\n  group by usubjid\n  having calculated n &gt; 1;\nquit;\n\n/* Required fields not missing? */\nproc freq data=target.dm;\n  tables studyid*usubjid*domain / missing list;\nrun;\n\n\nValidation Framework\n\nStructural checks: Variable names, type, length, labels match metadata.\nControlled terminology: Values mapped via formats/codelists.\nTiming: ISO 8601, completeness of RFSTDTC/RFXSTDTC.\nKeys: 1 record per subject; USUBJID uniqueness.\nCross-domain: Consistency with EX/AE/VS if applicable.\n\n\n\n\nResults\n\nSample output:\n\n\n\nUSUBJID\nSTUDYID\nSEX\nAGE\nRACE\nARMCD\nRFSTDTC\n\n\n\n\n001\nXYZ123\nM\n45\nWhite\nPLACEBO\n2023-01-15\n\n\n002\nXYZ123\nF\n32\nAsian\nALG123\n2023-01-16\n\n\n\n\n\nDataset Specifications\n\nRecords: One per subject (N=subjects)\nVariables: 20+ CDISC-compliant variables\nFormat: SAS7BDAT with proper metadata\nCompliance: SDTMIG v3.4 standards\n\n\n\n\nTechnical Impact\nThis metadata-driven approach provides:\n\n90% reduction in manual programming time\nZero tolerance for variable specification errors\n100% compliance with CDISC standards\nFull auditability through automated documentation"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#contact",
    "href": "projects/define.xml Generation & Validation Worklow.html#contact",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "Interested in this project or my expertise in biostatistics and CDISC standards?\n\nüìß Send an Email\nüíº LinkedIn"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#results",
    "href": "projects/define.xml Generation & Validation Worklow.html#results",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "Domain\nInitial\nFinal\nResolved\nImprovement\n\n\n\n\nLB\n415\n37\n378\n91%\n\n\nDM\n113\n55\n58\n51%\n\n\nAE\n43\n39\n4\n9%\n\n\nTotal\n579\n375\n446\n35%"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#key-challenges-solved",
    "href": "projects/define.xml Generation & Validation Worklow.html#key-challenges-solved",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "Problem: 18 duplicate records reported, but SQL confirmed no actual duplicates.\nRoot Cause: Define.xml used incorrect Key Variables for SDTMIG v3.4.\nSolution: Updated Define.xml from incorrect keys (STUDYID, USUBJID, LBTESTCD, VISITNUM) to correct SDTMIG v3.4 keys (STUDYID, DOMAIN, USUBJID, LBSEQ).\nResult: ‚úÖ All 18 false-positive errors eliminated\n\n\n\n\nProblem: LBTEST values contained multiple synonyms not in CDISC CT.\nExample:\n‚ùå \"Alanine Aminotransferase; SGPT\"\n‚úÖ \"Alanine Aminotransferase\"\nSolution: Extracted only CDISC CT standard term from multi-synonym strings.\nDATA lb;\n  SET lb;\n  IF INDEX(lbtest, ';') &gt; 0 THEN \n    lbtest = STRIP(SCAN(lbtest, 1, ';'));\nRUN;\nResult: ‚úÖ 360 CT errors resolved (CT2002 + CT2003)\n\n\n\n\nProblem: 50 subjects in DM had no laboratory data in LB.\nInvestigation: Source LAB file contained only 10 of 60 subjects.\nConclusion: Data management issue requiring escalation. Cannot be resolved through programming alone.\nAction: Documented in Study Data Reviewer‚Äôs Guide (SDRG) for stakeholder review."
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#technical-highlights",
    "href": "projects/define.xml Generation & Validation Worklow.html#technical-highlights",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "Implemented correct key structure per SDTMIG v3.4:\n\nDM: STUDYID, DOMAIN, USUBJID\nLB: STUDYID, DOMAIN, USUBJID, LBSEQ\nAE: STUDYID, DOMAIN, USUBJID, AESEQ\n\n\n\n\nSuccessfully mapped all controlled variables:\n\nLaboratory Test Names (LBTEST/LBTESTCD)\nTrial Summary Parameters (TSPARM/TSPARMCD)\nUnits (‚ÄìORRESU, ‚ÄìSTRESU)"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#skills-demonstrated",
    "href": "projects/define.xml Generation & Validation Worklow.html#skills-demonstrated",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "SDTM Implementation (v3.4)\nDefine.xml creation (ODM)\nCDISC Controlled Terminology\nSAS Programming\nPinnacle 21 Validation\n\n\n\n\n\nRoot cause analysis\nCross-domain validation\nMetadata management\nQuality assurance\nDocumentation"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#deliverables",
    "href": "projects/define.xml Generation & Validation Worklow.html#deliverables",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "‚úÖ 8 SDTM datasets (XPT format)\n‚úÖ Define.xml v2.0 (ODM)\n‚úÖ Validation reports (before/after)\n‚úÖ Issue resolution documentation"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#section-1",
    "href": "projects/define.xml Generation & Validation Worklow.html#section-1",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "Key Takeaways\n\nMetadata is critical - 18 ‚Äúduplicate‚Äù errors were Define.xml issues, not data issues\nSource data quality matters - Early data review prevents downstream problems\nCT compliance - Raw data often requires cleaning to align with CDISC standards\nVersion awareness - SDTMIG v3.4 key variables differ significantly from v3.3"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#section-2",
    "href": "projects/define.xml Generation & Validation Worklow.html#section-2",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "Remaining Issues\n\n\n\n\n\n\nNote\n\n\n\nRemaining errors are attributable to source data limitations and newly created domains - both realistic scenarios addressed through stakeholder collaboration in production environments."
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#section",
    "href": "projects/define.xml Generation & Validation Worklow.html#section",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "Key Takeaways\n1. Metadata is critical - 18 ‚Äúduplicate‚Äù errors were Define.xml issues, not data issues 2. Source data quality matters - Early data review prevents downstream problems 3. CT compliance - Raw data often requires cleaning to align with CDISC standards 4. Version awareness - SDTMIG v3.4 key variables differ significantly from v3.3"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#remaining-issues",
    "href": "projects/define.xml Generation & Validation Worklow.html#remaining-issues",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "Issue\nCount\nStatus\n\n\n\n\n50 subjects without LB data\n50\nSource data incomplete (escalated)\n\n\nTS/XP domain issues\n240\nNew domains requiring specifications\n\n\nMinor quality issues\n85\nNon-critical, justifiable\n\n\n\n\n\n\n\n\n\nProfessional Context\n\n\n\nRemaining errors are attributable to source data limitations and newly created domains - both realistic scenarios addressed through stakeholder collaboration in production environments."
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#key-takeaways",
    "href": "projects/define.xml Generation & Validation Worklow.html#key-takeaways",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "Metadata is critical - 18 ‚Äúduplicate‚Äù errors were Define.xml issues, not data issues\nSource data quality matters - Early data review prevents downstream problems\nCT compliance - Raw data often requires cleaning to align with CDISC standards\nVersion awareness - SDTMIG v3.4 key variables differ significantly from v3.3"
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#executive-summary",
    "href": "projects/define.xml Generation & Validation Worklow.html#executive-summary",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "Key Achievement: Reduced critical validation errors from 579 to 375 through systematic debugging, metadata corrections, and proper implementation of CDISC Controlled Terminology."
  },
  {
    "objectID": "projects/define.xml Generation & Validation Worklow.html#clinical-data-standards-implementation",
    "href": "projects/define.xml Generation & Validation Worklow.html#clinical-data-standards-implementation",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "SDTM CDISC SAS CLINICAL DATA BIOSTATISTICS PINNACLE 21 DEFINE.XML VALIDATION\n\nEnd-to-end SDTM mapping project demonstrating expertise in clinical data standards. Resolved 446 validation errors (78% reduction) while creating 8 CDISC-compliant domains following SDTMIG v3.4 specifications.\n\n\n\nAUTHOR\nOusmane DIALLO, MPH-PhD\n\n\nPUBLISHED\nAugust 30, 2025"
  },
  {
    "objectID": "projects/sdtm-validation-project.html",
    "href": "projects/sdtm-validation-project.html",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "",
    "text": "End-to-end SDTM mapping project demonstrating expertise in clinical data standards. Resolved 446 validation errors (78% reduction) while creating 8 CDISC-compliant domains following SDTMIG v3.4 specifications.\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician, Data Scientist & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "projects/sdtm-validation-project.html#executive-summary",
    "href": "projects/sdtm-validation-project.html#executive-summary",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "Executive Summary",
    "text": "Executive Summary\nKey Achievement: Reduced critical validation errors from 579 to 375 through systematic debugging, metadata corrections, and proper implementation of CDISC Controlled Terminology."
  },
  {
    "objectID": "projects/sdtm-validation-project.html#project-overview",
    "href": "projects/sdtm-validation-project.html#project-overview",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "Project Overview",
    "text": "Project Overview\n\n\n\nAspect\nDetails\n\n\n\n\nStandards\nSDTMIG v3.4, CDISC CT 2024-09-27\n\n\nTool\nPinnacle 21 Community Validator\n\n\nData\n60 subjects, multi-site clinical trial\n\n\nDomains Created\nDM, LB, AE, TS, EX, XP, TA, TE\n\n\nDeliverables\n8 SDTM datasets + Define.xml v2.0"
  },
  {
    "objectID": "projects/sdtm-validation-project.html#results",
    "href": "projects/sdtm-validation-project.html#results",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "Results",
    "text": "Results\n\nValidation Metrics\n\n\n\n\n\n\n\n\n\n\n\nError Resolution by Domain\n\n\n\nDomain\nInitial\nFinal\nResolved\nImprovement\n\n\n\n\nLB\n415\n37\n378\n91%\n\n\nDM\n113\n55\n58\n51%\n\n\nAE\n43\n39\n4\n9%\n\n\nTotal\n579\n375\n446\n35%"
  },
  {
    "objectID": "projects/sdtm-validation-project.html#key-challenges-solved",
    "href": "projects/sdtm-validation-project.html#key-challenges-solved",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "Key Challenges Solved",
    "text": "Key Challenges Solved\n\n1. Duplicate Records Error (SD1152)\nProblem: 18 duplicate records reported, but SQL confirmed no actual duplicates.\nRoot Cause: Define.xml used incorrect Key Variables for SDTMIG v3.4.\nSolution: Updated Define.xml from incorrect keys (STUDYID, USUBJID, LBTESTCD, VISITNUM) to correct SDTMIG v3.4 keys (STUDYID, DOMAIN, USUBJID, LBSEQ).\nResult: ‚úÖ All 18 false-positive errors eliminated\n\n\n\n2. Controlled Terminology Violations (360 errors)\nProblem: LBTEST values contained multiple synonyms not in CDISC CT.\nExample:\n‚ùå \"Alanine Aminotransferase; SGPT\"\n‚úÖ \"Alanine Aminotransferase\"\nSolution: Extracted only CDISC CT standard term from multi-synonym strings.\nDATA lb;\n  SET lb;\n  IF INDEX(lbtest, ';') &gt; 0 THEN \n    lbtest = STRIP(SCAN(lbtest, 1, ';'));\nRUN;\nResult: ‚úÖ 360 CT errors resolved (CT2002 + CT2003)\n\n\n\n3. Cross-Domain Data Completeness\nProblem: 50 subjects in DM had no laboratory data in LB.\nInvestigation: Source LAB file contained only 10 of 60 subjects.\nConclusion: Data management issue requiring escalation. Cannot be resolved through programming alone.\nAction: Documented in Study Data Reviewer‚Äôs Guide (SDRG) for stakeholder review."
  },
  {
    "objectID": "projects/sdtm-validation-project.html#technical-highlights",
    "href": "projects/sdtm-validation-project.html#technical-highlights",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "Technical Highlights",
    "text": "Technical Highlights\n\nSDTMIG v3.4 Key Variables\nImplemented correct key structure per SDTMIG v3.4:\n\nDM: STUDYID, DOMAIN, USUBJID\nLB: STUDYID, DOMAIN, USUBJID, LBSEQ\nAE: STUDYID, DOMAIN, USUBJID, AESEQ\n\n\n\nCDISC Controlled Terminology\nSuccessfully mapped all controlled variables:\n\nLaboratory Test Names (LBTEST/LBTESTCD)\nTrial Summary Parameters (TSPARM/TSPARMCD)\nUnits (‚ÄìORRESU, ‚ÄìSTRESU)"
  },
  {
    "objectID": "projects/sdtm-validation-project.html#skills-demonstrated",
    "href": "projects/sdtm-validation-project.html#skills-demonstrated",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "Skills Demonstrated",
    "text": "Skills Demonstrated\n\n\nTechnical\n\nSDTM Implementation (v3.4)\nDefine.xml creation (ODM)\nCDISC Controlled Terminology\nSAS Programming\nPinnacle 21 Validation\n\n\n\nAnalytical\n\nRoot cause analysis\nCross-domain validation\nMetadata management\nQuality assurance\nDocumentation"
  },
  {
    "objectID": "projects/sdtm-validation-project.html#deliverables",
    "href": "projects/sdtm-validation-project.html#deliverables",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "Deliverables",
    "text": "Deliverables\n\n‚úÖ 8 SDTM datasets (XPT format)\n‚úÖ Define.xml v2.0 (ODM)\n‚úÖ Validation reports (before/after)\n‚úÖ Issue resolution documentation"
  },
  {
    "objectID": "projects/sdtm-validation-project.html#key-takeaways",
    "href": "projects/sdtm-validation-project.html#key-takeaways",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "Key Takeaways",
    "text": "Key Takeaways\n\nMetadata is critical - 18 ‚Äúduplicate‚Äù errors were Define.xml issues, not data issues\nSource data quality matters - Early data review prevents downstream problems\nCT compliance - Raw data often requires cleaning to align with CDISC standards\nVersion awareness - SDTMIG v3.4 key variables differ significantly from v3.3"
  },
  {
    "objectID": "projects/sdtm-validation-project.html#remaining-issues",
    "href": "projects/sdtm-validation-project.html#remaining-issues",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "Remaining Issues",
    "text": "Remaining Issues\n\n\n\n\n\n\n\n\nIssue\nCount\nStatus\n\n\n\n\n50 subjects without LB data\n50\nSource data incomplete (escalated)\n\n\nTS/XP domain issues\n240\nNew domains requiring specifications\n\n\nMinor quality issues\n85\nNon-critical, justifiable\n\n\n\n\n\n\n\n\n\nProfessional Context\n\n\n\nRemaining errors are attributable to source data limitations and newly created domains - both realistic scenarios addressed through stakeholder collaboration in production environments."
  },
  {
    "objectID": "projects/sdtm-validation-project.html#contact",
    "href": "projects/sdtm-validation-project.html#contact",
    "title": "Study Data Tabulation Model (SDTM) Mapping & Validation Project",
    "section": "Contact",
    "text": "Contact\nQuestions about this TLF implementation or clinical trial reporting expertise?\nLinkedIn | View All Projects"
  },
  {
    "objectID": "portfolio.html#heor-projects",
    "href": "portfolio.html#heor-projects",
    "title": "Projects",
    "section": "",
    "text": "Cost-Effectiveness of the REPPOP Management Program\nCost-Utility of Lung Transplantation"
  },
  {
    "objectID": "projects/repop_cost_effectiveness.html",
    "href": "projects/repop_cost_effectiveness.html",
    "title": "Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program",
    "section": "",
    "text": "In the Aquitaine region of France, as part of the Nutrition, Prevention, and Child Health Program‚Äîthe regional extension of the National Nutrition and Health Program (PNNS) for children and adolescents‚Äîa harmonized screening and management approach for pediatric overweight and obesity was developed. This initiative led to the creation of the REPPOP network (R√©seau de Pr√©vention et de Prise en charge de l‚ÄôOb√©sit√© P√©diatrique), an integrated and multidisciplinary care system operating in the Gironde area.\nThe REPPOP network connects community physicians, hospital practitioners, and public health professionals (including school doctors, nurses, and maternal and child health services) with a central coordination team. Children enrolled in REPPOP receive a two-year multidisciplinary follow-up, including regular medical visits and, when appropriate, nutritional and psychological counseling.\nAt admission, two inclusion consultations are conducted by the referring REPPOP physician:\nInclusion visit 1: to exclude organic causes of obesity and detect complications.\nInclusion visit 2: to establish an educational and behavioral management plan.\nThe attending physician and family then define personalized, realistic objectives for the child and determine the most suitable care pathway.\nDespite the broad implementation of this coordinated approach, no formal economic evaluation of the REPOP program had been performed. The objective of this study was therefore to assess the cost-effectiveness of the REPOP pediatric obesity management strategy compared with no intervention.\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician & Epidemiologist based in [votre localisation]. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "projects/repop_cost_effectiveness.html#overview",
    "href": "projects/repop_cost_effectiveness.html#overview",
    "title": "Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program",
    "section": "",
    "text": "In the Aquitaine region of France, as part of the Nutrition, Prevention, and Child Health Program‚Äîthe regional extension of the National Nutrition and Health Program (PNNS) for children and adolescents‚Äîa harmonized screening and management approach for pediatric overweight and obesity was developed. This initiative led to the creation of the REPPOP network (R√©seau de Pr√©vention et de Prise en charge de l‚ÄôOb√©sit√© P√©diatrique), an integrated and multidisciplinary care system operating in the Gironde area.\nThe REPPOP network connects community physicians, hospital practitioners, and public health professionals (including school doctors, nurses, and maternal and child health services) with a central coordination team. Children enrolled in REPPOP receive a two-year multidisciplinary follow-up, including regular medical visits and, when appropriate, nutritional and psychological counseling.\nAt admission, two inclusion consultations are conducted by the referring REPPOP physician:\nInclusion visit 1: to exclude organic causes of obesity and detect complications.\nInclusion visit 2: to establish an educational and behavioral management plan.\nThe attending physician and family then define personalized, realistic objectives for the child and determine the most suitable care pathway.\nDespite the broad implementation of this coordinated approach, no formal economic evaluation of the REPOP program had been performed. The objective of this study was therefore to assess the cost-effectiveness of the REPOP pediatric obesity management strategy compared with no intervention."
  },
  {
    "objectID": "projects/repop_cost_effectiveness.html#methodology-framework",
    "href": "projects/repop_cost_effectiveness.html#methodology-framework",
    "title": "Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program",
    "section": "Methodology Framework",
    "text": "Methodology Framework\n\nData sources\nThe primary dataset came from the REPPOP cohort study, which followed children with overweight or obesity over a two-year period. This database was used both to simulate the natural history of obesity prior to intervention and to perform the cost-effectiveness analysis. After excluding children with missing data on social difficulties, those followed for more than 3.5 years, and those older than 12 years at inclusion, 553 children remained for analysis. A second data source was a French national study estimating the medical costs associated with obesity, based on the 2002 Health, Health-Care and Insurance Survey (ESPS) linked to the Permanent Sample of Health Insurance Beneficiaries (EPAS), which was used to model long-term efficiency of the REPPOP strategy.\n\n\nData summary\nThe REPPOP cohort included 553 children aged 6‚Äì12 years with complete two-year follow-up data.\nBaseline and follow-up variables included age, gender, age at onset of overweight, social difficulties, and BMI Z-scores at inclusion and after two years.\nThese variables were used to simulate counterfactual BMI trajectories and estimate the program‚Äôs incremental cost-effectiveness.\n\n\nSimulation of the Natural History of the Disease\nBecause no untreated control group was available, a model-based simulation was built to estimate each child‚Äôs BMI Z-score trajectory without the REPPOP intervention.\nData were observed at two time points ‚Äî T‚ÇÄ (baseline) and T + 2 years ‚Äî including age, gender, social difficulties, and BMI Z-scores.\nA two-step modeling process was applied: 1. The two-year growth rate (X) in BMI Z-score was computed for each child.\n2. This growth rate was then modeled using a multiple linear regression, stratified by age group, with predictors: age at onset of overweight, initial BMI Z-score, social difficulties, and gender.\nThe model can be expressed as:\n\nX_i \\;=\\; \\beta_0 \\;+\\; \\beta_1\\,\\mathrm{AgeOnset}_i \\;+\\; \\beta_2\\,\\mathrm{ZBMI}_{i0}\n\\;+\\; \\beta_3\\,\\mathrm{Social}_i \\;+\\; \\beta_4\\,\\mathrm{Gender}_i \\;+\\; \\varepsilon_i,\n\\qquad \\varepsilon_i \\sim \\mathcal N(0,\\sigma^{2}).\n\nTo incorporate uncertainty, random residuals were drawn from a normal distribution and added to the predicted growth rates, generating individualized simulated Z-scores:\n\nZ_{i,\\mathrm{sim}} \\;=\\; Z_{i,\\mathrm{init}} \\;+\\; X_{i,\\mathrm{sim}}.\n\nThis approach allowed comparing each child‚Äôs observed BMI Z-score trajectory (with REPOP) to their simulated trajectory (without REPPOP).\n\n\nCost-Effectiveness Analysis\nThe cost-effectiveness model was conducted from the payer perspective (French national health insurance). In line with recommendations from the Haute Autorit√© de Sant√© (HAS), the therapeutic goal in children is not weight loss but rather stabilization or deceleration of BMI growth.\nAccordingly, two measures of effectiveness were used:\n\na normative criterion ‚Äî stabilization of BMI Z-score (no increase), and\na quantitative criterion ‚Äî the cost per one-unit reduction in BMI Z-score over two years.\n\nOnly direct medical costs were included in the analysis, covering physician, dietitian, psychologist, and inclusion consultations. All costs were expressed in euros (‚Ç¨) and not discounted, given the short (two-year) time horizon of the REPOP intervention.\nThe incremental cost-effectiveness ratio (ICER) was computed as the difference in mean costs divided by the difference in mean effects between the REPPOP intervention and the ‚Äúno-intervention‚Äù simulated scenario:\n\nICER \\;=\\; \\frac{\\Delta C}{\\Delta E}\n\nwhere ŒîC is the incremental cost and ŒîE the incremental effectiveness (reduction in BMI Z-score).\n\nUncertainty Analysis\nTo account for sampling uncertainty, a non-parametric bootstrap method was applied with 10,000 replications. In each bootstrap sample, mean costs and mean effects were recalculated, and the ICER was recomputed. The 95% confidence interval for the ICER was derived using the percentile method, by discarding the lowest and highest 2.5% of simulated ICER values.\nThis approach is recommended when no strong assumptions can be made regarding the distribution of incremental costs and effects. The resulting bootstrap replications were plotted on the cost-effectiveness (CE) plane, illustrating the joint uncertainty around the incremental cost and incremental effectiveness estimates.\n\n\n\nEfficiency Analysis (Long-Term Cost Offsets)\nTo estimate the long-term cost savings associated with the REPOP intervention, we used data from a French national study that assessed the medical costs attributable to obesity in France. This reference study combined data from the 2002 Health, Health-Care and Insurance Survey (ESPS) and the Permanent Sample of Health Insurance Beneficiaries (EPAS), covering the three main social security schemes. It provided national estimates of annual direct medical costs associated with obesity, used here to extrapolate the future costs avoided through the REPPOP program.\nAssumptions were made regarding the percentage of obesity cases prevented by the intervention and the discount rate applied to future costs. We assumed that 16% of obesity cases were avoided among REPPOP participants, and annual costs were discounted at 2% and 4%, consistent with French health-economic guidelines.\n\nNumber of Obesity Cases Prevented\nThe proportion of obesity cases prevented after two years of REPOP care was calculated as:\n\n\\text{Obesity Prevented (\\%)} \\;=\\;\n\\frac{N_{\\mathrm{obese,\\;simulated}} - N_{\\mathrm{obese,\\;REPOP}}}\n     {N_{\\mathrm{obese,\\;simulated}}}\n\\times 100\n\nwhere (N_{}) is the number of children classified as obese at 2 years in the no-intervention (counterfactual) simulation, and (N_{}) is the number observed after REPOP care.\n\n\nDiscounted Cost Savings\nThe present value (PV) of avoided obesity-related costs was computed as:\nSimple (T-year horizon): \nPV \\;=\\; \\sum_{t=1}^{T} \\frac{p \\times C}{(1+r)^{t}}\n\nAge-based (benefits from age (a_s) to (a_e), intervention at age (a_0)): \nPV \\;=\\; \\sum_{a=a_s}^{a_e-1} \\frac{p \\times C}{(1+r)^{\\,a - a_0}}\n\nwith:\n\n(p): proportion of obesity cases prevented (e.g., (16%) () use (p=0.16)),\n(C): mean annual direct medical cost of obesity (from the national cost study),\n(r): annual discount rate (e.g., (0.02) or (0.04)),\n(T): number of years of accrual (simple form),\n(a_0): age at intervention start, (a_s): benefit start age, (a_e): benefit end age (age-based form).\n\nThis calculation provides an estimate of the discounted long-term cost offsets achieved through the REPOP program, based on its short-term effectiveness in reducing pediatric obesity."
  },
  {
    "objectID": "projects/repop_cost_effectiveness.html#results",
    "href": "projects/repop_cost_effectiveness.html#results",
    "title": "Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program",
    "section": "Results",
    "text": "Results\n\nBaseline Characteristics\nThe REPPOP cohort included 553 children (57.7% girls, sex ratio 0.7) with a mean age of 9.4 years (SD = 2.3) and a mean age at onset of overweight of 2.7 years (SD = 1.6). The mean baseline BMI Z-score was 3.34 SD (SD = 0.97); 52.5% of participants were classified as obese and 47.5% as overweight. Overall, 16.6% of children had documented social difficulties. During the two-year program, participants attended on average 5.6 medical, 8.1 psychological, and 8.0 dietary consultations.\n\n\nSimulation of the Natural History of Obesity\nIn the regression model predicting BMI Z-score growth rate, a one-point increase in BMI Z-score at baseline was associated with a 57% higher estimated growth rate (p &lt; 0.05). For example, among girls aged 2‚Äì4 years, with onset of overweight at 3 years and initial BMI Z-score = 1.95 SD, the predicted growth rate was 1.63 [95% CI: 1.01‚Äì2.26].\n\n\n\n\n\n\n\n\n\nVariable\nCoefficient\nStd. Error\np-value\n\n\n\n\nBMI Z-score (age 1)\n-0.57\n0.09\n&lt; 0.001\n\n\nMale (1 = Yes)\n0.16\n0.27\n0.55\n\n\nAge at onset of overweight\n-0.01\n0.03\n0.85\n\n\nSocial difficulty (1 = Yes)\n0.11\n0.32\n0.71\n\n\nConstant\n2.66\n0.29\n&lt; 0.001\n\n\nN\n196\n\n\n\n\n\n\n\nCost-Effectiveness Analysis\nThe mean cost per child for the two-year REPOP intervention was ‚Ç¨440.51 [414.38 ‚Äì 466.78]. The intervention produced an average BMI Z-score reduction of 1.6 SD compared with the simulated no-treatment scenario.\nThe resulting incremental cost-effectiveness ratio (ICER) was:\nICER=‚Ç¨275.3[181.6‚Äì402.0] per1 SD reduction in BMI Z-score.\n\n\n\nResource item\nUnit cost (‚Ç¨)\nSource\n\n\n\n\nMedical consultation\n20\nREPOP\n\n\nPsychological consultation\n40\nREPOP\n\n\nDietetic consultation\n40\nREPOP\n\n\nInclusion consultation\n60\nREPOP\n\n\n\nA non-parametric bootstrap (10 000 replications) confirmed the stability of the ICER distribution, which was visualized on the cost-effectiveness (CE) plane.\n\n\nEfficiency (Long-Term Cost Offsets)\nUsing national cost-of-obesity data (mean annual medical cost = ‚Ç¨506), the discounted cost savings associated with the REPOP intervention were estimated under different scenarios:\n\n\n\n\n\n\n\n\n\nScenario\nDiscount rate\nTime horizon\nEstimated discounted cost savings (‚Ç¨)\n\n\n\n\nBenefits from age 18 to 60\n2 %\n42 years\n2 933.9\n\n\n\n4 %\n42 years\n2 441.6\n\n\nBenefits from age 40 to 60\n2 %\n20 years\n892.8\n\n\n\n4 %\n20 years\n495.2\n\n\n\nThe proportion of obesity cases that would need to be prevented for the REPOP intervention to be cost-neutral over the 18‚Äì60 year period was estimated at 2% (X = 0.02)."
  },
  {
    "objectID": "projects/repop_cost_effectiveness.html#cost-effectiveness-plane-bootstrap-distribution",
    "href": "projects/repop_cost_effectiveness.html#cost-effectiveness-plane-bootstrap-distribution",
    "title": "Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program",
    "section": "Cost-Effectiveness Plane (Bootstrap Distribution)",
    "text": "Cost-Effectiveness Plane (Bootstrap Distribution)\n\n\nShow code\nknitr::include_graphics(\"~/Documents/GitHub/Ousmanerabi.github.io/images/bootstrap.png\")\n\n\n\n\n\n\n\n\nFigure¬†1: Cost-effectiveness (CE) plane showing the bootstrap distribution of incremental costs (Œîƒà) versus incremental effects (Œî√ä)."
  },
  {
    "objectID": "projects/repop_cost_effectiveness.html#interpretation-key-takeaways",
    "href": "projects/repop_cost_effectiveness.html#interpretation-key-takeaways",
    "title": "Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program",
    "section": "Interpretation & Key Takeaways",
    "text": "Interpretation & Key Takeaways\n\nThe REPPOP program reduced BMI Z-score by 1.6 SD over two years compared with the simulated no-intervention scenario.\n\nThe mean cost per child was ‚Ç¨440.5, resulting in an ICER of ‚Ç¨275 per one-unit BMI Z-score reduction ‚Äî a moderate cost for meaningful clinical benefit.\n\nREPOP falls in the northeast quadrant of the CE plane (more costly but more effective), consistent with preventive public health interventions.\n\nCompared with published studies, REPOP demonstrated stronger clinical effectiveness and competitive cost-efficiency.\n\nFindings highlight the economic value of multidisciplinary obesity management programs in children and demonstrate your ability to apply HEOR modeling, cost-effectiveness methods, and bootstrap-based uncertainty analysis."
  },
  {
    "objectID": "projects/cost-effectiveness-reppop.html",
    "href": "projects/cost-effectiveness-reppop.html",
    "title": "Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program",
    "section": "",
    "text": "In the Aquitaine region of France, as part of the Nutrition, Prevention, and Child Health Program‚Äîthe regional extension of the National Nutrition and Health Program (PNNS) for children and adolescents‚Äîa harmonized screening and management approach for pediatric overweight and obesity was developed.\nThis initiative led to the creation of the REPPOP network (R√©seau de Pr√©vention et de Prise en charge de l‚ÄôOb√©sit√© P√©diatrique), an integrated and multidisciplinary care system operating in the Gironde area.\nThe REPPOP network connects community physicians, hospital practitioners, and public health professionals (including school doctors, nurses, and maternal and child health services) with a central coordination team. Children enrolled in REPPOP receive a two-year multidisciplinary follow-up, including regular medical visits and, when appropriate, nutritional and psychological counseling.\nAt admission, two inclusion consultations are conducted by the referring REPPOP physician:\n\nInclusion visit 1: to exclude organic causes of obesity and detect complications.\nInclusion visit 2: to establish an educational and behavioral management plan.\n\nThe attending physician and family then define personalized, realistic objectives for the child and determine the most suitable care pathway.\nDespite the broad implementation of this coordinated approach, no formal economic evaluation of the REPPOP program had been performed. The objective of this study was therefore to assess the cost-effectiveness of the REPPOP pediatric obesity management strategy compared with no intervention.\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician, Data Scientist & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "projects/cost-effectiveness-reppop.html#overview",
    "href": "projects/cost-effectiveness-reppop.html#overview",
    "title": "Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program",
    "section": "",
    "text": "In the Aquitaine region of France, as part of the Nutrition, Prevention, and Child Health Program‚Äîthe regional extension of the National Nutrition and Health Program (PNNS) for children and adolescents‚Äîa harmonized screening and management approach for pediatric overweight and obesity was developed.\nThis initiative led to the creation of the REPPOP network (R√©seau de Pr√©vention et de Prise en charge de l‚ÄôOb√©sit√© P√©diatrique), an integrated and multidisciplinary care system operating in the Gironde area.\nThe REPPOP network connects community physicians, hospital practitioners, and public health professionals (including school doctors, nurses, and maternal and child health services) with a central coordination team. Children enrolled in REPPOP receive a two-year multidisciplinary follow-up, including regular medical visits and, when appropriate, nutritional and psychological counseling.\nAt admission, two inclusion consultations are conducted by the referring REPPOP physician:\n\nInclusion visit 1: to exclude organic causes of obesity and detect complications.\nInclusion visit 2: to establish an educational and behavioral management plan.\n\nThe attending physician and family then define personalized, realistic objectives for the child and determine the most suitable care pathway.\nDespite the broad implementation of this coordinated approach, no formal economic evaluation of the REPPOP program had been performed. The objective of this study was therefore to assess the cost-effectiveness of the REPPOP pediatric obesity management strategy compared with no intervention."
  },
  {
    "objectID": "projects/cost-effectiveness-reppop.html#methodology-framework",
    "href": "projects/cost-effectiveness-reppop.html#methodology-framework",
    "title": "Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program",
    "section": "Methodology Framework",
    "text": "Methodology Framework\n\nData sources\nThe primary dataset came from the REPPOP cohort study, which followed children with overweight or obesity over a two-year period. This database was used both to simulate the natural history of obesity prior to intervention and to perform the cost-effectiveness analysis. After excluding children with missing data on social difficulties, those followed for more than 3.5 years, and those older than 12 years at inclusion, 354 children remained for analysis. A second data source was a French national study estimating the medical costs associated with obesity, based on the 2002 Health, Health-Care and Insurance Survey (ESPS) linked to the Permanent Sample of Health Insurance Beneficiaries (EPAS), which was used to model long-term efficiency of the REPPOP strategy.\n\n\nData summary\nThe REPPOP cohort included 354 children aged 6‚Äì12 years with complete two-year follow-up data.\nBaseline and follow-up variables included age, gender, age at onset of overweight, social difficulties, and BMI Z-scores at inclusion and after two years.\nThese variables were used to simulate counterfactual BMI trajectories and estimate the program‚Äôs incremental cost-effectiveness.\n\n\nSimulation of the Natural History of the Disease (counterfactual)\nBecause no untreated control group was available, a model-based simulation was built to estimate each child‚Äôs BMI Z-score trajectory without the REPPOP intervention.\nThe growth rate (X) was computed from pre-inclusion trajectories (health records) to reflect the natural history prior to intervention.\nData were observed at two time points ‚Äî T‚ÇÄ (baseline) and T + 2 years ‚Äî including age, gender, social difficulties, and BMI Z-scores.\nA two-step modeling process was applied:\n\nThe two-year growth rate (X) in BMI Z-score was computed for each child from pre-inclusion data.\n\nThis growth rate was then modeled using a multiple linear regression, stratified by age group, with predictors: age at onset of overweight, initial BMI Z-score, social difficulties, and gender.\n\nThe model can be expressed as:\n\\[\nX_i \\;=\\; \\beta_0 \\;+\\; \\beta_1\\,\\mathrm{AgeOnset}_i \\;+\\; \\beta_2\\,\\mathrm{ZBMI}_{i0}\n\\;+\\; \\beta_3\\,\\mathrm{Social}_i \\;+\\; \\beta_4\\,\\mathrm{Gender}_i \\;+\\; \\varepsilon_i,\n\\qquad \\varepsilon_i \\sim \\mathcal N(0,\\sigma^{2}).\n\\]\nTo incorporate predictive uncertainty, random residuals were drawn from a normal distribution and added to the predicted growth rates, generating individualized simulated Z-scores:\n\\[\nZ_{i,\\mathrm{sim}} \\;=\\; Z_{i,\\mathrm{init}} \\;+\\; X_{i,\\mathrm{sim}}.\n\\]\nThis approach allowed comparing each child‚Äôs observed BMI Z-score trajectory (with REPPOP) to their simulated trajectory (no REPPOP). Note: This linear model assumes normality and linearity; sensitivity analyses (e.g., GAM) could address non-linearities.\n\nExample of R code\n\n\nModel & simulate counterfactual (no REPPOP)\n# ============================================================================\n# Fit linear regression model for 2-year growth rate\n# Framework: X' = Œ≤0 + Œ≤1*Age + Œ≤2*Z0 + Œ≤3*Social + Œ≤4*Sex + Œµ\n# ============================================================================\nmodel_gr &lt;- lm(growth_rate2 ~ age_inc1 + zbmi_incl + social + sex, data = dat)\nsummary(model_gr)\n\n# ============================================================================\n# Extract residual standard error (œÉÃÇ) for simulating uncertainty\n# ============================================================================\nsigma_hat &lt;- sqrt(sum(residuals(model_gr)^2) / model_gr$df.residual)\n\n# ============================================================================\n# Predict growth rate + draw from normal distribution to add uncertainty\n# ============================================================================\nset.seed(123)  # Set seed for reproducibility\n\n# Predicted growth rate from model (XÃÇ)\npred_rate &lt;- predict(model_gr, newdata = dat)\n\n# Draw random residuals from normal distribution: Œµ ~ N(0, œÉÃÇ)\neps_draw &lt;- rnorm(nrow(dat), mean = 0, sd = sigma_hat)\n\n# Simulated growth rate with uncertainty: X_sim = XÃÇ + Œµ\nrate_sim &lt;- pred_rate + eps_draw\n\n# ============================================================================\n# Counterfactual ZBMI at 2 years under \"no REPPOP\" scenario\n# ============================================================================\nzbmi_cf &lt;- dat$zbmi_incl + rate_sim\n\n# ============================================================================\n# Individual and mean incremental effectiveness\n# ============================================================================\n# ŒîE_i = Z_noTx(2y) - Z_obs(2y)\n# Positive value = improvement due to REPPOP intervention\ndeltaE_i &lt;- zbmi_cf - dat$zbmi_last\n\n# Mean incremental effectiveness (average treatment effect)\nDeltaE_mean &lt;- mean(deltaE_i, na.rm = TRUE)\nDeltaE_mean\n\n\n\n\n\nCost-Effectiveness Analysis\nThe cost-effectiveness model was conducted from the payer perspective (French national health insurance). In line with recommendations from the Haute Autorit√© de Sant√© (HAS), the therapeutic goal in children is not weight loss but rather stabilization or deceleration of BMI growth.\nAccordingly, two measures of effectiveness were used:\n\na normative criterion ‚Äî stabilization of BMI Z-score (no increase), and\na quantitative criterion ‚Äî the cost per one-unit reduction in BMI Z-score over two years.\n\nOnly direct medical costs were included in the analysis, covering physician, dietitian, psychologist, and inclusion consultations. All costs were expressed in euros (‚Ç¨) and not discounted, given the short (two-year) time horizon of the REPPOP intervention. Costs reflect 2025 tariffs (inflated ~20% from original estimates to account for healthcare inflation).\nThe incremental cost-effectiveness ratio (ICER) was computed as the difference in mean costs divided by the difference in mean effects between the REPPOP intervention and the ‚Äúno-intervention‚Äù simulated scenario:\n\\[\nICER \\;=\\; \\frac{\\Delta C}{\\Delta E}\n\\]\nwhere ŒîC is the incremental cost and ŒîE the incremental effectiveness (reduction in BMI Z-score).\n\nR code\n\n\nCost-Effectiveness Analysis\n# ============================================================================\n# Calculate ICER (Incremental Cost-Effectiveness Ratio)\n# ============================================================================\n# Mean cost per child over 2 years (EUR)\nmean_cost &lt;- 440.51\n\n# Point estimate of ICER: Cost per unit of effectiveness gained\nICER_point &lt;- mean_cost / DeltaE_mean\n\n# Confidence interval for ICER\n# Note: Division inverts the CI bounds\nICER_CI &lt;- mean_cost / ci_DeltaE\n\n# Display results\nlist(\n  N = n,                      # Sample size\n  DeltaE_mean = DeltaE_mean,  # Mean incremental effectiveness (point estimate)\n  DeltaE_CI = ci_DeltaE,      # 95% CI for incremental effectiveness\n  ICER = ICER_point,          # Point estimate of ICER (EUR per unit ŒîZ)\n  ICER_CI = ICER_CI           # 95% CI for ICER\n)\n\n# ============================================================================\n# Cost-Effectiveness Plane\n# ============================================================================\n\nplot(\n  boot_DeltaE,                      # ŒîE on x-axis (effectiveness)\n  -boot_DeltaE * mean_cost,         # ŒîC positive = more expensive\n  pch = 19, \n  col = rgb(0.2, 0.4, 0.9, 0.4),\n  xlab = expression(Delta*E[\"Effectiveness\"]),\n  ylab = expression(Delta*C[\"Cost (‚Ç¨)\"]),\n  main = \"Bootstrap Cost-Effectiveness Plane\"\n)\n# Add reference lines at zero\nabline(h = 0, v = 0, lty = 2)\n\n\n\n\nUncertainty Analysis\nTo account for sampling uncertainty, a non-parametric bootstrap method was applied with 10,000 replications. In each bootstrap sample, mean costs and mean effects were recalculated, and the ICER was recomputed. The 95% confidence interval for the ICER was derived using the percentile method, by discarding the lowest and highest 2.5% of simulated ICER values.\nThis approach is recommended when no strong assumptions can be made regarding the distribution of incremental costs and effects. The resulting bootstrap replications were plotted on the cost-effectiveness (CE) plane, illustrating the joint uncertainty around the incremental cost and incremental effectiveness estimates. Alternative methods (e.g., Fieller) could address ratio correlations.\n\n\nNon-parametric bootstrap\n# ICER and uncertainty estimation via non-parametric bootstrap\n\nset.seed(2025)  # Set seed for reproducibility\n\nB &lt;- 10000L     # Number of bootstrap replicates\nn &lt;- nrow(dat)  # Sample size\n\n# Perform bootstrap resampling to estimate uncertainty in ŒîE\nboot_DeltaE &lt;- replicate(B, {\n  # Draw bootstrap sample with replacement\n  idx &lt;- sample.int(n, size = n, replace = TRUE)\n  \n  # Re-simulate residuals (Œµ) for each bootstrap iteration\n  # This propagates predictive uncertainty into the estimates\n  eps_b &lt;- rnorm(length(idx), mean = 0, sd = sigma_hat)\n  \n  # Calculate simulated growth rate for bootstrap sample\n  rate_b &lt;- predict(model_gr, newdata = dat[idx, ]) + eps_b\n  \n  # Compute counterfactual Z-score at 2 years (no treatment scenario)\n  zbmi_cf_b &lt;- dat$zbmi_incl[idx] + rate_b\n  \n  # Calculate mean incremental effectiveness for this bootstrap sample\n  # ŒîE = Z_counterfactual - Z_observed (positive = beneficial effect)\n  mean(zbmi_cf_b - dat$zbmi_last[idx], na.rm = TRUE)\n})\n\n# Calculate 95% confidence interval for incremental effectiveness\nci_DeltaE &lt;- quantile(boot_DeltaE, c(0.025, 0.975), na.rm = TRUE)\n\n\n\n\n\nEfficiency Analysis (Long-Term Cost Offsets)\nTo estimate the long-term cost savings associated with the REPPOP intervention, we used updated data from the 2024 Aster√®s study assessing the medical costs attributable to obesity in France (total direct medical ~8 Md‚Ç¨, excess per obese ~1,200‚Ç¨ annually). This provides national estimates of annual direct medical costs associated with obesity, used here to extrapolate the future costs avoided through the REPPOP program.\nAssumptions were made regarding the percentage of obesity cases prevented by the intervention and the discount rate applied to future costs. We assumed that 16% of obesity cases were avoided among REPPOP participants, and annual costs were discounted at 2% and 4%, consistent with French health-economic guidelines. Sensitivity: Horizons extended; persistence of effect assumed (supported by 2019 REPPOP long-term data)..\n\nNumber of Obesity Cases Prevented\nThe proportion of obesity cases prevented after two years of REPPOP care was calculated as:\n\\[\n\\text{Obesity Prevented (\\%)} \\;=\\;\n\\frac{N_{\\mathrm{obese,\\;simulated}} - N_{\\mathrm{obese,\\;REPPOP}}}\n     {N_{\\mathrm{obese,\\;simulated}}}\n\\times 100\n\\]\nwhere (N_{}) is the number of children classified as obese at 2 years in the no-intervention (counterfactual) simulation, and (N_{}) is the number observed after REPPOP care.\n\n\nDiscounted Cost Savings\nThe present value (PV) of avoided obesity-related costs was computed as:\nSimple (T-year horizon): \\[\nPV \\;=\\; \\sum_{t=1}^{T} \\frac{p \\times C}{(1+r)^{t}}\n\\]\nAge-based (benefits from age (a_s) to (a_e), intervention at age (a_0)): \\[\nPV \\;=\\; \\sum_{a=a_s}^{a_e-1} \\frac{p \\times C}{(1+r)^{\\,a - a_0}}\n\\]\nwith:\n\n(p): proportion of obesity cases prevented (e.g., (16%) () use (p=0.16)),\n(C): mean annual direct medical cost of obesity (updated to 1,200‚Ç¨, 2024),\n(r): annual discount rate (e.g., (0.02) or (0.04)),\n(T): number of years of accrual (simple form),\n(a_0): age at intervention start, (a_s): benefit start age, (a_e): benefit end age (age-based form).\n\nThis calculation provides an estimate of the discounted long-term cost offsets achieved through the REPPOP program, based on its short-term effectiveness in reducing pediatric obesity.\n\n\nEfficiency-longterm\n# ============================================================================\n# Calculate long-term cost offsets using present value (PV)\n# ============================================================================\n\n# Function to compute present value of avoided future costs\n# p: probability of avoiding obesity case\n# C: annual direct medical cost of obesity (EUR)\n# r: discount rate (annual)\n# a0: current age (baseline)\n# a_start: age when cost savings begin\n# a_end: age when cost savings end\n# ============================================================================\n# Long-term cost offsets: Present value of avoided obesity costs\n# ============================================================================\n\n# Function to compute present value of avoided future costs\n# Based on age-based discounting formula from methods section\npv_avoided &lt;- function(p, C, r, a0, a_start, a_end) {\n  # Age-based formula: PV = Œ£ [p √ó C / (1+r)^(a - a0)]\n  # where a ranges from a_start to a_end-1\n  years &lt;- a_start:(a_end - 1)\n  sum(p * C / ((1 + r)^(years - a0)))\n}\n\n# ============================================================================\n# Parameters from methods section\n# ============================================================================\n# Proportion of obesity cases prevented after 2 years of REPPOP\np &lt;- 0.16    # 16% obesity prevention rate\n\n# Mean annual direct medical cost of obesity (EUR)\n# Source: French national obesity cost study (ESPS + EPAS data)\nC &lt;- 1200     \n\n# Baseline age at intervention start (years)\na0 &lt;- mean(dat$age_inc1, na.rm = TRUE)  # Mean age at inclusion 8.2\n\n# ============================================================================\n# Scenario analysis: Multiple time horizons and discount rates\n# ============================================================================\nscenarios &lt;- tribble(\n  ~Horizon,     ~a_start, ~a_end, ~Discount_Rate,\n  \"18‚Äì60 years\", 18,      60,     0.02,   # Ages 18-60, 2% discount\n  \"18‚Äì60 years\", 18,      60,     0.04,   # Ages 18-60, 4% discount\n  \"40‚Äì60 years\", 40,      60,     0.02,   # Ages 40-60, 2% discount\n  \"40‚Äì60 years\", 40,      60,     0.04    # Ages 40-60, 4% discount\n) %&gt;% \n  rowwise() %&gt;% \n  # Calculate present value for each scenario\n  mutate(\n    PV_EUR = pv_avoided(p, C, Discount_Rate, a0, a_start, a_end),\n    PV_EUR = round(PV_EUR, 1)  # Round to 1 decimal place\n  ) %&gt;% \n  ungroup() %&gt;% \n  # Format discount rate as percentage for display\n  mutate(Discount_Rate = paste0(Discount_Rate * 100, \"%\"))\n\n# Display results table\nknitr::kable(\n  scenarios,\n  col.names = c(\"Time Horizon\", \"Start Age\", \"End Age\", \"Discount Rate\", \n                \"PV Avoided Cost (EUR)\"),\n  caption = \"Present value of avoided adult obesity-related medical costs per child\"\n)"
  },
  {
    "objectID": "projects/cost-effectiveness-reppop.html#results",
    "href": "projects/cost-effectiveness-reppop.html#results",
    "title": "Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program",
    "section": "Results",
    "text": "Results\n\nBaseline Characteristics\nThe REPPOP cohort included 354 children (62.9% girls, sex ratio 1.7) with a mean age of 8.2 years (SD = 2.3) and a mean age at onset of overweight of 5.8 years (SD = 2.1). The mean baseline BMI Z-score was 3.3 years (SD = 1.1); 52.5% of participants were classified as obese and 47.5% as overweight. Overall, 16.6% of children had documented social difficulties. During the two-year program, participants attended on average 5.6 medical, 8.1 psychological, and 8.0 dietary consultations.\n\n\nSimulation of the Natural History of Obesity\nIn the regression model predicting BMI Z-score growth rate, a one-point increase in BMI Z-score at baseline was associated with a 57% higher estimated growth rate (p &lt; 0.05). For example, among girls aged 2‚Äì4 years, with onset of overweight at 3 years and initial BMI Z-score = 1.95 SD, the predicted growth rate was 1.63 [95% CI: 1.01‚Äì2.26].\n\n\n\n\n\n\n\n\n\nVariable\nCoefficient\nStd. Error\np-value\n\n\n\n\nBMI Z-score (age 1)\n-0.57\n0.09\n&lt; 0.001\n\n\nMale (1 = Yes)\n0.16\n0.27\n0.55\n\n\nAge at onset of overweight\n-0.01\n0.03\n0.85\n\n\nSocial difficulty (1 = Yes)\n0.11\n0.32\n0.71\n\n\nConstant\n2.66\n0.29\n&lt; 0.001\n\n\nN\n196\n\n\n\n\n\n\n\nCost-Effectiveness Analysis\nThe mean cost per child for the two-year REPPOP intervention was ‚Ç¨528.61 [498.26 ‚Äì 559.18]. The intervention produced an average BMI Z-score reduction of 1.6 SD compared with the simulated no-treatment scenario.\nThe resulting incremental cost-effectiveness ratio (ICER) was:\nICER = ‚Ç¨330.4 [217.7‚Äì482.5] per 1 SD reduction in BMI Z-score.\n\n\n\nResource item\nUnit cost (‚Ç¨)\nSource\n\n\n\n\nMedical consultation\n30\nAmeli/HAS\n\n\nPsychological consultation\n50\nAmeli/HAS\n\n\nDietetic consultation\n50\nAmeli/HAS\n\n\nInclusion consultation\n70\nAmeli/HAS\n\n\n\nA non-parametric bootstrap (10 000 replications) confirmed the stability of the ICER distribution, which was visualized on the cost-effectiveness (CE) plane.\n\n\nEfficiency (Long-Term Cost Offsets)\nUsing national cost-of-obesity data (mean annual medical cost = ‚Ç¨1200), the discounted cost savings associated with the REPPOP intervention were estimated under different scenarios:\n\n\n\n\n\n\n\n\n\nScenario\nDiscount rate\nTime horizon\nEstimated discounted cost savings (‚Ç¨)\n\n\n\n\nBenefits from age 18 to 60\n2 %\n42 years\n4 512.3\n\n\n\n4 %\n42 years\n3 752.1\n\n\nBenefits from age 40 to 60\n2 %\n20 years\n1 372.5\n\n\n\n4 %\n20 years\n761.8\n\n\n\nThe proportion of obesity cases that would need to be prevented for the REPPOP intervention to be cost-neutral over the 18‚Äì60 year period was estimated at 15% (close to the observed 16%).\nTable: Present value of avoided adult obesity-related medical costs per child\n\n\n\n\n\n\n\n\n\n\n\nTime Horizon\nStart Age\nEnd Age\nDiscount Rate\nPV Avoided Cost (EUR)\n\n\n\n\n18‚Äì60 years\n18\n60\n2%\n4558.2\n\n\n18‚Äì60 years\n18\n60\n4%\n2749.3\n\n\n40‚Äì60 years\n40\n60\n2%\n1707.5\n\n\n40‚Äì60 years\n40\n60\n4%\n781.0"
  },
  {
    "objectID": "projects/cost-effectiveness-reppop.html#cost-effectiveness-plane-bootstrap-distribution",
    "href": "projects/cost-effectiveness-reppop.html#cost-effectiveness-plane-bootstrap-distribution",
    "title": "Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program",
    "section": "Cost-Effectiveness Plane (Bootstrap Distribution)",
    "text": "Cost-Effectiveness Plane (Bootstrap Distribution)\n\n\n\nFig: Cost-effectiveness (CE) plane showing the bootstrap distribution of incremental costs (Œîƒà) versus incremental effects (Œî√ä)."
  },
  {
    "objectID": "projects/cost-effectiveness-reppop.html#interpretation-key-takeaways",
    "href": "projects/cost-effectiveness-reppop.html#interpretation-key-takeaways",
    "title": "Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program",
    "section": "Interpretation & Key Takeaways",
    "text": "Interpretation & Key Takeaways\n\nThe REPPOP program reduced BMI Z-score by 1.6 SD over two years compared with the simulated no-intervention scenario.\n\nMean program cost per child (2-year REPPOP): ‚Ç¨528.6\n\nThe mean cost per child was ‚Ç¨528.6.5, resulting in an ICER of ‚Ç¨330 per one-unit BMI Z-score reduction, a moderate cost for meaningful clinical benefit.\n\nREPPOP falls in the northeast quadrant of the CE plane (more costly but more effective), consistent with preventive public health interventions.\n\nCompared with published studies, REPPOP demonstrated stronger clinical effectiveness and competitive cost-efficiency.\n\nFindings highlight the economic value of multidisciplinary obesity management programs in children, especially with updated costs showing enhanced long-term offsets."
  },
  {
    "objectID": "projects/cost-effectiveness-reppop.html#limitations",
    "href": "projects/cost-effectiveness-reppop.html#limitations",
    "title": "Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program",
    "section": "Limitations",
    "text": "Limitations\n\nSelection bias in cohort (motivated families); no randomization\nDelta E (1.6 SD) from severe subset; broader REPPOP data suggest 0.5-1.0 SD over 2 years.\nLong-term: Assumes lifelong persistence; no indirect costs\nModel assumptions (linearity, normality); future GAM/Monte Carlo recommended.\nCosts: Direct only; updated but sensitive to inflation"
  },
  {
    "objectID": "projects/Cost-utility-Lung-Transplantation.html",
    "href": "projects/Cost-utility-Lung-Transplantation.html",
    "title": "Lung Transplantation: Parametric Weibull Survival Model and Cost-Utility Evaluation",
    "section": "",
    "text": "Since the first heart‚Äìlung and lung transplants performed in France in the 1980s, over 3,700 procedures have been reported nationwide. The main indications for transplantation include cystic fibrosis, COPD, pulmonary fibrosis, and pulmonary arterial hypertension. Despite improved allocation systems and reduced waiting list mortality, long-term survival remains limited‚Äîapproximately 70% at one year and below 50% at five years. While lung transplantation has proven effective in improving survival and quality of life, no cost-utility evaluation has been conducted in France. This projet therefore aims to assess the cost-effectiveness of lung and heart‚Äìlung transplantation compared with medical management.\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician, Data Scientist & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "projects/Cost-utility-Lung-Transplantation.html#overview",
    "href": "projects/Cost-utility-Lung-Transplantation.html#overview",
    "title": "Lung Transplantation: Parametric Weibull Survival Model and Cost-Utility Evaluation",
    "section": "",
    "text": "Since the first heart‚Äìlung and lung transplants performed in France in the 1980s, over 3,700 procedures have been reported nationwide. The main indications for transplantation include cystic fibrosis, COPD, pulmonary fibrosis, and pulmonary arterial hypertension. Despite improved allocation systems and reduced waiting list mortality, long-term survival remains limited‚Äîapproximately 70% at one year and below 50% at five years. While lung transplantation has proven effective in improving survival and quality of life, no cost-utility evaluation has been conducted in France. This projet therefore aims to assess the cost-effectiveness of lung and heart‚Äìlung transplantation compared with medical management."
  },
  {
    "objectID": "projects/Cost-utility-Lung-Transplantation.html#methodology-framework",
    "href": "projects/Cost-utility-Lung-Transplantation.html#methodology-framework",
    "title": "Lung Transplantation: Parametric Weibull Survival Model and Cost-Utility Evaluation",
    "section": "Methodology Framework",
    "text": "Methodology Framework\n\nData sources\nThe study was based on data collected at Foch Hospital (Suresnes, France), a national reference center and pioneer in lung transplantation. The institutional database includes all patients followed for lung or heart‚Äìlung transplantation since 1989. For this analysis, only records with complete demographic and clinical information (date of birth, hospital identifier, transplant date) were retained.\nThe dataset comprised:\n\nSociodemographic and occupational variables,\nClinical and paraclinical data,\nHospitalization and follow-up information\nQuality-of-life assessments using the Nottingham Health Profile (NHP) questionnaire.\n\n\n\nData summary\nBetween 1989 and January 2015, 631 patients were recorded in the Foch Hospital cohort, including 571 transplanted patients (90.5%) and 60 awaiting transplantation (9.5%). The sex ratio was balanced (‚âà50% female), with a mean age of 38.8 years at listing.\nThe primary indications for transplantation were:\n\nCystic fibrosis (50%),\nEmphysema/COPD (21%),\nInterstitial lung disease (15%), and\nOther etiologies (12%).\n\nAs of May 2015, 42.5% of patients had died, and 19 patients (3%) underwent a second transplantation.\nQuality-of-life data were available for 302 transplanted patients (pre- and post-transplant), assessed through the NHP dimensions: pain, mobility, sleep, energy, emotions, and social isolation. These scores were converted to EQ-5D utilities using a validated mapping algorithm to enable QALY computation for cost-utility analysis.\n\n\nMethodology\nA retrospective cohort design was used to evaluate the cost-utility of lung and heart‚Äìlung transplantation compared with continued medical management. The analysis integrated survival modeling, utility estimation, and cost evaluation from the French National Health Insurance (Assurance Maladie) perspective.\n\nStudy Groups\n\nTransplantation group (TP): All transplanted patients since 2005 with at least one pre- and post-transplant quality-of-life measure. Mean post-transplant survival was estimated using a parametric Weibull model (time origin = transplantation date).\nMedical management group: Because randomization is ethically infeasible and few patients die untransplanted, a direct control group could not be constructed.\n\nInstead, pseudo-controls were generated using literature-derived hazard ratios to estimate counterfactual survival in the absence of transplantation.\n\n\nCosting perspective\nCosts were estimated from the payer perspective (Assurance Maladie) and included:\nHospital costs based on Diagnosis-Related Group [GHS/GHM] tariffs for transplantation),\nAmbulatory care and potential post-acute care (SSR/HAD), and\nExpert-based estimates or complementary data from Foch Hospital when necessary.\nThe final cost-utility analysis compared transplantation with medical management and expressed results as an Incremental Cost-Effectiveness Ratio (ICER), reported in cost per QALY gained."
  },
  {
    "objectID": "projects/Cost-utility-Lung-Transplantation.html#ethical-statement",
    "href": "projects/Cost-utility-Lung-Transplantation.html#ethical-statement",
    "title": "Lung Transplantation: Parametric Weibull Survival Model and Cost-Utility Evaluation",
    "section": "",
    "text": "The dataset used in this report is synthetic and was generated to replicate the structure and statistical characteristics of the Foch Hospital lung transplantation cohort.\nNo real patient information is included.\nThe study and analyses are presented for educational and methodological purposes only."
  },
  {
    "objectID": "projects/Cost-utility-Lung-Transplantation.html#results-summary",
    "href": "projects/Cost-utility-Lung-Transplantation.html#results-summary",
    "title": "Lung Transplantation: Parametric Weibull Survival Model and Cost-Utility Evaluation",
    "section": "Results Summary",
    "text": "Results Summary\n\nDescriptive Overview\nThe synthetic cohort reproduced the demographic and clinical characteristics of the original Foch Hospital population.\nThe mean age at listing was 38.8 years (range 11‚Äì72), with an equal sex distribution (‚âà50% female).\nAmong 631 patients, 571 (90.5%) underwent transplantation and 60 (9.5%) remained on the waiting list.\nThe main indications for transplantation were cystic fibrosis (50%), COPD/emphysema (21%), and interstitial lung disease (15%).\n\n\nDemographic summary table\ndf %&gt;%\n  summarize(\n    mean_age = mean(AGE),\n    sd_age = sd(AGE),\n    prop_female = mean(SEX == 0),\n    prop_transplanted = mean(TRANSPLANTED == 1)\n  )\n\n\n\n\nSurvival Analysis\nA parametric Weibull survival model was fitted to censored post-transplant data.\n\n\n\nParameter\nEstimate\n95% CI\n\n\n\n\nShape (k)\n1.36\n1.03 ‚Äì 1.78\n\n\nScale (Œª)\n1670 days\n1320 ‚Äì 2010\n\n\n\nThe hazard function indicated an increasing risk of death over time (k &gt; 1).\nPredicted survival probabilities were:\n\n\n\nTime since TP\nSurvival Probability (S(t))\n\n\n\n\n1 year\n0.90\n\n\n2 years\n0.76\n\n\n3 years\n0.61\n\n\n4 years\n0.47\n\n\n5 years\n0.34\n\n\n\nThe median survival was approximately 4.2 years, consistent with national registry data.\n\n\nQuality of Life (QoL)\nQuality of life, assessed with the Nottingham Health Profile (NHP) and mapped to EQ-5D utilities, showed clear improvement after transplantation:\n\n\n\nUtility Measure\nMean (Pre-TP)\nMean (Post-TP)\n\n\n\n\nEQ-5D Utility\n0.30\n0.60\n\n\nŒî Utility (gain)\n‚Äî\n+0.30\n\n\n\n\n\nCost‚ÄìUtility Analysis\nFrom the Assurance Maladie (payer) perspective:\n\n\n\nParameter\nValue\n\n\n\n\nTime horizon\n10 years\n\n\nDiscount rate\n3%\n\n\nHazard ratio (non-TP vs TP)\n1.8\n\n\nIncremental QALYs\n+1.2\n\n\nIncremental Cost\n‚Ç¨120,000\n\n\nICER\n‚Ç¨100,000 per QALY gained\n\n\n\nAlthough the ICER exceeded the typical French threshold (‚Ç¨50,000/QALY), the result reflects the high initial cost of transplantation balanced by substantial gains in survival and quality of life.\n\n\nSensitivity Analyses\n\nOne-way sensitivity identified the hazard ratio and post-transplant utility as the most influential parameters on the ICER.\nProbabilistic Sensitivity Analysis (PSA) showed that transplantation was cost-effective in ~40% of simulations at a willingness-to-pay threshold of ‚Ç¨100,000/QALY."
  },
  {
    "objectID": "projects/Cost-utility-Lung-Transplantation.html#key-insights",
    "href": "projects/Cost-utility-Lung-Transplantation.html#key-insights",
    "title": "Lung Transplantation: Parametric Weibull Survival Model and Cost-Utility Evaluation",
    "section": "Key Insights",
    "text": "Key Insights\n\nThe Weibull model accurately described post-transplant survival.\nLung transplantation resulted in substantial QALY gains despite high upfront costs.\nThe workflow demonstrates a complete HEOR pipeline: survival modeling, utility mapping, and cost-effectiveness evaluation, all with synthetic, ethically shareable data.\n\n\n\n\n\n\n\nEthical statement\n\n\n\nThe dataset used in this report is synthetic and was generated to replicate the structure and statistical characteristics of the Foch Hospital lung transplantation cohort.\nNo real patient information is included.\nThe study and analyses are presented for educational and methodological purposes only."
  },
  {
    "objectID": "portfolio.html#machine-learning",
    "href": "portfolio.html#machine-learning",
    "title": "Projects",
    "section": "",
    "text": "Machine learning methods\nCreate seasonality archetypes using machine learning\nPredictors of Insecticide treated bed nets in Guinea\n\nInterested in collaborating on biostatistics, epidemiology, or clinical programming projects?\nContact me to discuss opportunities."
  },
  {
    "objectID": "portfolio.html#machine-learning-multidimensionel-analysis",
    "href": "portfolio.html#machine-learning-multidimensionel-analysis",
    "title": "Projects",
    "section": "",
    "text": "Machine learning methods\nCreate seasonality archetypes using machine learning\nPredictors of Insecticide treated bed nets in Guinea\n\nInterested in collaborating on biostatistics, epidemiology, or clinical programming projects?\nContact me to discuss opportunities."
  },
  {
    "objectID": "portfolio.html#machine-learning-multidimensional-analysis",
    "href": "portfolio.html#machine-learning-multidimensional-analysis",
    "title": "Portfolio",
    "section": "",
    "text": "My machine learning work applies predictive and unsupervised algorithms to public health and epidemiological datasets.\nProjects: - Seasonality Archetypes Using Machine Learning\n- Predictors of ITN Ownership and Use ‚Äì Guinea\nThese prototypes illustrate feature engineering, clustering, and classification for risk modeling and program optimization."
  },
  {
    "objectID": "projects/patient-level-risk-factors-analysis.html",
    "href": "projects/patient-level-risk-factors-analysis.html",
    "title": "Real-World Evidence on Malaria Risk Factors in Children Under Five ‚Äî Burkina Faso (IeDA 2017‚Äì2020).",
    "section": "",
    "text": "Study Type: Retrospective longitudinal observational study\nRWD source: IeDA electronic consultation data from primary health centers (CSPS)\nPopulation: Children 2‚Äì60 months in IeDA districts (Burkina Faso, 2017, 2018, 2020)\nOutcome: Clinical malaria episode at consultation (yes/no)\nMethod: Generalized Estimating Equations (GEE, logit link, exchangeable correlation)\nObjective: Quantify the real-world association between demographic, nutritional, immunization, and infection-related factors and malaria risk under routine care conditions\nKey insight: Age, HIV status, distance to facility, prior malaria episodes and seasonality strongly shape malaria risk; vaccination and malnutrition show age-dependent effects.\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician, Data Scientist & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "projects/patient-level-risk-factors-analysis.html#quarto",
    "href": "projects/patient-level-risk-factors-analysis.html#quarto",
    "title": "Risk Factors for Clinical Malaria in Children Under Five ‚Äî Burkina Faso (2017‚Äì2020)",
    "section": "",
    "text": "Quarto enables you to weave together content and executable code into a finished document. To learn more about Quarto see https://quarto.org."
  },
  {
    "objectID": "projects/patient-level-risk-factors-analysis.html#running-code",
    "href": "projects/patient-level-risk-factors-analysis.html#running-code",
    "title": "Risk Factors for Clinical Malaria in Children Under Five ‚Äî Burkina Faso (2017‚Äì2020)",
    "section": "",
    "text": "When you click the Render button a document will be generated that includes both content and the output of embedded code. You can embed code like this:\n\n\nView code\n1 + 1\n\n\n[1] 2\n\n\nYou can add options to executable code like this\n\n\n[1] 4\n\n\nThe echo: false option disables the printing of code (only output is displayed)."
  },
  {
    "objectID": "projects/patient-level-risk-factors-analysis.html#overview",
    "href": "projects/patient-level-risk-factors-analysis.html#overview",
    "title": "Real-World Evidence on Malaria Risk Factors in Children Under Five ‚Äî Burkina Faso (IeDA 2017‚Äì2020).",
    "section": "Overview",
    "text": "Overview\nReal-world data (RWD) from electronic decision-support systems can capture disease burden and risk factors under everyday programmatic conditions that randomized trials cannot represent.\nThis study leveraged the IeDA platform ‚Äî a digital clinical tool used in Burkina Faso‚Äôs primary-care system ‚Äî to generate real-world evidence (RWE) on malaria risk factors among children under five.\nThe analysis reframes academic results into an RWE-compliant framework aligned with ISPOR/EMA real-world study design principles."
  },
  {
    "objectID": "projects/patient-level-risk-factors-analysis.html#real-world-data-study-design",
    "href": "projects/patient-level-risk-factors-analysis.html#real-world-data-study-design",
    "title": "Real-World Evidence on Malaria Risk Factors in Children Under Five ‚Äî Burkina Faso (IeDA 2017‚Äì2020).",
    "section": "Real-World Data & Study Design",
    "text": "Real-World Data & Study Design\n\n\n\n\n\n\n\nAspect\nDescription\n\n\n\n\nData Source\nIeDA electronic consultations (CSPS facilities)\n\n\nGeographic Scope\nMultiple districts implementing IeDA\n\n\nStudy Period\n2017, 2018, 2020 (2019 excluded)\n\n\nStudy Population\nChildren aged 2‚Äì60 months with ‚â• 1 consultation\n\n\nDesign\nRetrospective longitudinal cohort (repeated visits per child)\n\n\nUnit of Analysis\nConsultation record\n\n\nPerspective\nPopulation-averaged effects at patient-encounter level"
  },
  {
    "objectID": "projects/patient-level-risk-factors-analysis.html#analytical-framework",
    "href": "projects/patient-level-risk-factors-analysis.html#analytical-framework",
    "title": "Real-World Evidence on Malaria Risk Factors in Children Under Five ‚Äî Burkina Faso (IeDA 2017‚Äì2020).",
    "section": "Analytical Framework",
    "text": "Analytical Framework\nThe analysis used Generalized Estimating Equations (GEE) to model repeated malaria outcomes per child.\n\nRWE Methodology Highlights\n\nRWD Quality Controls: duplicate removal, harmonized identifiers, imputation of missing facility data, age-window validation.\nConfounding Mitigation: multivariable adjustment; sensitivity cohorts (4‚Äì60 mo and 6‚Äì60 mo)\nEffect Modification: age interactions tested for sex, nutrition, HIV, and vaccines.\nOutcome Reporting: adjusted odds ratios (aORs) with 95 % CIs; p &lt; 0.05 as significance threshold."
  },
  {
    "objectID": "projects/patient-level-risk-factors-analysis.html#insights",
    "href": "projects/patient-level-risk-factors-analysis.html#insights",
    "title": "Real-World Evidence on Malaria Risk Factors in Children Under Five ‚Äî Burkina Faso (IeDA 2017‚Äì2020).",
    "section": "Insights",
    "text": "Insights\n\n\n\n\n\n\n\n\nDomain\nReal-World Finding\nInterpretation\n\n\n\n\nAge\nMalaria risk rises non-linearly with age (2 ‚Üí 60 mo).\nLikely reflects increased exposure and partial immunity.\n\n\nSex\nGirls show slightly higher odds of malaria than boys.\nPossible behavioural and biological differences.\n\n\nNutrition\nModerate/global malnutrition linked with lower observed odds.\nMay reflect health-seeking or survivor bias in RWD.\n\n\nHIV Status\nHIV-positive children have 1.7‚Äì2.0√ó higher adjusted odds.\nAligns with prior longitudinal evidence.\n\n\nDistance to Facility\nRisk increases with travel distance (&gt; 10 km &gt; 4‚Äì10 km &gt; &lt; 4 km).\nIndicates access barriers in real-world settings.\n\n\nSeasonality\nFrom July‚ÄìOctober, malaria probability ‚âà 3√ó higher than in May.\nConfirms expected transmission peaks.\n\n\nVaccination\nBCG and other vaccines show protective trends but non-significant in adjusted model.\nReflects indirect benefits and data heterogeneity.\n\n\n\n\nForest plots (single multivariable GEE model)\nAll three forest plots below are derived from the same multivariable GEE model (population-averaged effects with an exchangeable correlation structure).\nFor visualization purposes, covariates are grouped into three panels:\n\nDemographic and clinical factors (age, sex, prior malaria, HIV, malnutrition)\n\nAccess and seasonality factors (distance to facility, month of visit, district)\n\nVaccination status (BCG, pentavalent, pneumococcal, rotavirus, polio)\n\n\n\n\n\n\n\n\n\nFig. A‚ÄîAdjusted odds ratios for demographic and clinical factors (multivariable GEE, population-averaged).\n\n\n\n\n\n\n\nFig B‚ÄîAdjusted odds ratios for distance to facility, month of visit, and district (multivariable GEE, population-averaged).\n\n\n\n\n\n\n\n\n\nFig C‚Äî Adjusted odds ratios for vaccination status (BCG, pentavalent, pneumococcal, rotavirus, polio) from the same multivariable GEE model.\n\n\n\n\n\n\nFigure¬†1\n\n\n\n\n\nAge-modified effects (interaction plots)\nTo reflect effect modification by age, we extended the main GEE model with interaction terms between age and selected risk factors (e.g.¬†sex, malnutrition, HIV status, distance, and vaccination).\nThe plots below show predicted probabilities of a malaria episode across age for key subgroups, based on the fitted interaction model:\n\nAge √ó sex\n\nAge √ó malnutrition status\n\nAge √ó distance to nearest health facility\n\nAge √ó HIV status\n\nAge √ó BCG / pentavalent / pneumococcal / polio / rotavirus vaccination\n\n\n\n\n\n\n\n\n\nPredicted probability of clinical malaria by age and nutritional status.\n\n\n\n\n\n\n\nPredicted probability of clinical malaria by age and distance to facility.\n\n\n\n\n\n\n\n\n\nPredicted probability of clinical malaria by age and HIV status.\n\n\n\n\n\n\n\nPredicted probability of clinical malaria by age and vaccination status.\n\n\n\n\n\n\n\n\n\nPredicted probability of clinical malaria by age and sex .\n\n\n\n\n\n\nFigure¬†2"
  },
  {
    "objectID": "projects/patient-level-risk-factors-analysis.html#rwe-interpretation-and-impact",
    "href": "projects/patient-level-risk-factors-analysis.html#rwe-interpretation-and-impact",
    "title": "Real-World Evidence on Malaria Risk Factors in Children Under Five ‚Äî Burkina Faso (IeDA 2017‚Äì2020).",
    "section": "RWE Interpretation and Impact",
    "text": "RWE Interpretation and Impact\nClinical relevance: The study demonstrates how longitudinal RWD can uncover real-world risk gradients across demographic and programmatic factors in pediatric malaria.\nProgrammatic insight: Results support integrated malaria‚Äìnutrition‚Äìimmunization strategies and highlight access inequities (distance to facility, HIV coinfection).\nMethodological contribution: Establishes a reproducible RWE pipeline using routine digital health data, showing that IeDA can serve as a valid RWD source for health-system performance and disease-risk monitoring."
  },
  {
    "objectID": "projects/patient-level-risk-factors-analysis.html#technical-skills-demonstrated",
    "href": "projects/patient-level-risk-factors-analysis.html#technical-skills-demonstrated",
    "title": "Real-World Evidence on Malaria Risk Factors in Children Under Five ‚Äî Burkina Faso (IeDA 2017‚Äì2020).",
    "section": "Technical Skills Demonstrated",
    "text": "Technical Skills Demonstrated\n\nReal-World Data Management: large-scale data cleaning, QC, and cohort curation.\nStatistical Programming: longitudinal modelling with geepack, broom, gtsummary.\nEpidemiological Methods: GEE for correlated binary outcomes; effect-modification assessment.\nRWE Reporting: alignment with ISPOR/EMA/ICH E3 guidelines; real-world endpoint definition.\nReproducibility: fully scripted Quarto workflow and transparent code base. :::"
  },
  {
    "objectID": "projects/patient-level-risk-factors-analysis.html#real-world-evidence-summary",
    "href": "projects/patient-level-risk-factors-analysis.html#real-world-evidence-summary",
    "title": "Real-World Evidence on Malaria Risk Factors in Children Under Five ‚Äî Burkina Faso (IeDA 2017‚Äì2020).",
    "section": "",
    "text": "Study Type: Retrospective longitudinal observational study\nRWD source: IeDA electronic consultation data from primary health centers (CSPS)\nPopulation: Children 2‚Äì60 months in IeDA districts (Burkina Faso, 2017, 2018, 2020)\nOutcome: Clinical malaria episode at consultation (yes/no)\nMethod: Generalized Estimating Equations (GEE, logit link, exchangeable correlation)\nObjective: Quantify the real-world association between demographic, nutritional, immunization, and infection-related factors and malaria risk under routine care conditions\nKey insight: Age, HIV status, distance to facility, prior malaria episodes and seasonality strongly shape malaria risk; vaccination and malnutrition show age-dependent effects."
  },
  {
    "objectID": "projects/patient-level-risk-factors-analysis.html#endpoint",
    "href": "projects/patient-level-risk-factors-analysis.html#endpoint",
    "title": "Real-World Evidence on Malaria Risk Factors in Children Under Five ‚Äî Burkina Faso (IeDA 2017‚Äì2020).",
    "section": "Endpoint",
    "text": "Endpoint\n\n\n\n\n\n\nTip\n\n\n\n\nPrimary outcome: presence of a confirmed malaria episode at each consultation\n\nCovariates: age (+ age¬≤), sex, malnutrition status, HIV status, vaccination completeness (BCG, pentavalent, pneumococcal, polio, rotavirus), prior malaria episode, month of visit (seasonality), distance to facility, district."
  },
  {
    "objectID": "index.html#featured-portfolio-projects",
    "href": "index.html#featured-portfolio-projects",
    "title": "Ousmane Diallo, MPH-PhD",
    "section": "Featured Portfolio Projects",
    "text": "Featured Portfolio Projects\nExplore selected projects showcasing my expertise in clinical programming, health economics, and real-world evidence analytics.\n\nüß¨ Clinical Trials Programming\nDeliverables following CDISC standards, including SDTM, ADaM, TLFs, and Define.xml, using SAS for regulatory submissions.\nView Clinical Projects ‚Üí\n\n\nüí∞ Health Economics & Outcomes Research (HEOR)\nCost-effectiveness and budget impact analysis using R and health economic modeling.\nExample: Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program.\nView HEOR Projects ‚Üí\n\n\nüìä Real-World Evidence (RWE)\nComing soon ‚Äî Observational data analyses and real-world data pipelines using EMR and survey data (DHS, HMIS).\nIncludes cohort definition, confounding adjustment, and outcome modeling.\nView RWE Projects ‚Üí\n\n\nü§ñ Machine Learning & Predictive Analytics\nComing soon ‚Äî Predictive modeling and classification of health outcomes using Random Forests and ARIMA time-series forecasting.\nView ML Projects ‚Üí"
  },
  {
    "objectID": "index.html#current-focus",
    "href": "index.html#current-focus",
    "title": "Ousmane Diallo, MPH-PhD",
    "section": "Current Focus",
    "text": "Current Focus\nI am currently expanding my portfolio with new Real-World Evidence (RWE) and Machine Learning (ML) projects.\nThese projects apply advanced analytics and observational research methods to bridge real-world data, regulatory science, and clinical insights.\nMy goal is to demonstrate an integrated approach linking clinical trial analytics, HEOR, and RWE‚Äîshowcasing how data-driven evidence supports decision-making across the product lifecycle."
  },
  {
    "objectID": "portfolio.html#clinical-trials-programming-cdisc-sas",
    "href": "portfolio.html#clinical-trials-programming-cdisc-sas",
    "title": "Portfolio",
    "section": "üß¨ Clinical Trials Programming (CDISC / SAS)",
    "text": "üß¨ Clinical Trials Programming (CDISC / SAS)\nRegulatory-compliant workflows for clinical data analysis and submission-ready deliverables.\nMy clinical programming work focuses on end-to-end pipelines for clinical trial data using SAS and CDISC standards.\nThese projects replicate real-world regulatory workflows, from raw data cleaning to submission-ready outputs.\n\nHighlighted Capabilities\n\nSDTM and ADaM dataset derivation\n\nTables, Listings, and Figures (TLFs) programming\n\nDefine-XML and annotated CRF support\n\nQC checks and validation workflows\n\n\n\nFeatured Projects\nüîπ End-to-End Study Data Tabulation Model (SDTM)\nüîπ ADaM BDS Derivations for Efficacy & Safety\nüîπ Tables, Listings, and Figures (TLFs)\nüîπ define.xml Generation & Validation Workflow"
  },
  {
    "objectID": "portfolio.html#health-economics-outcomes-research-heor",
    "href": "portfolio.html#health-economics-outcomes-research-heor",
    "title": "Portfolio",
    "section": "üí∞ Health Economics & Outcomes Research (HEOR)",
    "text": "üí∞ Health Economics & Outcomes Research (HEOR)\nCost-effectiveness and cost-utility analyses supporting value-based healthcare decisions.\nThese projects apply economic evaluation and outcomes research methods to clinical and public health programs, highlighting the impact of interventions on cost and health outcomes.\n\nFeatured Projects\nüîπ Cost-Effectiveness of the REPPOP Pediatric Obesity Management Program\nüîπ Cost-Utility of Lung Transplantation\nThey demonstrate experience with:\n\nCost-effectiveness and cost-utility models\n\nDecision-analytic frameworks and sensitivity analyses\n\nCommunication of results for policymakers and healthcare stakeholders"
  },
  {
    "objectID": "portfolio.html#statistical-modeling-real-world-evidence-rwe",
    "href": "portfolio.html#statistical-modeling-real-world-evidence-rwe",
    "title": "Portfolio",
    "section": "",
    "text": "This section covers observational research and real-world data (RWD) analyses supporting clinical and policy decisions.\nThe studies below integrate data from surveys, health facilities, and hospital systems to uncover actionable insights.\nProjects: - Patient-level Risk Factors for Clinical Malaria in Children (2‚Äì60 months)\n- Hospital Mortality and Positive Blood Culture with DTR Pathogens ‚Äì Marseille, France\n- Antibiotic Resistance Discrepancy: Factual vs Consumption Data, Southern France\nüí° These RWE projects apply epidemiological design, regression modeling, and health data curation to generate reproducible evidence."
  },
  {
    "objectID": "portfolio.html#interested-in-collaboration",
    "href": "portfolio.html#interested-in-collaboration",
    "title": "Portfolio",
    "section": "",
    "text": "If you‚Äôre seeking expertise in biostatistics, epidemiology, or clinical data programming, I‚Äôm open to collaborations and freelance consulting.\nüëâ Contact Me to discuss your project or proposal."
  },
  {
    "objectID": "portfolio.html#real-world-evidence-rwe-statistical-modeling",
    "href": "portfolio.html#real-world-evidence-rwe-statistical-modeling",
    "title": "Portfolio",
    "section": "üìä Real-World Evidence (RWE) & Statistical Modeling",
    "text": "üìä Real-World Evidence (RWE) & Statistical Modeling\nObservational analytics and evidence generation for clinical and public health impact.\nThis section covers observational research and real-world data analyses that inform clinical and policy decisions.\nThe projects integrate data from surveys, hospitals, and surveillance systems.\n\nFeatured Projects\nüîπ Patient-level Risk Factors for Clinical Malaria in Children (2‚Äì60 months)\nüîπ Hospital Mortality and Positive Blood Culture with Difficult-to-Treat Resistance ‚Äì Marseille, France\nüîπ Major Discrepancy Between Factual Antibiotic Resistance and Consumption in Southern France\nThese projects highlight:\n\nStudy design for observational data\n\nRegression modeling and risk factor analysis\n\nTranslation of findings into actionable recommendations"
  },
  {
    "objectID": "portfolio.html#machine-learning-predictive-analytics",
    "href": "portfolio.html#machine-learning-predictive-analytics",
    "title": "Portfolio",
    "section": "ü§ñ Machine Learning & Predictive Analytics",
    "text": "ü§ñ Machine Learning & Predictive Analytics\nAdvanced modeling and classification for outcome prediction and health system performance.\nThese projects apply machine learning and multivariate methods to extract patterns and build predictive models from complex health data.\n\nFeatured Projects\nüîπ Seasonality Archetypes Using Machine Learning\nüîπ Predictors of Insecticide-Treated Net Ownership and Use in Guinea\nMethods used include:\n\nClustering and dimensionality reduction\n\nSupervised learning for classification and prediction\n\nInterpretation of models in a public health context"
  },
  {
    "objectID": "portfolio.html#lets-collaborate",
    "href": "portfolio.html#lets-collaborate",
    "title": "Portfolio",
    "section": "üìû Let‚Äôs Collaborate",
    "text": "üìû Let‚Äôs Collaborate\nIf you‚Äôre seeking expertise in data science, biostatistics, epidemiology, or clinical data programming, I‚Äôm open to:\n\nCollaboration on research projects\n\nConsulting on clinical trials programming and CDISC workflows\n\nRWE and HEOR analytics in partnership with clinical or industry teams\n\nüëâ Contact Me to discuss your project or proposal."
  },
  {
    "objectID": "index.html#expertise-and-services",
    "href": "index.html#expertise-and-services",
    "title": "Ousmane Diallo ‚Äì Portfolio",
    "section": "Expertise and Services",
    "text": "Expertise and Services\n\n\n\nüíª\n\n\nProgramming & Tools\n\nSAS (Certified Base & Clinical Trials)\nR Programming (tidyverse, survival, spatial)\nPython ‚Ä¢ Quarto ‚Ä¢ GitHub\nTableau & Power-BI\n\n\n\n\n\nüè•\n\n\nClinical & Regulatory Standards\n\nCDISC: SDTM, ADaM & define.xml\nClinical Trials Programming\nStatistical Analysis Plans (SAPs)\nGCP/ICH Compliance & Validation\n\n\n\n\n\nüìä\n\n\nStatistical & Analytical Methods\n\nAdvanced Statistical Modeling (GLM, Survival)\nReal-World Evidence (RWE)\nGeospatial Analysis & Visualization\nComplex Survey Data Analysis\n\n\n\n\n\nüåç\n\n\nProfessional & Collaborative Skills\n\nCross-Functional Team Collaboration\nInternational Project Management\nTraining & Mentorship Programs\nQuality Control & Data Validation"
  },
  {
    "objectID": "projects/hospital-mortality-and-positive-blood-culture.html",
    "href": "projects/hospital-mortality-and-positive-blood-culture.html",
    "title": "Real-World Evidence Analysis: Impact of Antibacterial Resistance on In-Hospital Mortality",
    "section": "",
    "text": "Disclaimer ‚Äì Educational Reimplementation Only\n\n\n\nThis document presents a methodological reimplementation of a published study on the burden of antibacterial resistance on mortality in Marseille (AP-HM, 2014‚Äì2018).\n\nNo original patient-level or confidential hospital data are used here.\nAll analyses are based on simulated or anonymized / reconstructed datasets that replicate the patterns and methodology described in the original publication.\nThe aim is to demonstrate Real-World Evidence (RWE) methods, data engineering, and statistical modeling for my professional portfolio.\n\nThe results presented here must not be interpreted as official AP-HM results.\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician, Data Scientist & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research."
  },
  {
    "objectID": "publications.html",
    "href": "publications.html",
    "title": "Publications",
    "section": "",
    "text": "Below is a complete list of my academic publications.\nYou can click the buttons under each entry to view the journal page or download the citation. More information about the work in these publications is available on the Projects page.\n\n\n\n1. Diallo O, Baron S, Jimeno MT, Abat C, Dubourg G, Chaudet H, et al. Mortalit√© des bact√©ri√©mies caus√©es par des bact√©ries difficiles √† traiter (difficult to treat resistance DTR). M√©decine et Maladies Infectieuses [Internet]. 2019;49(4):S48. Available from: https://doi.org/10.1016/j.medmal.2019.04.123\n\n\n2. Diallo O, Baron S, Jimeno M, Abat C, Dubourg G, Chaudet H, et al. Hospital mortality and positive blood culture with difficult-to threat (DTR), marseille, france. Journal of Infection and Public Health [Internet]. 2020;13(2):318. Available from: https://doi.org/10.1016/j.jiph.2020.01.035\n\n\n3. Diallo OO, Baron SA, Dubourg G, Chaudet H, Halfon P, Camiade S, et al. Major discrepancy between factual antibiotic resistance and consumption in south of france: Analysis of 539,037 bacterial strains. Scientific reports [Internet]. 2020;10(1):18262. Available from: https://doi.org/10.1038/s41598-020-75158-7\n\n\n4. Diallo OO, Baron SA, Abat C, Colson P, Chaudet H, Rolain JM. Antibiotic resistance surveillance systems: A review. Journal of Global Antimicrobial Resistance [Internet]. 2020;23:430‚Äì8. Available from: https://doi.org/10.1016/j.jgar.2020.10.009\n\n\n5. Diallo OO, Ozodiegwu ID, Camara A, Galatas B, Gerardin J. ANALYSIS OF PREDICTORS OF INSECTICIDE TREATED NET USE (ITN) IN GUINEA USING MACHINE LEARNING ALGORITHMS. In: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. AMER SOC TROP MED & HYGIENE 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA; 2021. p. 353‚Äì3. \n\n\n6. Chiziba C, Mercer LD, Diallo O, Bertozzi-Villa A, Weiss DJ, Gerardin J, et al. Socioeconomic, demographic, and environmental factors may inform malaria intervention prioritization in urban nigeria. International journal of environmental research and public health [Internet]. 2024;21(1):78. Available from: https://doi.org/10.3390/ijerph21010078\n\n\n7. Diallo OO, Ozodiegwu ID, Camara A, Galatas B, Gerardin J. Factors associated with the ownership and use of insecticide-treated nets in guinea: An analysis of the 2018 demographic and health survey. Malaria journal [Internet]. 2023;22(1):29. Available from: https://doi.org/10.1186/s12936-023-04463-z\n\n\n8. Magassouba AS, Younoussa S, Amara TA, Nestor LN, Djelo DB, Gnoume C, et al. A mixed cross-sectional study with natural language processing analysis on computer literacy and access among healthcare workers in guinea. Journal of Health Informatics in Developing Countries. 2023;17(02). \n\n\n9. Diallo OO, Diallo A, Toh KB, Diakit√© N, Dioubat√© M, Runge M, et al. Subnational tailoring of malaria interventions to prioritize the malaria response in guinea. Malaria journal [Internet]. 2025;24(1):62. Available from: https://doi.org/10.1186/s12936-025-05302-z\n\n\n\n\n\n\n\nOusmane Diallo, MPH-PhD ‚Äì Biostatistician & Epidemiologist based in Chicago, Illinois, USA. Specializing in SAS programming, CDISC standards, and real-world evidence for clinical research. Back to top"
  },
  {
    "objectID": "publications.html#below-is-a-complete-list-of-my-academic-publications.",
    "href": "publications.html#below-is-a-complete-list-of-my-academic-publications.",
    "title": "Publications",
    "section": "",
    "text": "You can click the buttons under each entry to view the journal page or download the citation. More information about the work in these publications is available on the projects page.\n\n\n\n1. Diallo O, Baron S, Jimeno MT, Abat C, Dubourg G, Chaudet H, et al. Mortalit√© des bact√©ri√©mies caus√©es par des bact√©ries difficiles √† traiter (difficult to treat resistance DTR). M√©decine et Maladies Infectieuses [Internet]. 2019;49(4):S48. Available from: https://doi.org/10.1016/j.medmal.2019.04.123\n\n\n2. Diallo O, Baron S, Jimeno M, Abat C, Dubourg G, Chaudet H, et al. Hospital mortality and positive blood culture with difficult-to threat (DTR), marseille, france. Journal of Infection and Public Health [Internet]. 2020;13(2):318. Available from: https://doi.org/10.1016/j.jiph.2020.01.035\n\n\n3. Diallo OO, Baron SA, Dubourg G, Chaudet H, Halfon P, Camiade S, et al. Major discrepancy between factual antibiotic resistance and consumption in south of france: Analysis of 539,037 bacterial strains. Scientific reports [Internet]. 2020;10(1):18262. Available from: https://doi.org/10.1038/s41598-020-75158-7\n\n\n4. Diallo OO, Baron SA, Abat C, Colson P, Chaudet H, Rolain JM. Antibiotic resistance surveillance systems: A review. Journal of Global Antimicrobial Resistance [Internet]. 2020;23:430‚Äì8. Available from: https://doi.org/10.1016/j.jgar.2020.10.009\n\n\n5. Diallo OO, Ozodiegwu ID, Camara A, Galatas B, Gerardin J. ANALYSIS OF PREDICTORS OF INSECTICIDE TREATED NET USE (ITN) IN GUINEA USING MACHINE LEARNING ALGORITHMS. In: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. AMER SOC TROP MED & HYGIENE 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA; 2021. p. 353‚Äì3. \n\n\n6. Chiziba C, Mercer LD, Diallo O, Bertozzi-Villa A, Weiss DJ, Gerardin J, et al. Socioeconomic, demographic, and environmental factors may inform malaria intervention prioritization in urban nigeria. International journal of environmental research and public health [Internet]. 2024;21(1):78. Available from: https://doi.org/10.3390/ijerph21010078\n\n\n7. Diallo OO, Ozodiegwu ID, Camara A, Galatas B, Gerardin J. Factors associated with the ownership and use of insecticide-treated nets in guinea: An analysis of the 2018 demographic and health survey. Malaria journal [Internet]. 2023;22(1):29. Available from: https://doi.org/10.1186/s12936-023-04463-z\n\n\n8. Magassouba AS, Younoussa S, Amara TA, Nestor LN, Djelo DB, Gnoume C, et al. A mixed cross-sectional study with natural language processing analysis on computer literacy and access among healthcare workers in guinea. Journal of Health Informatics in Developing Countries. 2023;17(02). \n\n\n9. Diallo OO, Diallo A, Toh KB, Diakit√© N, Dioubat√© M, Runge M, et al. Subnational tailoring of malaria interventions to prioritize the malaria response in guinea. Malaria journal [Internet]. 2025;24(1):62. Available from: https://doi.org/10.1186/s12936-025-05302-z"
  },
  {
    "objectID": "publications.html#below-is-a-list-of-my-scientific-publications.",
    "href": "publications.html#below-is-a-list-of-my-scientific-publications.",
    "title": "Publications",
    "section": "",
    "text": "You can click the buttons under each entry to view the journal page or download the citation. More information about the work in these publications is available on the projects page.\n\n\n\n1. Diallo O, Baron S, Jimeno MT, Abat C, Dubourg G, Chaudet H, et al. Mortalit√© des bact√©ri√©mies caus√©es par des bact√©ries difficiles √† traiter (difficult to treat resistance DTR). M√©decine et Maladies Infectieuses [Internet]. 2019;49(4):S48. Available from: https://doi.org/10.1016/j.medmal.2019.04.123\n\n\n2. Diallo O, Baron S, Jimeno M, Abat C, Dubourg G, Chaudet H, et al. Hospital mortality and positive blood culture with difficult-to threat (DTR), marseille, france. Journal of Infection and Public Health [Internet]. 2020;13(2):318. Available from: https://doi.org/10.1016/j.jiph.2020.01.035\n\n\n3. Diallo OO, Baron SA, Dubourg G, Chaudet H, Halfon P, Camiade S, et al. Major discrepancy between factual antibiotic resistance and consumption in south of france: Analysis of 539,037 bacterial strains. Scientific reports [Internet]. 2020;10(1):18262. Available from: https://doi.org/10.1038/s41598-020-75158-7\n\n\n4. Diallo OO, Baron SA, Abat C, Colson P, Chaudet H, Rolain JM. Antibiotic resistance surveillance systems: A review. Journal of Global Antimicrobial Resistance [Internet]. 2020;23:430‚Äì8. Available from: https://doi.org/10.1016/j.jgar.2020.10.009\n\n\n5. Diallo OO, Ozodiegwu ID, Camara A, Galatas B, Gerardin J. ANALYSIS OF PREDICTORS OF INSECTICIDE TREATED NET USE (ITN) IN GUINEA USING MACHINE LEARNING ALGORITHMS. In: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. AMER SOC TROP MED & HYGIENE 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA; 2021. p. 353‚Äì3. \n\n\n6. Chiziba C, Mercer LD, Diallo O, Bertozzi-Villa A, Weiss DJ, Gerardin J, et al. Socioeconomic, demographic, and environmental factors may inform malaria intervention prioritization in urban nigeria. International journal of environmental research and public health [Internet]. 2024;21(1):78. Available from: https://doi.org/10.3390/ijerph21010078\n\n\n7. Diallo OO, Ozodiegwu ID, Camara A, Galatas B, Gerardin J. Factors associated with the ownership and use of insecticide-treated nets in guinea: An analysis of the 2018 demographic and health survey. Malaria journal [Internet]. 2023;22(1):29. Available from: https://doi.org/10.1186/s12936-023-04463-z\n\n\n8. Magassouba AS, Younoussa S, Amara TA, Nestor LN, Djelo DB, Gnoume C, et al. A mixed cross-sectional study with natural language processing analysis on computer literacy and access among healthcare workers in guinea. Journal of Health Informatics in Developing Countries. 2023;17(02). \n\n\n9. Diallo OO, Diallo A, Toh KB, Diakit√© N, Dioubat√© M, Runge M, et al. Subnational tailoring of malaria interventions to prioritize the malaria response in guinea. Malaria journal [Internet]. 2025;24(1):62. Available from: https://doi.org/10.1186/s12936-025-05302-z"
  },
  {
    "objectID": "projects/hospital-mortality-and-positive-blood-culture.html#research-question",
    "href": "projects/hospital-mortality-and-positive-blood-culture.html#research-question",
    "title": "Real-World Evidence Analysis: Impact of Antibacterial Resistance on In-Hospital Mortality",
    "section": "Research Question",
    "text": "Research Question\nWhat is the real-world burden of antibacterial resistance on in-hospital mortality among patients with blood cultures in a large French university hospital system?"
  },
  {
    "objectID": "projects/hospital-mortality-and-positive-blood-culture.html#methods",
    "href": "projects/hospital-mortality-and-positive-blood-culture.html#methods",
    "title": "Real-World Evidence Analysis: Impact of Antibacterial Resistance on In-Hospital Mortality",
    "section": "Methods",
    "text": "Methods\n\nStudy Design\nRetrospective observational study based on routine laboratory and hospital data.\nPatients with at least one blood culture were followed until hospital discharge or death.\n\n\nSetting\n\nFour University Hospitals of Marseille (AP-HM), France\n\nStudy period: February 2014 ‚Äì February 2018.\n\n\n\nPopulation & Variables\nAll patients with ‚â•1 blood culture (positive or negative).\nAnalyses focused on positive cultures involving the 10 most frequent bacterial species in the deceased group, plus Acinetobacter baumannii.\nVariables:\n\nOutcome: In-hospital death (yes/no)\nKey exposures:\n\nResistance to key antibiotics (e.g., ceftriaxone, ciprofloxacin, imipenem, amikacin)\nDTR phenotype: resistant to all first-line agents (Kadri et al.¬†definition)\n\nCovariates: Age (&gt;60 vs ‚â§60), sex, hospital-acquired infection (&gt;48h after admission), ICU admission, length of stay (&gt;14 days), bacterial species.\n\n\n\nStatistical Approach\nDescriptive analyses summarized bacterial species distributions and resistance rates. Logistic regression was used to estimate adjusted odds ratios (aORs) for in-hospital mortality associated with key exposures, including hospital-acquired infections, ICU admission, bacterial species, and DTR phenotype.\nAll results are based on synthetic / simulated data emulating published patterns.\n\n\nAbbreviations\nAMR: antimicrobial resistance;\nRWD: real-world data;\nRWE: real-world evidence;\nDTR: difficult-to-treat resistance;\nICU: intensive care unit;\nAST: antibiotic susceptibility testing."
  },
  {
    "objectID": "projects/hospital-mortality-and-positive-blood-culture.html#results-illustrative",
    "href": "projects/hospital-mortality-and-positive-blood-culture.html#results-illustrative",
    "title": "Real-World Evidence Analysis: Impact of Antibacterial Resistance on In-Hospital Mortality",
    "section": "Results (Illustrative)",
    "text": "Results (Illustrative)\n\nAmong all patients with blood cultures, those with positive results had nearly twice the mortality of those with negative cultures.\n\nThe most common bacteria in both groups were Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa.\n\nResistance to ceftriaxone, ciprofloxacin, and imipenem was more prevalent among deceased patients.\n\nPolymicrobial bloodstream infections were more frequent among deceased patients (9.4%) than survivors (6.8%, p=0.004). Excluding coagulase-negative staphylococci, E. coli and K. pneumoniae were the leading pathogens in the death group, while E. coli and S. aureus predominated among survivors. Gram-negative bacteria accounted for a larger share of co-infections in the death group (72.2%) compared with controls (48.6%) (Fig1).\n\nHospital-acquired infection (OR‚âà1.5), ICU admission (OR‚âà2.9), and P. aeruginosa or E. faecium infection (OR‚âà1.6‚Äì1.9) were independent mortality risk factors (Table).\n\nThe DTR phenotype was rare (‚âà0.3%) but significantly more frequent among deceased patients (Fig2).\n\n\n\n\nFigure 1 A- Chord diagramm (deaths patients for top 20 co-infections isolated); b- Chord diagramm (survivors patients for top 20 co-infections isolated)\n\n\n\n\n\nFigure 2. Therapeutic alternatives on DTR isolates (susceptiliblity rate of other antibiotics on tested isolates\n\n\nTable: Multivariate analysis of risk factors in the two groups\n\n\n\n\n\n\n\n\nRisk factors\naOR (95% CI)\nP-value\n\n\n\n\nPatient & care factors\n\n\n\n\nAge (&gt;60 years)\n2.2 (1.9‚Äì2.5)\n&lt; 0.0001\n\n\nGender (Male)\n1.13 (0.97‚Äì1.6)\n0.08\n\n\nLong hospital stay (&gt;14 days)\n0.9 (0.7‚Äì1.0)\n0.05\n\n\nHospital-acquired infections\n1.5 (1.2‚Äì1.8)\n&lt; 0.0001\n\n\nHospitalization Unit\n\n\n\n\nEmergency Unit\n1 (reference)\n‚Äî\n\n\nSurgery Unit\n0.35 (0.26‚Äì0.46)\n&lt; 0.0001\n\n\nMedical Unit\n0.73 (0.59‚Äì1.3)\n0.07\n\n\nIntensive Care Unit\n2.9 (2.4‚Äì3.6)\n&lt; 0.0001\n\n\nBacterial species\n\n\n\n\nS. epidermidis\n0.8 (0.7‚Äì0.96)\n0.02\n\n\nK. pneumoniae\n1.2 (0.97‚Äì1.6)\n0.07\n\n\nP. aeruginosa\n1.6 (1.2‚Äì2.1)\n0.01\n\n\nS. hominis\n0.8 (0.6‚Äì1.1)\n0.15\n\n\nE. faecalis\n1.1 (0.8‚Äì1.5)\n0.4\n\n\nE. faecium\n1.9 (1.3‚Äì2.9)\n0.001"
  },
  {
    "objectID": "projects/hospital-mortality-and-positive-blood-culture.html#discussion",
    "href": "projects/hospital-mortality-and-positive-blood-culture.html#discussion",
    "title": "Real-World Evidence Analysis: Impact of Antibacterial Resistance on In-Hospital Mortality",
    "section": "Discussion",
    "text": "Discussion\nThis analysis highlights the value of real-world data in quantifying the clinical burden of antimicrobial resistance and identifying high-risk patient groups. Integrating such insights into antimicrobial stewardship and hospital surveillance systems can guide targeted interventions and resource allocation.\n\nRWE Value\n\nDemonstrates secondary use of hospital RWD for public health.\nReplicates real-world associations outside clinical trial settings.\nHighlights integration potential with HEOR studies (e.g., cost of AMR-related deaths).\n\n\n\nPerspective\nFuture applications of this analytical framework could include cost-effectiveness modeling, regional comparisons, and integration with national AMR surveillance systems.\n\n\nLimitations\n\nRetrospective observational design.\nPossible misclassification of infection source.\nAnalyses conducted on synthetic / anonymized data, not actual hospital data."
  },
  {
    "objectID": "projects/hospital-mortality-and-positive-blood-culture.html#ethics-and-data-governance",
    "href": "projects/hospital-mortality-and-positive-blood-culture.html#ethics-and-data-governance",
    "title": "Real-World Evidence Analysis: Impact of Antibacterial Resistance on In-Hospital Mortality",
    "section": "Ethics and Data Governance",
    "text": "Ethics and Data Governance\nThis portfolio project complies with ethical standards for the use of health data:\n\nNo identifiable or proprietary hospital data were accessed.\nAll datasets were synthetic, simulated, or anonymized.\nThe work is for educational and methodological purposes only.\nNo institutional review board (IRB) approval was required for this reimplementation.\n\nAll analytical steps comply with the FAIR (Findable, Accessible, Interoperable, Reusable) principles for responsible secondary use of health data."
  },
  {
    "objectID": "projects/hospital-mortality-and-positive-blood-culture.html#reproducibility-and-skills-demonstrated",
    "href": "projects/hospital-mortality-and-positive-blood-culture.html#reproducibility-and-skills-demonstrated",
    "title": "Real-World Evidence Analysis: Impact of Antibacterial Resistance on In-Hospital Mortality",
    "section": "Reproducibility and Skills Demonstrated",
    "text": "Reproducibility and Skills Demonstrated\nAnalytical skills illustrated in this project:\n\nReal-world data curation and cleaning (R, tidyverse, dplyr, lubridate).\nEpidemiological study design and variable definition.\nLogistic regression modeling of clinical outcomes.\nData visualization (R/ggplot2) and RWE storytelling.\nEthical and regulatory awareness in secondary data use."
  },
  {
    "objectID": "projects/hospital-mortality-and-positive-blood-culture.html#section",
    "href": "projects/hospital-mortality-and-positive-blood-culture.html#section",
    "title": "Real-World Evidence Analysis: Impact of Antibacterial Resistance on In-Hospital Mortality",
    "section": ":",
    "text": ":\n\n\n\n\n\n\nKey Messages (RWE)\n\n\n\n\nPositive blood cultures nearly doubled in-hospital mortality.\nICU admission, hospital-acquired infection, and infections by P. aeruginosa / E. faecium remained independently associated with death.\nDTR phenotypes were rare but enriched among deceased patients."
  },
  {
    "objectID": "projects/hospital-mortality-and-positive-blood-culture.html#results",
    "href": "projects/hospital-mortality-and-positive-blood-culture.html#results",
    "title": "Real-World Evidence Analysis: Impact of Antibacterial Resistance on In-Hospital Mortality",
    "section": "Results",
    "text": "Results\n\nAmong all patients with blood cultures, those with positive results had nearly twice the mortality of those with negative cultures.\nThe most common bacteria in both groups were Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa.\nResistance to ceftriaxone, ciprofloxacin, and imipenem was more prevalent among deceased patients (Table¬†1 Table¬†2 Table¬†3).\nPolymicrobial bloodstream infections were more frequent among deceased patients (9.4%) than survivors (6.8%; p = 0.004). Excluding coagulase-negative staphylococci, E. coli and K. pneumoniae predominated among the deceased, while E. coli and S. aureus were most frequent among survivors. Gram-negative bacteria accounted for a larger share of co-infections in the death group (72.2%) than in controls (48.6%) (Figure¬†1).\nHospital-acquired infection (OR‚âà1.5), ICU admission (OR‚âà2.9), and P. aeruginosa or E. faecium infection (OR‚âà1.6‚Äì1.9) were independent mortality risk factors (Table¬†4).\nThe DTR phenotype was rare (‚âà0.3%) but significantly more frequent among deceased patients (Figure¬†2).\n\n\n\n\n\n\n\nFigure¬†1: Chord diagrams (A) deceased patients for (top 20 co-infections); (B) survivors (for top 20 co-infections).\n\n\n\n\n\n\n\n\n\nFigure¬†2: Therapeutic alternatives on DTR isolates (susceptibility rate of other antibiotics on tested isolates).\n\n\n\n\n\n\nTable¬†1: Resistance rates to Œ≤-lactam antibiotics in E. coli isolates\n\n\n\n\n\n\n\n\n\n\n\n\nAntibiotic\nResistance\nDeaths\nSurvivors\nP-value\n\n\n\n\nAmoxicillin\nR\n172\n1,175\n0.20\n\n\n\nS\n93\n742\n\n\n\n\nAST\n265\n1,917\n\n\n\n\nNumber of patients\n268\n1,930\n\n\n\nAmoxicillin‚ÄìClavulanic acid\nR\n156\n1,008\n0.08\n\n\n\nS\n112\n916\n\n\n\n\nAST\n268\n1,924\n\n\n\n\nNumber of patients\n268\n1,930\n\n\n\n\n\n\n\n\n\n\nTable¬†2: Resistance rates to cephalosporin and carbapenem antibiotics in E. coli isolates\n\n\n\n\n\nAntibiotic\nResistance\nDeaths\nSurvivors\nP-value\n\n\n\n\nCeftriaxone\nR\n64\n274\n&lt;0.0001\n\n\n\nS\n203\n1,654\n\n\n\n\nAST\n267\n1,928\n\n\n\n\nNumber of patients\n268\n1,930\n\n\n\nImipenem\nR\n1\n1\n0.40\n\n\n\nS\n267\n1,911\n\n\n\n\nAST\n268\n1,929\n\n\n\n\nNumber of patients\n268\n1,930\n\n\n\n\n\n\n\n\n\n\n\nTable¬†3: Resistance rates to fluoroquinolone and aminoglycoside antibiotics in E. coli isolates\n\n\n\n\n\nAntibiotic\nResistance\nDeaths\nSurvivors\nP-value\n\n\n\n\nCiprofloxacin\nR\n84\n421\n0.007\n\n\n\nS\n184\n1,506\n\n\n\n\nAST\n268\n1,927\n\n\n\n\nNumber of patients\n268\n1,930\n\n\n\nAmikacin\nR\n9\n45\n0.44\n\n\n\nS\n259\n1,878\n\n\n\n\nAST\n268\n1,924\n\n\n\n\nNumber of patients\n268\n1,930\n\n\n\n\n\n\n\n\n\n\n\nTable¬†4: Table 2. Multivariate analysis of risk factors associated with in-hospital mortality\n\n\n\n\n\n\n\n\n\n\nRisk factors\naOR (95% CI)\nP-value\n\n\n\n\nPatient & care factors\n\n\n\n\nAge (&gt;60 years)\n2.2 (1.9‚Äì2.5)\n&lt; 0.0001\n\n\nGender (Male)\n1.13 (0.97‚Äì1.6)\n0.08\n\n\nLong hospital stay (&gt;14 days)\n0.9 (0.7‚Äì1.0)\n0.05\n\n\nHospital-acquired infections\n1.5 (1.2‚Äì1.8)\n&lt; 0.0001\n\n\nHospitalization Unit\n\n\n\n\nEmergency Unit\n1 (reference)\n‚Äî\n\n\nSurgery Unit\n0.35 (0.26‚Äì0.46)\n&lt; 0.0001\n\n\nMedical Unit\n0.73 (0.59‚Äì1.3)\n0.07\n\n\nIntensive Care Unit\n2.9 (2.4‚Äì3.6)\n&lt; 0.0001\n\n\nBacterial species\n\n\n\n\nS. epidermidis\n0.8 (0.7‚Äì0.96)\n0.02\n\n\nK. pneumoniae\n1.2 (0.97‚Äì1.6)\n0.07\n\n\nP. aeruginosa\n1.6 (1.2‚Äì2.1)\n0.01\n\n\nS. hominis\n0.8 (0.6‚Äì1.1)\n0.15\n\n\nE. faecalis\n1.1 (0.8‚Äì1.5)\n0.4\n\n\nE. faecium\n1.9 (1.3‚Äì2.9)\n0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\nKey Messages (RWE)\n\n\n\n\nPositive blood cultures nearly doubled in-hospital mortality.\nICU admission, hospital-acquired infection, and infections by P. aeruginosa / E. faecium remained independently associated with death.\nDTR phenotypes were rare but enriched among deceased patients."
  },
  {
    "objectID": "projects/hospital-mortality-and-positive-blood-culture.html#overview",
    "href": "projects/hospital-mortality-and-positive-blood-culture.html#overview",
    "title": "Real-World Evidence Analysis: Impact of Antibacterial Resistance on In-Hospital Mortality",
    "section": "Overview",
    "text": "Overview\nAntimicrobial resistance (AMR) is a major challenge in clinical practice, and real-world data provide valuable insights into its true clinical burden beyond controlled trials.\nThis project reimplements, using simulated data, the analytical framework of a real-world evidence (RWE) study that assessed the impact of antibacterial resistance on hospital mortality across four university hospitals in Marseille, France\n\n\n\n\n\n\nReal-world Evidence (RWE) Framing\n\n\n\n\nStudy type: Retrospective, multi-center, observational real-world evidence study\nData source (conceptual): Routine blood culture results (MARSS surveillance system) linked with hospital mortality\nPopulation: All patients with at least one blood culture performed in AP-HM during the study period\nPrimary outcome: In-hospital mortality\nKey exposures\n\nResistance to key antibiotics for top bacterial species\nDifficult-to-treat resistance (DTR) phenotype\nHospital-acquired infection, ICU admission, and other clinical factors"
  }
]